deferoxamine has been researched along with Thalassemias in 488 studies
Deferoxamine: Natural product isolated from Streptomyces pilosus. It forms iron complexes and is used as a chelating agent, particularly in the mesylate form.
desferrioxamine B : An acyclic desferrioxamine that is butanedioic acid in which one of the carboxy groups undergoes formal condensation with the primary amino group of N-(5-aminopentyl)-N-hydroxyacetamide and the second carboxy group undergoes formal condensation with the hydroxyamino group of N(1)-(5-aminopentyl)-N(1)-hydroxy-N(4)-[5-(hydroxyamino)pentyl]butanediamide. It is a siderophore native to Streptomyces pilosus biosynthesised by the DesABCD enzyme cluster as a high affinity Fe(III) chelator.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The iron chelator deferiprone is frequently used in individuals with thalassemia syndromes, but data in patients with SCD are limited." | 9.51 | Deferiprone vs deferoxamine for transfusional iron overload in SCD and other anemias: a randomized, open-label noninferiority study. ( Adly, AAM; Alshehri, A; Badr, M; Ebeid, FSE; El-Beshlawy, A; Elalfy, MS; Hamdy, M; Inusa, B; Kanter, J; Kilinc, Y; Kwiatkowski, JL; Lee, D; Tricta, F; Williams, S, 2022) |
| "The possible healing effect of deferoxamine and pentoxifylline on persisting lower limb ulcers was studied in 51 patients with thalassemia major." | 9.07 | Effect of pentoxifylline on treatment of lower limb ulcers in patients with thalassemia major. ( Angastiniotis, C; Angelides, NS; Pavlides, N, 1992) |
| "Deferasirox (DFX) has recently been used to treat thalassemia with iron overload; however, its long-term effectiveness and safety await multi-year studies." | 9.01 | Effectiveness and Safety of Deferasirox in Thalassemia with Iron Overload: A Meta-Analysis. ( Chen, G; Dou, H; Qin, Y; Zhao, Y, 2019) |
| "To assess the effectiveness and safety of oral deferasirox in people with thalassaemia and iron overload." | 8.95 | Deferasirox for managing iron overload in people with thalassaemia. ( Allert, R; Bassler, D; Bollig, C; Meerpohl, JJ; Motschall, E; Niemeyer, CM; Rücker, G; Schell, LK, 2017) |
| "A meta-analysis was conducted to investigate the efficacy and safety of three main iron chelators, namely, deferoxamine (DFO), deferiprone (DFP) and deferasirox (DFX) for thalassemia major (TM) patients." | 8.89 | Comparative efficacy and safety of deferoxamine, deferiprone and deferasirox on severe thalassemia: a meta-analysis of 16 randomized controlled trials. ( Huang, L; Jiang, H; Xia, S; Zhang, W, 2013) |
| "To assess the effectiveness and safety of oral deferasirox in people with thalassaemia and secondary iron overload." | 8.88 | Deferasirox for managing iron overload in people with thalassaemia. ( Antes, G; Bassler, D; Fleeman, N; Meerpohl, JJ; Motschall, E; Niemeyer, CM; Rücker, G, 2012) |
| "Deferiprone (L1), and appropriate combinations with deferoxamine (DFO), can be used effectively for the treatment of thalassemia and other transfusional iron loading conditions." | 8.83 | Future chelation monotherapy and combination therapy strategies in thalassemia and other conditions. comparison of deferiprone, deferoxamine, ICL670, GT56-252, L1NAll and starch deferoxamine polymers. ( Kontoghiorghes, GJ, 2006) |
| "The role of the orally active iron (Fe) chelator deferiprone in the treatment of beta-thalassemia remains a controversial subject." | 8.81 | The controversial role of deferiprone in the treatment of thalassemia. ( Richardson, DR, 2001) |
| "The newly available iron chelator deferasirox (Exjade, Novartis) is expected to provide better long-term clinical outcomes and improved quality of life for patients with thalassemia than its predecessor, deferoxamine (Desferal, Novartis), because of its oral tablet form." | 7.79 | A pharmaco-economic evaluation of deferasirox for treating patients with iron overload caused by transfusion-dependent thalassemia in Taiwan. ( Chang, HH; Chung, KP; Ho, WL; Jou, ST; Lin, DT; Lin, KH; Lu, MY; Yang, SS; Yang, YL, 2013) |
| "The Thalassemia Clinical Research Network collected adherence information from 79 patients on deferoxamine and 186 on deferasirox from 2007 to 2009." | 7.77 | Iron chelation adherence to deferoxamine and deferasirox in thalassemia. ( Coates, T; Giardina, PJ; Haines, D; Kwiatkowski, J; Mednick, L; Neufeld, EJ; Olivieri, N; Pakbaz, Z; Porter, J; Sobota, A; Thompson, AA; Trachtenberg, F; Vichinsky, E; Yamashita, R, 2011) |
| "In this report we firstly describe a case of reactivation of hepatitis B virus (HBV) replication occurred in a patient affected by Thalassemia major which underwent a combined chelation therapy with desferioxamine (DFO) and deferiprone (DFP)." | 7.75 | Hepatitis B virus reactivation during combined therapy with deferiprone and desferioxamine in a hepatitis B surface antigen thalassemic carrier. ( Ammirabile, M; Cinque, P; Di Matola, T; Lanza Galeota, A; Prossomariti, L; Ricchi, P, 2009) |
| " The known predisposing factors of infection include prior splenectomy, iron overload and use of iron chelator such as deferoxamine (DFO)." | 7.75 | Effects of chelators (deferoxamine, deferiprone and deferasirox) on the growth of Klebsiella pneumoniae and Aeromonas hydrophila isolated from transfusion-dependent thalassemia patients. ( Chan, GC; Chan, S; Ha, SY; Ho, PL, 2009) |
| "Deferoxamine mesylate (DFO) reduces morbidity and mortality associated with transfusional iron overload." | 7.74 | Outcomes, utilization, and costs among thalassemia and sickle cell disease patients receiving deferoxamine therapy in the United States. ( Baladi, JF; Coates, TD; Delea, TE; Hagiwara, M; Phatak, PD; Thomas, SK, 2008) |
| "For the past 2-6 years, two groups of thalassemia patients, one of 16 patients on deferoxamine (DFO) monotherapy (35-80 mg/kg, 2-5 days/week) and the other group comprising 19 patients on a deferiprone (L1) and DFO combination therapy (L1 75-100 mg/kg/day and DFO 30-60 mg/kg, 1-5 days/week), have been studied and compared before and after the introduction of the combination therapy." | 7.74 | Long term comparative studies in thalassemia patients treated with deferoxamine or a deferoxamine/deferiprone combination. Identification of effective chelation therapy protocols. ( Economides, C; Eracleous, E; Kolnagou, A; Kontoghiorghes, GJ, 2008) |
| "A number of studies have shown that regular chelation therapy with deferoxamine is effective in patients with secondary hemochromatosis." | 7.69 | [Long-term efficacy of subcutaneous administration of deferoxamine in patients with secondary hemochromatosis]. ( Fujisawa, S; Kobayashi, M; Yano, K, 1996) |
| "To assess the effects of deferoxamine (DFO) on the kidneys, we studied 27 patients with thalassemia major on chronic subcutaneous (s." | 7.68 | The effects of subcutaneous deferoxamine administration on renal function in thalassemia major. ( Bentur, Y; Kochavi-Atiya, Y; Koren, G; Olivieri, NF, 1991) |
| "Metaphyseal irregularity and abnormal vertebral bodies resembling a bone dysplasia were seen in two of five children with thalassemia major who were begun on a regimen of hypertransfusion and chelation with deferoxamine before the age of 3 years." | 7.68 | Deferoxamine-induced bone dysplasia in patients with thalassemia major. ( Brill, PW; Cunningham-Rundles, S; Giardina, PJ; Winchester, P, 1991) |
| "To determine whether survival of patients with beta-thalassemia major has been prolonged by management that utilizes hypertransfusion and chelation with deferoxamine, we analyzed longevity by the Kaplan-Meier product-limit method." | 7.68 | Prolonged survival in patients with beta-thalassemia major treated with deferoxamine. ( Ehlers, KH; Engle, MA; Giardina, PJ; Hilgartner, MW; Lesser, ML, 1991) |
| "Eight patients with transfusion-dependent thalassemia major were given continuous intravenous infusions of the chelator, deferoxamine mesylate, to reduce iron overload." | 7.68 | Pulmonary syndrome in patients with thalassemia major receiving intravenous deferoxamine infusions. ( Freedman, MH; Grisaru, D; MacLusky, I; Olivieri, N; Thorner, PS, 1990) |
| "We examined the efficacy of long-term subcutaneous deferoxamine therapy in the prevention of iron-related cardiac disease in patients with thalassemia major who began treatment after the age of 10 years." | 7.67 | Prevention of cardiac disease by subcutaneous deferoxamine in patients with thalassemia major. ( Colan, S; Freedman, MH; Nathan, DG; Olivieri, N; Propper, R; Rose, V; Sallan, D; Wolfe, L, 1985) |
| "We evaluated decreasing deferoxamine-induced urinary iron excretion during intensive chelation therapy in four children with thalassemia." | 7.66 | Response to long-term deferoxamine therapy in thalassemia. ( Cohen, A; Martin, M; Schwartz, E, 1981) |
| "Iron overload is the primary cause of mortality and morbidity in thalassemia major despite advances in chelation therapy." | 6.78 | Combined chelation therapy with deferasirox and deferoxamine in thalassemia. ( Evans, P; Harmatz, P; Kurio, G; Lal, A; Neumayr, L; Ng, V; Porter, J; Sweeters, N; Vichinsky, E, 2013) |
| " There was no significant difference in the proportion of patients with adverse events in the two therapy groups although the nature of the adverse events differed according to the chelation regimen." | 6.72 | A prospective randomized controlled trial on the safety and efficacy of alternating deferoxamine and deferiprone in the treatment of iron overload in patients with thalassemia. ( Fischer, R; Galanello, R; Kattamis, A; Ladis, V; Leoni, G; Lund, U; Piga, A; Tricta, F; Voi, V, 2006) |
| "The most frequent side effects were joint pain, stiffness or swelling in 6 patients (35." | 6.69 | Efficacy and side effects of deferiprone (L1) in thalassemia patients not compliant with desferrioxamine. ( Chamoun, FM; Khoriaty, AI; Koussa, S; Mourad, FH; Neeman, R; Saad, MA; Taher, A, 1999) |
| " Selected protocols using DFO, L1, and their combination can be designed for personalized chelation therapy in TI, which can effectively and safely remove all the excess toxic iron and prevent cardiac, liver, and other organ damage." | 6.53 | Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with non-transfusion-dependent thalassemia syndromes. ( Kontoghiorghe, CN; Kontoghiorghes, GJ, 2016) |
| "Iron overload is a major complication of transfusion-dependent thalassemia (TDT) and requires iron chelation (IC) therapy." | 5.62 | Using of deferasirox and deferoxamine in refractory iron overload thalassemia. ( Buaboonnam, J; Narkbunnam, N; Phuakpet, K; Pongtanakul, B; Sanpakit, K; Takpradit, C; Vathana, N; Viprakasit, V, 2021) |
| "Reversal of arrhythmia to sinus rhythm was noted in all patients." | 5.56 | Combined chelation with high-dose deferiprone and deferoxamine to improve survival and restore cardiac function effectively in patients with transfusion-dependent thalassemia presenting severe cardiac complications. ( Chao, YH; Chuang, TY; Li, JP; Weng, TF; Wu, KH, 2020) |
| " The iron chelator deferiprone is frequently used in individuals with thalassemia syndromes, but data in patients with SCD are limited." | 5.51 | Deferiprone vs deferoxamine for transfusional iron overload in SCD and other anemias: a randomized, open-label noninferiority study. ( Adly, AAM; Alshehri, A; Badr, M; Ebeid, FSE; El-Beshlawy, A; Elalfy, MS; Hamdy, M; Inusa, B; Kanter, J; Kilinc, Y; Kwiatkowski, JL; Lee, D; Tricta, F; Williams, S, 2022) |
| "Deferoxamine was given intravenously for 12 months and subcutaneously in the next 18 months." | 5.26 | [Role and therapeutic use of deferoxamine in iron overload due to thalassemia (author's transl)]. ( Bachelot, C; Bost, M; Joannard, A; Lévy, G, 1980) |
| " Transfusional iron overload in patients with thalassaemia could be reduced to normal body iron range levels using effective deferiprone/deferoxamine combinations." | 5.14 | Reduction of body iron stores to normal range levels in thalassaemia by using a deferiprone/deferoxamine combination and their maintenance thereafter by deferiprone monotherapy. ( Kleanthous, M; Kolnagou, A; Kontoghiorghes, GJ, 2010) |
| " The following prospective, randomized trial was carried out to determine the effectiveness, in children and young adults, of combined deferiprone (DFP) and deferoxamine (DFO) in reducing transfusional iron overload compared to either drug alone and to assess the safety and tolerability of DFP." | 5.13 | Iron chelation in thalassemia: combined or monotherapy? The Egyptian experience. ( El-Beshlawy, A; Eltagui, M; Hamdy, M; Hoffbrand, AV; Manz, C; Mostafa, A; Naja, M; Shaker, O; Sharaf, I; Sobh, H; Taher, A; Tarabishi, C; Youssry, I, 2008) |
| "The possible healing effect of deferoxamine and pentoxifylline on persisting lower limb ulcers was studied in 51 patients with thalassemia major." | 5.07 | Effect of pentoxifylline on treatment of lower limb ulcers in patients with thalassemia major. ( Angastiniotis, C; Angelides, NS; Pavlides, N, 1992) |
| "Deferasirox (DFX) has recently been used to treat thalassemia with iron overload; however, its long-term effectiveness and safety await multi-year studies." | 5.01 | Effectiveness and Safety of Deferasirox in Thalassemia with Iron Overload: A Meta-Analysis. ( Chen, G; Dou, H; Qin, Y; Zhao, Y, 2019) |
| "To compare the efficacy and safety of desferrioxamine (DFO), deferiprone (DFP), deferasirox (DFX) and silymarin in patients with either thalassemia or sickle cell disorder through network meta-analysis." | 4.98 | Efficacy and safety of iron chelators in thalassemia and sickle cell disease: a multiple treatment comparison network meta-analysis and trial sequential analysis. ( Sivaramakrishnan, G; Sridharan, K, 2018) |
| "To assess the effectiveness and safety of oral deferasirox in people with thalassaemia and iron overload." | 4.95 | Deferasirox for managing iron overload in people with thalassaemia. ( Allert, R; Bassler, D; Bollig, C; Meerpohl, JJ; Motschall, E; Niemeyer, CM; Rücker, G; Schell, LK, 2017) |
| "Desferrioxamine is the recommended first-line therapy for iron overload in people with thalassaemia major and deferiprone or deferasirox are indicated for treating iron overload when desferrioxamine is contraindicated or inadequate." | 4.89 | Desferrioxamine mesylate for managing transfusional iron overload in people with transfusion-dependent thalassaemia. ( Brunskill, SJ; Chowdhury, O; Doree, C; Fisher, SA; Gooding, S; Roberts, DJ, 2013) |
| "In the absence of data from randomised controlled trials, there is no evidence to suggest the need for a change in current treatment recommendations; namely that deferiprone is indicated for treating iron overload in people with thalassaemia major when desferrioxamine is contraindicated or inadequate." | 4.89 | Oral deferiprone for iron chelation in people with thalassaemia. ( Brunskill, SJ; Chowdhury, O; Doree, C; Fisher, SA; Gooding, S; Roberts, DJ, 2013) |
| "A meta-analysis was conducted to investigate the efficacy and safety of three main iron chelators, namely, deferoxamine (DFO), deferiprone (DFP) and deferasirox (DFX) for thalassemia major (TM) patients." | 4.89 | Comparative efficacy and safety of deferoxamine, deferiprone and deferasirox on severe thalassemia: a meta-analysis of 16 randomized controlled trials. ( Huang, L; Jiang, H; Xia, S; Zhang, W, 2013) |
| "To assess the effectiveness and safety of oral deferasirox in people with thalassaemia and secondary iron overload." | 4.88 | Deferasirox for managing iron overload in people with thalassaemia. ( Antes, G; Bassler, D; Fleeman, N; Meerpohl, JJ; Motschall, E; Niemeyer, CM; Rücker, G, 2012) |
| "We found no reason to change current treatment recommendations, namely deferiprone is indicated for treating iron overload in people with thalassaemia major when desferrioxamine is contraindicated or inadequate." | 4.84 | Oral deferiprone for iron chelation in people with thalassaemia. ( Brunskill, SJ; Doree, C; Howard, J; Hyde, CJ; Roberts, DJ; Williams, S, 2007) |
| "The iron chelators deferoxamine (DFO) and deferiprone (L1) have demonstrated their ability to normalize cardiac function in patients with iron overload-induced cardiac disease." | 4.84 | Effects of chelation therapy on cardiac function improvement in thalassemia patients: literature review and the Taiwanese experience. ( Peng, CT; Tsai, CH; Wu, KH, 2008) |
| "Deferiprone (L1), and appropriate combinations with deferoxamine (DFO), can be used effectively for the treatment of thalassemia and other transfusional iron loading conditions." | 4.83 | Future chelation monotherapy and combination therapy strategies in thalassemia and other conditions. comparison of deferiprone, deferoxamine, ICL670, GT56-252, L1NAll and starch deferoxamine polymers. ( Kontoghiorghes, GJ, 2006) |
| "Therapy with either deferiprone (DFP) or deferoxamine (DFO) is inadequate in achieving negative iron balance in many patients with thalassemia." | 4.82 | Combined therapy with deferoxamine and deferiprone. ( Kattamis, A, 2005) |
| "In patients with thalassemia, the assessment of liver iron concentration (LIC) can be used to initiate chelation treatment with desferrioxamine (DFO), deferiprone (DFP), or novel chelators (deferasirox); to adjust chelation dose according to the actual blood transfusion rate; and to monitor chelation efficacy." | 4.82 | Monitoring long-term efficacy of iron chelation treatment with biomagnetic liver susceptometry. ( Fischer, R; Harmatz, P; Nielsen, P; Piga, A, 2005) |
| "The role of the orally active iron (Fe) chelator deferiprone in the treatment of beta-thalassemia remains a controversial subject." | 4.81 | The controversial role of deferiprone in the treatment of thalassemia. ( Richardson, DR, 2001) |
| " Such is the case for iron chelating agents used in transfusion-dependent patients of Thalassemia, of which deferoxamine (DFO) is the most widely used." | 4.31 | Lifting the iron curtain of vision. ( Rosin, B; Sahel, JA, 2023) |
| "We report two cases of bilateral macular pattern dystrophy in transfusion dependent patients undergoing chronic chelation therapy with deferoxamine due to thalassemias." | 3.88 | Pattern dystrophies in patients treated with deferoxamine: report of two cases and review of the literature. ( Georgakopoulos, CD; Kostopoulou, EV; Makri, OE; Tsapardoni, F, 2018) |
| " Time after splenectomy >10 years, deferoxamine therapy, and iron overload may be clinical risk factors for severe bacterial infection in patients with NTDT." | 3.81 | Severe bacterial infections in patients with non-transfusion-dependent thalassemia: prevalence and clinical risk factors. ( Chansung, K; Jetsrisuparb, A; Sirijerachai, C; Teawtrakul, N; Wanitpongpun, C, 2015) |
| "A 34-year-old man with thalassemia major complained of nyctalopia and decreased vision following high-dose intravenous deferoxamine to treat systemic iron overload." | 3.80 | Deferoxamine retinopathy: spectral domain-optical coherence tomography findings. ( Chen, YH; Lai, CC; Wu, CH; Wu, WC; Yang, CP, 2014) |
| "The newly available iron chelator deferasirox (Exjade, Novartis) is expected to provide better long-term clinical outcomes and improved quality of life for patients with thalassemia than its predecessor, deferoxamine (Desferal, Novartis), because of its oral tablet form." | 3.79 | A pharmaco-economic evaluation of deferasirox for treating patients with iron overload caused by transfusion-dependent thalassemia in Taiwan. ( Chang, HH; Chung, KP; Ho, WL; Jou, ST; Lin, DT; Lin, KH; Lu, MY; Yang, SS; Yang, YL, 2013) |
| " The generic drugs deferiprone, deferoxamine and their combination offer a safer, less expensive and complete treatment of iron overload in thalassaemia and other iron loading conditions." | 3.79 | A record number of fatalities in many categories of patients treated with deferasirox: loopholes in regulatory and marketing procedures undermine patient safety and misguide public funds? ( Kontoghiorghes, GJ, 2013) |
| " The complete treatment of transfusional iron overload in thalassaemia using the deferiprone (L1) and deferoxamine combination is a paradigm to be followed in the treatment of many other metal toxicity conditions." | 3.79 | The proceedings of the 20th International Conference on Chelation held in the USA: advances on new and old chelation therapies. ( Kontoghiorghes, GJ, 2013) |
| "The Thalassemia Clinical Research Network collected adherence information from 79 patients on deferoxamine and 186 on deferasirox from 2007 to 2009." | 3.77 | Iron chelation adherence to deferoxamine and deferasirox in thalassemia. ( Coates, T; Giardina, PJ; Haines, D; Kwiatkowski, J; Mednick, L; Neufeld, EJ; Olivieri, N; Pakbaz, Z; Porter, J; Sobota, A; Thompson, AA; Trachtenberg, F; Vichinsky, E; Yamashita, R, 2011) |
| "In iron overload conditions, plasma contains non-transferrin bound iron species, collectively referred to as plasma NTBI." | 3.76 | Mechanisms for the shuttling of plasma non-transferrin-bound iron (NTBI) onto deferoxamine by deferiprone. ( Eccleston, J; Evans, P; Hider, RC; Kayyali, R; Porter, JB, 2010) |
| "Deferiprone (DFP) has been evaluated in a wide range of disorders, but most data come from transfusion-dependent thalassemia." | 3.76 | Deferiprone. ( Longo, F; Massano, D; Piga, A; Roggero, S; Salussolia, I; Serra, M, 2010) |
| "In this report we firstly describe a case of reactivation of hepatitis B virus (HBV) replication occurred in a patient affected by Thalassemia major which underwent a combined chelation therapy with desferioxamine (DFO) and deferiprone (DFP)." | 3.75 | Hepatitis B virus reactivation during combined therapy with deferiprone and desferioxamine in a hepatitis B surface antigen thalassemic carrier. ( Ammirabile, M; Cinque, P; Di Matola, T; Lanza Galeota, A; Prossomariti, L; Ricchi, P, 2009) |
| " The introduction of effective chelation therapy protocols using primarily deferiprone (L1) in combination with deferoxamine (DFO) resulted in the reduction of iron overload induced cardiac failures, which is the main cause of death in thalassemia major." | 3.75 | Advances in the prevention and treatment are changing thalassemia from a fatal to a chronic disease. experience from a Cyprus model and its use as a paradigm for future applications. ( Kolnagou, A; Kontoghiorghes, GJ, 2009) |
| " The known predisposing factors of infection include prior splenectomy, iron overload and use of iron chelator such as deferoxamine (DFO)." | 3.75 | Effects of chelators (deferoxamine, deferiprone and deferasirox) on the growth of Klebsiella pneumoniae and Aeromonas hydrophila isolated from transfusion-dependent thalassemia patients. ( Chan, GC; Chan, S; Ha, SY; Ho, PL, 2009) |
| "Non-transferrin-bound iron (NTBI) is detectable in plasma of beta-thalassemia patients with transfusional iron overload." | 3.74 | Curcumin contributes to in vitro removal of non-transferrin bound iron by deferiprone and desferrioxamine in thalassemic plasma. ( Fucharoen, S; Phisalaphong, C; Porter, JB; Srichairatanakool, S; Thephinlap, C, 2007) |
| "Deferoxamine mesylate (DFO) reduces morbidity and mortality associated with transfusional iron overload." | 3.74 | Outcomes, utilization, and costs among thalassemia and sickle cell disease patients receiving deferoxamine therapy in the United States. ( Baladi, JF; Coates, TD; Delea, TE; Hagiwara, M; Phatak, PD; Thomas, SK, 2008) |
| "For the past 2-6 years, two groups of thalassemia patients, one of 16 patients on deferoxamine (DFO) monotherapy (35-80 mg/kg, 2-5 days/week) and the other group comprising 19 patients on a deferiprone (L1) and DFO combination therapy (L1 75-100 mg/kg/day and DFO 30-60 mg/kg, 1-5 days/week), have been studied and compared before and after the introduction of the combination therapy." | 3.74 | Long term comparative studies in thalassemia patients treated with deferoxamine or a deferoxamine/deferiprone combination. Identification of effective chelation therapy protocols. ( Economides, C; Eracleous, E; Kolnagou, A; Kontoghiorghes, GJ, 2008) |
| "The incidence of cardiomyopathy was monitored in a 6-year follow-up study involving 56 transfused thalassemia patients treated with deferoxamine (DFO), deferiprone (L1) or their combination." | 3.73 | Low serum ferritin levels are misleading for detecting cardiac iron overload and increase the risk of cardiomyopathy in thalassemia patients. The importance of cardiac iron overload monitoring using magnetic resonance imaging T2 and T2*. ( Economides, C; Eracleous, E; Kolnagou, A; Kontoghiorghes, GJ, 2006) |
| "In patients with thalassemia major (TM) who are non-compliant with long-term deferoxamine (DFO) chelation, survival is limited mainly because of cardiac complications of transfusional siderosis." | 3.72 | Reversal of cardiac complications in thalassemia major by long-term intermittent daily intensive iron chelation. ( Berant, M; Hershko, C; Miskin, H; Tamary, H; Yaniv, I, 2003) |
| "We studied the changing pattern of the distribution of ferritin levels in 430 regularly-transfused patients with thalassemia in an attempt to evaluate compliance of chelation with deferoxamine." | 3.71 | Variations of ferritin levels over a period of 15 years as a compliance chelation index in thalassemic patients. ( Berdousi, H; Dinopoulos, A; Kattamis, A; Kattamis, C; Ladis, V, 2001) |
| "Compliance with parenteral administration of deferoxamine is often poor in thalassemic patients with iron overload." | 3.71 | Long-term administration of high-dose deferoxamine 2 days per week in thalassemic patients. ( Becker, A; Girot, R; Hagège, I; Kanfer, A; Kerdaffrec, T, 2001) |
| "A number of studies have shown that regular chelation therapy with deferoxamine is effective in patients with secondary hemochromatosis." | 3.69 | [Long-term efficacy of subcutaneous administration of deferoxamine in patients with secondary hemochromatosis]. ( Fujisawa, S; Kobayashi, M; Yano, K, 1996) |
| "We reviewed the linear growth and growth plate morphology in all children with homozygous beta thalassemia followed in Toronto, for whom monthly height percentiles were available before, and for a 36-month period after, the initiation of nightly subcutaneous deferoxamine therapy." | 3.68 | Growth failure and bony changes induced by deferoxamine. ( Bailey, JD; Freedman, MH; Harris, J; Khattak, S; Koren, G; Olivieri, NF; Reilly, BJ; Templeton, DM, 1992) |
| "The effect of the iron chelator deferoxamine (DFO) on resistance to infection with Listeria monocytogenes in mice with a condition analogous to human beta-thalassemia was studied." | 3.68 | Deferoxamine increases the susceptibility of beta-thalassemic, iron-overloaded mice to infection with Listeria monocytogenes. ( Ampel, NM; Bejarano, GC; Saavedra, M, 1992) |
| "Deferoxamine is still today the only preventive and curative treatment of transfusional hemochromatosis." | 3.68 | [Intensifying iron chelating therapy with desferrioxamine using implantable venous access catheters (Port-A-Cath)]. ( Clairicia, M; de Montalembert, M; Girot, R; Hannedouche, T; Jan, D; Sidi, D, 1992) |
| "To assess the effects of deferoxamine (DFO) on the kidneys, we studied 27 patients with thalassemia major on chronic subcutaneous (s." | 3.68 | The effects of subcutaneous deferoxamine administration on renal function in thalassemia major. ( Bentur, Y; Kochavi-Atiya, Y; Koren, G; Olivieri, NF, 1991) |
| " We describe a case of this unusual condition in a 17-year-old male patient with thalassemia intermedia requiring transfusion, who was also taking deferoxamine." | 3.68 | Yersinia enterocolitica infection with ileal perforation associated with iron overload and deferoxamine therapy. ( deSa, D; Gately, J; Mazzoleni, G; Riddell, RH, 1991) |
| "Metaphyseal irregularity and abnormal vertebral bodies resembling a bone dysplasia were seen in two of five children with thalassemia major who were begun on a regimen of hypertransfusion and chelation with deferoxamine before the age of 3 years." | 3.68 | Deferoxamine-induced bone dysplasia in patients with thalassemia major. ( Brill, PW; Cunningham-Rundles, S; Giardina, PJ; Winchester, P, 1991) |
| "To determine whether survival of patients with beta-thalassemia major has been prolonged by management that utilizes hypertransfusion and chelation with deferoxamine, we analyzed longevity by the Kaplan-Meier product-limit method." | 3.68 | Prolonged survival in patients with beta-thalassemia major treated with deferoxamine. ( Ehlers, KH; Engle, MA; Giardina, PJ; Hilgartner, MW; Lesser, ML, 1991) |
| "Daily subcutaneous infusion of deferoxamine in thalassemia and other transfusion dependent-patients can successfully treat iron overload, but most patients, mainly young children and teenagers may not comply with this method." | 3.68 | [Intravenous administration of deferoxamine in over-night hospitalization: efficacy and good psychological tolerance in thalassemic children]. ( Bachelot, C; Plantaz, D, 1990) |
| "The use of deferoxamine for iron chelation in transfusion-dependent thalassemia major is limited by serious neurotoxicity (hearing and vision loss)." | 3.68 | Comparison of deferoxamine pharmacokinetics between asymptomatic thalassemic children and those exhibiting severe neurotoxicity. ( Bentur, Y; Carley, H; Freedman, MH; Koren, G; Olivieri, N; Tesoro, A, 1990) |
| "Eight patients with transfusion-dependent thalassemia major were given continuous intravenous infusions of the chelator, deferoxamine mesylate, to reduce iron overload." | 3.68 | Pulmonary syndrome in patients with thalassemia major receiving intravenous deferoxamine infusions. ( Freedman, MH; Grisaru, D; MacLusky, I; Olivieri, N; Thorner, PS, 1990) |
| "Beginning chelation treatment with deferoxamine before the age of puberty can help children with transfusion-dependent thalassemia major to attain normal sexual maturation." | 3.68 | Effect of age at the start of iron chelation therapy on gonadal function in beta-thalassemia major. ( Andrews, DF; Bronspiegel-Weintrob, N; Freedman, MH; Holland, FJ; Olivieri, NF; Tyler, B, 1990) |
| "Sixteen patients (age range, 3 to 17 years) with transfusion-dependent beta-thalassemia major were studied prospectively, beginning at the onset of chelation therapy with deferoxamine (desferrioxamine)." | 3.67 | A prospective evaluation of iron chelation therapy in children with severe beta-thalassemia. A six-year study. ( Gonzalez-Crussi, F; Honig, GR; Ingrisano, C; Lloyd-Still, JD; Maurer, HS, 1988) |
| "Of 89 patients receiving nightly subcutaneous deferoxamine for transfusion-dependent thalassemia major or Diamond-Blackfan anemia, 13 presented with visual loss or deafness of acute onset or both." | 3.67 | Visual and auditory neurotoxicity in patients receiving subcutaneous deferoxamine infusions. ( Buncic, JR; Chew, E; Gallant, T; Harrison, RV; Keenan, N; Logan, W; Mitchell, D; Olivieri, NF; Ricci, G; Skarf, B, 1986) |
| "We examined the efficacy of long-term subcutaneous deferoxamine therapy in the prevention of iron-related cardiac disease in patients with thalassemia major who began treatment after the age of 10 years." | 3.67 | Prevention of cardiac disease by subcutaneous deferoxamine in patients with thalassemia major. ( Colan, S; Freedman, MH; Nathan, DG; Olivieri, N; Propper, R; Rose, V; Sallan, D; Wolfe, L, 1985) |
| "We evaluated decreasing deferoxamine-induced urinary iron excretion during intensive chelation therapy in four children with thalassemia." | 3.66 | Response to long-term deferoxamine therapy in thalassemia. ( Cohen, A; Martin, M; Schwartz, E, 1981) |
| " Deferoxamine-induced urinary excretion of iron was considerably less than that reported in patients with thalassemia major who were receiving regular blood transfusions." | 3.66 | Iron burden in sickle cell anemia. ( O'Brien, RT, 1978) |
| "The iron-chelating agent, deferoxamine, was studied in 16 patients with thalassemia major." | 3.66 | Iron chelation therapy with deferoxamine in Cooley anemia. ( Cohen, A; Schwartz, E, 1978) |
| "Iron overload is the primary cause of mortality and morbidity in thalassemia major despite advances in chelation therapy." | 2.78 | Combined chelation therapy with deferasirox and deferoxamine in thalassemia. ( Evans, P; Harmatz, P; Kurio, G; Lal, A; Neumayr, L; Ng, V; Porter, J; Sweeters, N; Vichinsky, E, 2013) |
| " There was no significant difference in the proportion of patients with adverse events in the two therapy groups although the nature of the adverse events differed according to the chelation regimen." | 2.72 | A prospective randomized controlled trial on the safety and efficacy of alternating deferoxamine and deferiprone in the treatment of iron overload in patients with thalassemia. ( Fischer, R; Galanello, R; Kattamis, A; Ladis, V; Leoni, G; Lund, U; Piga, A; Tricta, F; Voi, V, 2006) |
| "The most frequent side effects were joint pain, stiffness or swelling in 6 patients (35." | 2.69 | Efficacy and side effects of deferiprone (L1) in thalassemia patients not compliant with desferrioxamine. ( Chamoun, FM; Khoriaty, AI; Koussa, S; Mourad, FH; Neeman, R; Saad, MA; Taher, A, 1999) |
| " During the course of the trial, several possible adverse effects have been encountered." | 2.67 | Efficacy and possible adverse effects of the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1) in thalassemia major. ( al-Refaie, FN; Hoffbrand, AV; Kontoghiorghes, GJ; Nortey, P; Wickens, DG; Wonke, B, 1992) |
| " Selected protocols using DFO, L1, and their combination can be designed for personalized chelation therapy in TI, which can effectively and safely remove all the excess toxic iron and prevent cardiac, liver, and other organ damage." | 2.53 | Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with non-transfusion-dependent thalassemia syndromes. ( Kontoghiorghe, CN; Kontoghiorghes, GJ, 2016) |
| "Thalassemia is a chronic inherited blood disorder that reduces hemoglobin production, causing chronic hemolytic anemia." | 2.53 | Clinical Management of Patients With Thalassemia Syndromes. ( Haines, D; Martin, M, 2016) |
| "Iron overload has many different causes, both genetic and environmental." | 2.48 | Iron mobilization using chelation and phlebotomy. ( Aaseth, J; Andersen, O; Flaten, TP; Kontoghiorghes, GJ, 2012) |
| "Thalassemia is an autosomal recessive disorder associated with defective synthesis of the α- or β-chain of hemoglobin." | 2.48 | Hematopoietic stem cell transplantation for thalassemia. ( Elborai, Y; Lehmann, L; Uwumugambi, A, 2012) |
| "Iron overload is a major cause of morbidity and mortality in transfusion-dependent anemias." | 2.46 | An update on disordered iron metabolism and iron overload. ( Ward, R, 2010) |
| "Monitoring of iron overload has advanced with the increasing use of MRI techniques to estimate iron balance (changes in liver iron concentration) and extrahepatic iron distribution (myocardial T2*)." | 2.46 | Iron overload in thalassemia and related conditions: therapeutic goals and assessment of response to chelation therapies. ( Porter, JB; Shah, FT, 2010) |
| "Thalassemia is anemia of variable severity, arising from mutations of genes encoding the hemoglobin alpha and beta chains." | 2.44 | Mechanisms of and obstacles to iron cardiomyopathy in thalassemia. ( Chang, JS; Lin, HS; Peng, CT; Tsai, CH; Wu, KH, 2008) |
| "Deferiprone is a three-times-daily oral iron chelator, but has limited availability in the United States." | 2.44 | Consequences and costs of noncompliance with iron chelation therapy in patients with transfusion-dependent thalassemia: a literature review. ( Baladi, JF; Coates, TD; Delea, TE; Edelsberg, J; Phatak, PD; Sofrygin, O; Thomas, SK, 2007) |
| " Increasing DFO dosing does not increase NTBI removal, but instead leads to a greater rebound in NTBI on cessation of intravenous infusion." | 2.43 | Recent insights into interactions of deferoxamine with cellular and plasma iron pools: Implications for clinical use. ( Davis, BA; Evans, P; Hair, T; Porter, JB; Rafique, R; Shah, FT; Srichairatanakool, S, 2005) |
| "If untreated, iron overload is responsible for heart, liver and endocrine diseases." | 2.42 | Pharmacotherapy of iron overload in thalassaemic patients. ( Ceci, A; De Mattia, D; De Sanctis, V; Felisi, M, 2003) |
| " This substance is well absorbed orally and has been shown to enhance the excretion of ferric ion in iron loaded rats." | 2.36 | [Iron chelation. Biological significance and medical application]. ( Peter, HH, 1983) |
| "Hemochromatosis is a syndrome which, when fully expressed, is manifested by melanoderma , diabetes mellitus, and liver cirrhosis, with iron overload involving parenchymal and reticuloendothelial cells in many organ systems." | 2.36 | Iron overload disorders: natural history, pathogenesis, diagnosis, and therapy. ( Kellermeyer, RW; McLaren, GD; Muir, WA, 1983) |
| " In the United States, deferiprone has been approved for three times daily dosing since 2011 and has recently gained approval for twice-daily administration." | 1.91 | An evaluation of deferiprone as twice-a-day tablets or in combination therapy for the treatment of transfusional iron overload in thalassemia syndromes. ( Badawy, SM; Shah, A; Shah, R, 2023) |
| "Iron overload is a major complication of transfusion-dependent thalassemia (TDT) and requires iron chelation (IC) therapy." | 1.62 | Using of deferasirox and deferoxamine in refractory iron overload thalassemia. ( Buaboonnam, J; Narkbunnam, N; Phuakpet, K; Pongtanakul, B; Sanpakit, K; Takpradit, C; Vathana, N; Viprakasit, V, 2021) |
| "Reversal of arrhythmia to sinus rhythm was noted in all patients." | 1.56 | Combined chelation with high-dose deferiprone and deferoxamine to improve survival and restore cardiac function effectively in patients with transfusion-dependent thalassemia presenting severe cardiac complications. ( Chao, YH; Chuang, TY; Li, JP; Weng, TF; Wu, KH, 2020) |
| "Iron overload was assessed by the T2* technique." | 1.48 | The effect of desferrioxamine chelation versus no therapy in patients with non transfusion-dependent thalassaemia: a multicenter prospective comparison from the MIOT network. ( Allò, M; Campisi, S; Gamberini, MR; Lisi, R; Mangione, M; Meloni, A; Missere, M; Peluso, A; Pepe, A; Pistoia, L; Positano, V; Renne, S; Ricchi, P; Spasiano, A; Spiga, A, 2018) |
| "Cardiac iron overload was induced to a greater extent than in a previous study by feeding the mice with an iron-enriched diet for 4 months." | 1.43 | Dual T-type and L-type calcium channel blocker exerts beneficial effects in attenuating cardiovascular dysfunction in iron-overloaded thalassaemic mice. ( Chattipakorn, N; Chattipakorn, SC; Fucharoen, S; Kumfu, S, 2016) |
| "Thalassemia is a congenital blood disorder requiring chronic blood transfusions and daily iron chelation therapy." | 1.38 | Beliefs about chelation among thalassemia patients. ( Grady, R; Haines, D; Horne, R; Kwiatkowski, JL; Mednick, L; Neufeld, EJ; Olivieri, N; Pakbaz, Z; Quinn, CT; Sobota, A; Thompson, AA; Trachtenberg, FL; Yamashita, R, 2012) |
| "Thalassemia is a chronic hereditary disease in which patients with severe disease present with anemia during their first year of life." | 1.37 | Health-related quality of life in Thai thalassemic children treated with iron chelation. ( Pankaew, T; Torcharus, K, 2011) |
| "Dental caries were significantly higher in thalassemics." | 1.33 | Physical growth patterns and dental caries in thalassemia. ( Dewan, P; Gomber, S, 2006) |
| "Body disproportion and severe degree of osteopenia (BMD SDSBA -2." | 1.31 | Persistence of delayed adrenarche in boys with thalassemia. ( De Martinis, F; De Terlizzi, F; Di Maio, S; Esposito, G; Filosa, A, 2001) |
| "6 patients who developed liver cirrhosis before or after their thalassemia was cured by bone marrow transplantation (age at transplantation, 11 to 25 years)." | 1.31 | Reversibility of cirrhosis in patients cured of thalassemia by bone marrow transplantation. ( Angelucci, E; Lucarelli, G; Muretto, P, 2002) |
| " The results show that L1 is less toxic than DF to normal bone marrow myeloid progenitors (ID50:130 mumol/l versus 7." | 1.29 | Differential toxicity of alpha-keto hydroxypyridine iron chelators and desferrioxamine to human haemopoietic precursors in vitro. ( al-Refaie, FN; Cunningham, JM; Hoffbrand, AV; Hunter, AE; Sheppard, LN, 1994) |
| "To determine the frequency of eye and auditory complications and their relationship to drug dosage and iron stores in patients receiving deferoxamine, we studied 52 regularly transfused patients who received deferoxamine by subcutaneous or intravenous infusion in doses from 26 to 136 mg/kg/day, and whose serum ferritin levels of 185 to 17,775 micrograms/L reflected a wide range of iron stores." | 1.28 | Vision and hearing during deferoxamine therapy. ( Cohen, A; Konkle, DF; Martin, M; Mizanin, J; Schwartz, E, 1990) |
| "Forty-seven patients with thalassaemia have been studied to define risk factors for development of sensorineural hearing loss, and to establish guidelines for safe chelation." | 1.28 | Desferrioxamine ototoxicity: evaluation of risk factors in thalassaemic patients and guidelines for safe dosage. ( East, CA; Hazell, JW; Huehns, ER; Jaswon, MS; Porter, JB, 1989) |
| " The dosage and the route of administration (IV, IM, SC) were adapted to the amount of iron transfused and to the nature of the disease." | 1.28 | [Treatment of post-transfusion iron overload by deferoxamine]. ( de Montalembert, M; Girot, R; Hannedouche, T; Llados, A, 1989) |
| "Successful pregnancy is described in a patient with beta-thalassaemia major, transfusion-dependent from four months of age and treated with desferrioxamine from 13 years of age." | 1.27 | Successful pregnancy in beta-thalassaemia major. ( Martin, K, 1983) |
| " The incidence of such changes is not related to drug dosage or to ferritin level but to abnormality of the extended glucose tolerance test." | 1.27 | Ocular changes in patients undergoing long-term desferrioxamine treatment. ( Arden, GB; Huehns, ER; Kennedy, C; Wonke, B, 1984) |
| "Among our patients, conductive hearing loss was not more frequent than in patients without beta thalassemia." | 1.27 | Hearing loss and desferrioxamine in homozygous beta-thalassemia. ( Albera, R; Bianco, L; Gabutti, V; Lacilla, M; Morra, B; Pia, F; Piga, A, 1988) |
| " However, the desferrioxamine dosage was similar in both our groups (less than 60 mg/kg a day), and lower in the affected group than other authors have reported." | 1.27 | Hearing loss attributed to desferrioxamine in patients with beta-thalassaemia major. ( Barratt, PS; Toogood, IR, 1987) |
| "The liver iron content of patients with liver cirrhosis was within the normal range." | 1.27 | Comparison between serum ferritin and computed tomographic densities of liver, spleen, kidney and pancreas in beta-thalassaemia major. ( Babiker, MA; Hafeez, MH; Karrar, ZA; Patel, PJ, 1987) |
| " Since dose-response curves were highly variable the treatment schedule should be tailored to the individual needs of each patient." | 1.26 | Iron chelation in transfusion-dependent thalassemia with chronic hepatitis. ( Cao, A; Cornacchia, G; Cossu, P; De Virgiliis, S; Frau, F; Lobrano, R; Loi, A; Loi, E; Nucaro, A; Sanna, G; Toccafondi, C, 1982) |
| "Since patients with thalassemia are not growth hormone deficient, the data suggest the possibility of defective hepatic biosynthesis of somatomedin." | 1.26 | Depressed serum somatomedin activity in beta-thalassemia. ( Graziano, JH; Hilgartner, MW; Levine, LS; Markenson, AL; New, MI; Saenger, P; Schwartz, E, 1980) |
| "Deferoxamine was given intravenously for 12 months and subcutaneously in the next 18 months." | 1.26 | [Role and therapeutic use of deferoxamine in iron overload due to thalassemia (author's transl)]. ( Bachelot, C; Bost, M; Joannard, A; Lévy, G, 1980) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 288 (59.02) | 18.7374 |
| 1990's | 71 (14.55) | 18.2507 |
| 2000's | 65 (13.32) | 29.6817 |
| 2010's | 54 (11.07) | 24.3611 |
| 2020's | 10 (2.05) | 2.80 |
| Authors | Studies |
|---|---|
| Kwiatkowski, JL | 3 |
| Hamdy, M | 2 |
| El-Beshlawy, A | 2 |
| Ebeid, FSE | 1 |
| Badr, M | 1 |
| Alshehri, A | 1 |
| Kanter, J | 1 |
| Inusa, B | 1 |
| Adly, AAM | 1 |
| Williams, S | 2 |
| Kilinc, Y | 1 |
| Lee, D | 1 |
| Tricta, F | 3 |
| Elalfy, MS | 1 |
| Kolnagou, A | 12 |
| Kleanthous, M | 3 |
| Kontoghiorghes, GJ | 23 |
| Rosin, B | 1 |
| Sahel, JA | 1 |
| Shah, R | 1 |
| Shah, A | 1 |
| Badawy, SM | 1 |
| Geneen, LJ | 1 |
| Dorée, C | 4 |
| Estcourt, LJ | 1 |
| Chuang, TY | 1 |
| Li, JP | 1 |
| Weng, TF | 1 |
| Wu, KH | 3 |
| Chao, YH | 1 |
| Takpradit, C | 1 |
| Viprakasit, V | 3 |
| Narkbunnam, N | 1 |
| Vathana, N | 1 |
| Phuakpet, K | 1 |
| Pongtanakul, B | 1 |
| Sanpakit, K | 1 |
| Buaboonnam, J | 1 |
| Shafie, AA | 1 |
| Wong, JHY | 1 |
| Ibrahim, HM | 1 |
| Mohammed, NS | 1 |
| Chhabra, IK | 1 |
| Zardkhoni, SZ | 1 |
| Moghaddam, AG | 1 |
| Rad, F | 1 |
| Ghatee, MA | 1 |
| Omidifar, N | 1 |
| Ghaedi, M | 1 |
| Etemadfar, P | 1 |
| Hadjidemetriou, M | 1 |
| Bollig, C | 1 |
| Schell, LK | 1 |
| Rücker, G | 2 |
| Allert, R | 1 |
| Motschall, E | 2 |
| Niemeyer, CM | 2 |
| Bassler, D | 2 |
| Meerpohl, JJ | 2 |
| Sridharan, K | 1 |
| Sivaramakrishnan, G | 1 |
| Ricchi, P | 2 |
| Meloni, A | 1 |
| Pistoia, L | 1 |
| Spasiano, A | 1 |
| Spiga, A | 1 |
| Allò, M | 1 |
| Gamberini, MR | 2 |
| Lisi, R | 1 |
| Campisi, S | 2 |
| Peluso, A | 1 |
| Missere, M | 1 |
| Renne, S | 1 |
| Mangione, M | 1 |
| Positano, V | 1 |
| Pepe, A | 3 |
| Wahidiyat, PA | 1 |
| Yosia, M | 1 |
| Sari, TT | 1 |
| Georgakopoulos, CD | 1 |
| Tsapardoni, F | 1 |
| Kostopoulou, EV | 1 |
| Makri, OE | 1 |
| Taher, AT | 2 |
| Origa, R | 1 |
| Perrotta, S | 1 |
| Kouraklis, A | 1 |
| Ruffo, GB | 1 |
| Kattamis, A | 5 |
| Goh, AS | 1 |
| Huang, V | 1 |
| Zia, A | 1 |
| Herranz, RM | 1 |
| Porter, JB | 9 |
| Hider, RC | 2 |
| Hoffbrand, AV | 17 |
| Dou, H | 1 |
| Qin, Y | 1 |
| Chen, G | 1 |
| Zhao, Y | 1 |
| Ho, WL | 1 |
| Chung, KP | 1 |
| Yang, SS | 1 |
| Lu, MY | 1 |
| Jou, ST | 1 |
| Chang, HH | 1 |
| Yang, YL | 1 |
| Lin, DT | 1 |
| Lin, KH | 1 |
| Olivieri, NF | 10 |
| Brittenham, GM | 2 |
| Fisher, SA | 2 |
| Brunskill, SJ | 3 |
| Gooding, S | 2 |
| Chowdhury, O | 2 |
| Roberts, DJ | 4 |
| Xia, S | 1 |
| Zhang, W | 1 |
| Huang, L | 1 |
| Jiang, H | 1 |
| Al-Kloub, MI | 1 |
| Salameh, TN | 1 |
| Froelicher, ES | 1 |
| Wu, CH | 1 |
| Yang, CP | 1 |
| Lai, CC | 1 |
| Wu, WC | 1 |
| Chen, YH | 1 |
| Tanphaichitr, A | 1 |
| Kusuwan, T | 1 |
| Limviriyakul, S | 1 |
| Atipas, S | 1 |
| Pooliam, J | 1 |
| Sangpraypan, T | 1 |
| Tanphaichitr, VS | 1 |
| Karimi, M | 1 |
| Haghpanah, S | 1 |
| Adly, AA | 1 |
| Ebeid, FS | 1 |
| Teawtrakul, N | 1 |
| Jetsrisuparb, A | 2 |
| Sirijerachai, C | 1 |
| Chansung, K | 1 |
| Wanitpongpun, C | 1 |
| Kumfu, S | 2 |
| Chattipakorn, SC | 2 |
| Fucharoen, S | 4 |
| Chattipakorn, N | 2 |
| Conte, R | 1 |
| Ruggieri, L | 1 |
| Gambino, A | 1 |
| Bartoloni, F | 1 |
| Baiardi, P | 1 |
| Bonifazi, D | 1 |
| Bonifazi, F | 1 |
| Felisi, M | 2 |
| Giannuzzi, V | 1 |
| Padula, R | 1 |
| Putti, MC | 1 |
| Del Vecchio, GC | 2 |
| Maggio, A | 3 |
| Filosa, A | 3 |
| Iacono, A | 1 |
| Mangiarini, L | 1 |
| Ceci, A | 2 |
| Kontoghiorghe, CN | 1 |
| Yadav, SP | 1 |
| Martin, M | 5 |
| Haines, D | 3 |
| El-Shazly, AA | 1 |
| Ebeid, WM | 1 |
| Elkitkat, RS | 1 |
| Deghedy, MR | 1 |
| Cappellini, MD | 2 |
| Furlan, L | 1 |
| Graziadei, G | 1 |
| Colombo, G | 1 |
| Forzenigo, LV | 1 |
| Solbiati, M | 1 |
| Peng, CT | 2 |
| Chang, JS | 1 |
| Tsai, CH | 2 |
| Lin, HS | 1 |
| Cinque, P | 1 |
| Lanza Galeota, A | 1 |
| Di Matola, T | 1 |
| Ammirabile, M | 1 |
| Prossomariti, L | 2 |
| Vitrano, A | 1 |
| Capra, M | 2 |
| Cuccia, L | 2 |
| Gagliardotto, F | 1 |
| Romeo, MA | 4 |
| Magnano, C | 1 |
| Caruso, V | 1 |
| Argento, C | 1 |
| Gerardi, C | 1 |
| Violi, P | 1 |
| Malizia, R | 1 |
| Cianciulli, P | 1 |
| Rizzo, M | 1 |
| D'Ascola, DG | 1 |
| Quota, A | 1 |
| Fidone, C | 1 |
| Rigano, P | 2 |
| D'Amico, G | 2 |
| Morabito, A | 2 |
| Gluud, C | 1 |
| Dahlui, M | 1 |
| Hishamshah, MI | 1 |
| Rahman, AJ | 1 |
| Aljunid, SM | 1 |
| Yazman, D | 1 |
| Economides, C | 4 |
| Eracleous, E | 4 |
| Chan, GC | 2 |
| Chan, S | 1 |
| Ho, PL | 1 |
| Ha, SY | 2 |
| Efstathiou, A | 1 |
| Michaelides, Y | 2 |
| Berdoukas, V | 3 |
| Carson, S | 1 |
| Nord, A | 1 |
| Dongelyan, A | 1 |
| Gavin, S | 1 |
| Hofstra, TC | 1 |
| Wood, JC | 2 |
| Coates, T | 3 |
| Komvilaisak, P | 1 |
| Wiangnon, S | 1 |
| Jetsrisuparb, C | 1 |
| Fragatou, S | 1 |
| Tsourveloudis, I | 1 |
| Manesis, G | 1 |
| Evans, P | 3 |
| Kayyali, R | 1 |
| Eccleston, J | 1 |
| Hershko, C | 12 |
| Piga, A | 12 |
| Roggero, S | 3 |
| Salussolia, I | 1 |
| Massano, D | 1 |
| Serra, M | 1 |
| Longo, F | 3 |
| Terpos, E | 1 |
| Voskaridou, E | 1 |
| Ward, R | 1 |
| Shah, FT | 2 |
| Farmaki, K | 1 |
| Lee, WS | 1 |
| Toh, TH | 1 |
| Chai, PF | 1 |
| Soo, TL | 1 |
| Trachtenberg, F | 1 |
| Vichinsky, E | 2 |
| Pakbaz, Z | 2 |
| Mednick, L | 2 |
| Sobota, A | 2 |
| Kwiatkowski, J | 1 |
| Thompson, AA | 2 |
| Porter, J | 2 |
| Giardina, PJ | 8 |
| Olivieri, N | 5 |
| Yamashita, R | 2 |
| Neufeld, EJ | 2 |
| Mavrogeni, S | 1 |
| Torcharus, K | 1 |
| Pankaew, T | 1 |
| Antes, G | 1 |
| Fleeman, N | 1 |
| Flaten, TP | 1 |
| Aaseth, J | 1 |
| Andersen, O | 1 |
| Gaur, A | 1 |
| Elborai, Y | 1 |
| Uwumugambi, A | 1 |
| Lehmann, L | 1 |
| Lal, A | 1 |
| Sweeters, N | 1 |
| Ng, V | 1 |
| Neumayr, L | 1 |
| Kurio, G | 1 |
| Harmatz, P | 2 |
| Trachtenberg, FL | 1 |
| Quinn, CT | 1 |
| Grady, R | 1 |
| Horne, R | 1 |
| Davis, BA | 2 |
| Miskin, H | 1 |
| Yaniv, I | 1 |
| Berant, M | 1 |
| Tamary, H | 1 |
| Bansal, V | 1 |
| Elgarbly, I | 1 |
| Ghanchi, FD | 1 |
| Atkinson, PL | 1 |
| Neocleous, K | 1 |
| REWALD, EF | 1 |
| WOEHLER, F | 2 |
| RAY, RN | 1 |
| CHATTERJEA, JB | 1 |
| GHOSH, SK | 1 |
| CARLOS, AG | 1 |
| SOARES, AD | 1 |
| SCOVILLE, B | 1 |
| BORCHERS, HG | 1 |
| SCHAUER, A | 1 |
| REWALD, E | 1 |
| SCURO, LA | 1 |
| BROCCIA, G | 1 |
| DOBRILLA, G | 1 |
| TAGLIAMONTE, A | 1 |
| ROMANO, C | 1 |
| MASSIMO, L | 1 |
| TORTOROLO, G | 1 |
| STEINER, M | 1 |
| BALDINI, M | 1 |
| DAMESHEK, W | 1 |
| ERLANDSON, ME | 1 |
| GOLUBOW, J | 1 |
| WEHMAN, J | 1 |
| SMITH, CH | 1 |
| SMITH, RS | 1 |
| MOESCHLIN, S | 1 |
| SCHNIDER, U | 1 |
| RITTER, M | 1 |
| CHANTRAINE, JM | 1 |
| NEIMANN, N | 1 |
| PIERSON, M | 1 |
| MANCIAUX, M | 1 |
| VERT, P | 1 |
| SCHAACK, JC | 1 |
| De Sanctis, V | 7 |
| De Mattia, D | 2 |
| Di Stefano, M | 1 |
| Chiabotto, P | 1 |
| Roggia, C | 1 |
| Garofalo, F | 1 |
| Lala, R | 1 |
| Isaia, GC | 1 |
| Gomber, S | 2 |
| Saxena, R | 1 |
| Madan, N | 1 |
| Sodani, P | 2 |
| Gaziev, D | 3 |
| Polchi, P | 5 |
| Erer, B | 3 |
| Giardini, C | 4 |
| Angelucci, E | 5 |
| Baronciani, D | 4 |
| Andreani, M | 2 |
| Manna, M | 1 |
| Nesci, S | 1 |
| Lucarelli, B | 1 |
| Clift, RA | 1 |
| Lucarelli, G | 7 |
| D'Angelo, E | 1 |
| Mirra, N | 1 |
| Rocca, A | 1 |
| Carnelli, V | 1 |
| Ng, DM | 1 |
| Fong, DY | 1 |
| Lau, YL | 1 |
| Borgna-Pignatti, C | 4 |
| Rugolotto, S | 1 |
| De Stefano, P | 4 |
| Zhao, H | 1 |
| Forni, GL | 1 |
| Ghilardi, R | 1 |
| Cnaan, A | 1 |
| Anderson, LJ | 1 |
| Westwood, MA | 1 |
| Holden, S | 1 |
| Davis, B | 1 |
| Prescott, E | 1 |
| Wonke, B | 14 |
| Walker, JM | 1 |
| Pennell, DJ | 2 |
| Marletto, F | 1 |
| Sacchetti, L | 3 |
| Rees, D | 1 |
| Howard, J | 2 |
| Hyde, C | 1 |
| Alderson, P | 1 |
| Brunskill, S | 1 |
| Link, G | 5 |
| Konijn, AM | 2 |
| Cabantchik, ZI | 1 |
| Rafique, R | 1 |
| Srichairatanakool, S | 2 |
| Hair, T | 1 |
| Vinciguerra, T | 1 |
| Gallo, V | 1 |
| Gaziev, J | 1 |
| Telfer, P | 2 |
| Constantinidou, G | 1 |
| Andreou, P | 1 |
| Christou, S | 2 |
| Modell, B | 9 |
| Angastiniotis, M | 2 |
| Fischer, R | 2 |
| Nielsen, P | 1 |
| Mudiyanse, RM | 1 |
| Coen, PG | 1 |
| Hadjigavriel, M | 1 |
| Kolnakou, A | 1 |
| Pangalou, E | 1 |
| Pavlides, N | 2 |
| Psiloines, M | 1 |
| Simamonian, K | 1 |
| Skordos, G | 1 |
| Sitarou, M | 1 |
| Galanello, R | 1 |
| Leoni, G | 1 |
| Ladis, V | 2 |
| Voi, V | 1 |
| Lund, U | 1 |
| Dewan, P | 1 |
| Hyde, CJ | 1 |
| Payne, KA | 1 |
| Desrosiers, MP | 1 |
| Caro, JJ | 1 |
| Baladi, JF | 3 |
| Lordan, N | 1 |
| Proskorovsky, I | 1 |
| Ishak, K | 1 |
| Rofail, D | 1 |
| Delea, TE | 2 |
| Edelsberg, J | 1 |
| Sofrygin, O | 1 |
| Thomas, SK | 2 |
| Phatak, PD | 2 |
| Coates, TD | 2 |
| Thephinlap, C | 1 |
| Phisalaphong, C | 1 |
| Hagiwara, M | 1 |
| Kidson-Gerber, GL | 1 |
| Francis, S | 1 |
| Lindeman, R | 1 |
| Kontos, C | 1 |
| Kyriacou, K | 1 |
| Manz, C | 1 |
| Naja, M | 1 |
| Eltagui, M | 1 |
| Tarabishi, C | 1 |
| Youssry, I | 1 |
| Sobh, H | 1 |
| Sharaf, I | 1 |
| Mostafa, A | 1 |
| Shaker, O | 1 |
| Taher, A | 2 |
| Carcassi, U | 1 |
| Bannerman, RM | 1 |
| Keusch, G | 1 |
| Kreimer-Birnbaum, M | 1 |
| Vance, VK | 1 |
| Vaughan, S | 1 |
| Wöhler, F | 1 |
| Gyftaki, H | 1 |
| Kesse-Elias, M | 1 |
| Constantoulakis, M | 2 |
| Malamos, B | 1 |
| Cohen, A | 11 |
| Witzleben, C | 1 |
| Schwartz, E | 12 |
| Callender, ST | 8 |
| Weatherall, DJ | 9 |
| Kattamis, C | 3 |
| Fitsialos, J | 1 |
| Sinopoulou, C | 1 |
| Smith, GN | 1 |
| Davies, SC | 3 |
| Marcus, RE | 3 |
| Hungerford, JL | 1 |
| Miller, MH | 1 |
| Arden, GB | 2 |
| Huehns, ER | 6 |
| Bousquet, J | 1 |
| Navarro, M | 1 |
| Robert, G | 1 |
| Aye, P | 1 |
| Michel, FB | 1 |
| Robins-Browne, RM | 1 |
| Prpic, JK | 1 |
| Gordts, B | 1 |
| Rummens, E | 1 |
| deMeirleir, L | 1 |
| Butzler, JP | 1 |
| Bantock, HM | 1 |
| Underwood, SR | 1 |
| Walton, S | 1 |
| Broglia, AM | 1 |
| Scharnetzky, M | 1 |
| König, R | 4 |
| Lakomek, M | 1 |
| Tillmann, W | 7 |
| Schröter, W | 8 |
| Triadou, P | 3 |
| Girot, R | 11 |
| Lapoumeroulie, C | 1 |
| Pomarede, R | 2 |
| Constant, S | 2 |
| Nienhuis, AW | 6 |
| Anagnou, NP | 1 |
| Ley, TJ | 1 |
| Peter, HH | 1 |
| Engle, MA | 3 |
| Ehlers, KH | 4 |
| O'Loughlin, JE | 1 |
| Hilgartner, MW | 7 |
| Propper, R | 2 |
| Nathan, D | 2 |
| North, ML | 1 |
| Lang, JM | 1 |
| Bergerat, JP | 1 |
| Giron, C | 1 |
| Oberling, F | 1 |
| Mayer, S | 1 |
| McLaren, GD | 1 |
| Muir, WA | 1 |
| Kellermeyer, RW | 1 |
| Beck, W | 1 |
| Roeser, HP | 1 |
| Martin, K | 1 |
| Bianco, I | 4 |
| Graziani, B | 3 |
| Lerone, M | 2 |
| Congedo, P | 2 |
| Clemente, GF | 1 |
| Ingrao, G | 1 |
| Ciccone, F | 1 |
| Di Nucci, GD | 1 |
| Mandelli, F | 1 |
| Isacchi, G | 1 |
| Di Gregorio, F | 4 |
| Schiliro, G | 4 |
| Cerami, A | 4 |
| Grady, RW | 7 |
| Peterson, CM | 2 |
| Bhargava, KK | 2 |
| Rappaport, R | 1 |
| Gibertini, P | 1 |
| Rocchi, E | 1 |
| Cassanelli, M | 1 |
| Pietrangelo, A | 1 |
| Ventura, E | 1 |
| Krüger, N | 4 |
| Kijewski, H | 1 |
| Kennedy, C | 1 |
| Poncz, M | 1 |
| Meadows, K | 1 |
| Freeman, AP | 2 |
| Giles, RW | 2 |
| Berdoukas, VA | 3 |
| Walsh, WF | 1 |
| Choy, D | 1 |
| Murray, PC | 1 |
| Biener, R | 1 |
| Freundlich, E | 2 |
| Rachmilewitz, E | 1 |
| Petrou, M | 2 |
| Forteleoni, G | 1 |
| Pacitti, C | 1 |
| Mulas, G | 1 |
| Careddu, F | 1 |
| Antona, C | 1 |
| Luscrì, MF | 1 |
| Cressie, NA | 1 |
| Sheffield, LJ | 1 |
| Whitford, HJ | 1 |
| Pippard, MJ | 14 |
| Hathirat, P | 4 |
| Sasanakul, W | 2 |
| Areekul, S | 3 |
| Chantachum, Y | 2 |
| Isarangkura, P | 4 |
| Cavallo, L | 2 |
| Mautone, A | 3 |
| Altomare, M | 3 |
| Licciulli, M | 1 |
| Pascazio, A | 1 |
| Schettini, F | 4 |
| Cantore, N | 1 |
| Tortarolo, M | 1 |
| Volpe, E | 1 |
| Gonnella, F | 1 |
| Valente, A | 1 |
| Buonanno, G | 1 |
| Montagna, O | 1 |
| Dell'Edera, L | 1 |
| De Virgiliis, S | 6 |
| Cossu, P | 4 |
| Sanna, G | 5 |
| Frau, F | 5 |
| Loi, E | 1 |
| Lobrano, R | 3 |
| Nucaro, A | 4 |
| Toccafondi, C | 4 |
| Cornacchia, G | 4 |
| Loi, A | 3 |
| Cao, A | 6 |
| Letsky, EA | 3 |
| Flynn, DM | 10 |
| Peto, R | 1 |
| Murray, JA | 1 |
| Silvestroni, E | 3 |
| Valente, M | 1 |
| Ponzini, D | 1 |
| Costantini, S | 2 |
| Politis, D | 2 |
| Argiolu, F | 4 |
| Rais, M | 1 |
| Ferreli, A | 1 |
| Erttmann, R | 1 |
| Hausdorf, G | 1 |
| Landbeck, G | 1 |
| Bertolino, F | 2 |
| Huebers, H | 1 |
| Dolfin, G | 1 |
| Lumare, A | 1 |
| Tinetti, E | 1 |
| Monetti, C | 1 |
| Jacob, R | 1 |
| Martoglio, G | 1 |
| Brown, EB | 3 |
| Propper, RD | 4 |
| Griffith, P | 1 |
| Strawczynski, H | 1 |
| Henry, W | 2 |
| Borer, J | 1 |
| Leon, M | 1 |
| Anderson, WF | 3 |
| Piomelli, S | 8 |
| Graziano, J | 2 |
| Karpatkin, M | 3 |
| Dudell, GG | 1 |
| Hart, D | 2 |
| Hilgartner, M | 2 |
| Khanna, K | 1 |
| Valdes-Cruz, LM | 1 |
| Vora, S | 1 |
| Aloia, JF | 1 |
| Ostuni, JA | 1 |
| Yeh, JK | 2 |
| Zaino, EC | 2 |
| Siller, V | 1 |
| Frank, M | 1 |
| Economidou, J | 3 |
| Ridley, CM | 1 |
| Schröder, K | 1 |
| Finch, CA | 1 |
| Bosi, S | 1 |
| Spinolo, L | 1 |
| Cavallini, B | 1 |
| Guadagni, C | 1 |
| Lama, A | 1 |
| Santarelli, R | 1 |
| Baccini, C | 1 |
| Bories, D | 1 |
| Jeannel, F | 2 |
| Thevenin, M | 2 |
| Rymer, JC | 2 |
| Fargion, S | 1 |
| Taddei, MT | 1 |
| Gabutti, V | 6 |
| Di Palma, A | 4 |
| Capra, L | 1 |
| Fontanelli, G | 1 |
| Avanzini, A | 1 |
| Lovejoy, FH | 1 |
| Graziano, JH | 6 |
| Giardina, P | 2 |
| Andrew, M | 1 |
| LoIacono, N | 1 |
| Seaman, C | 2 |
| Vardeu, F | 1 |
| Janka, GE | 1 |
| Möhring, P | 1 |
| Helmig, M | 1 |
| Haas, RJ | 1 |
| Betke, K | 1 |
| Marsh, MN | 1 |
| Holbrook, IB | 1 |
| Clark, C | 1 |
| Shaffer, JL | 1 |
| Pisano, GF | 1 |
| Binaghi, F | 1 |
| Putzu, ML | 1 |
| Bragotti, R | 1 |
| Manconi, E | 1 |
| Urgu, G | 1 |
| Pitzus, F | 1 |
| Saenger, P | 1 |
| Markenson, AL | 2 |
| Levine, LS | 1 |
| New, MI | 1 |
| Matthews, RN | 2 |
| Bouveret, JP | 1 |
| Halliday, JW | 1 |
| Bassett, ML | 1 |
| Thomas, RM | 1 |
| Skalicka, AE | 1 |
| Balducci, G | 1 |
| Antonelli, GF | 1 |
| Di Lecce, A | 1 |
| Lévy, G | 1 |
| Bachelot, C | 2 |
| Joannard, A | 1 |
| Bost, M | 1 |
| Benso, L | 1 |
| Gambotto, S | 2 |
| Pastorin, L | 1 |
| Signorile, F | 1 |
| Tanner, JM | 1 |
| Galimberti, M | 3 |
| La Nasa, G | 1 |
| Barbanti, I | 2 |
| Mehta, J | 1 |
| Chablani, A | 1 |
| Reporter, R | 1 |
| Singhal, S | 1 |
| Mehta, BC | 1 |
| al-Refaie, FN | 3 |
| Wickens, DG | 2 |
| Aydinok, Y | 1 |
| Fielding, A | 1 |
| Leonardi, S | 1 |
| Musumeci, S | 1 |
| Cunningham, JM | 1 |
| Hunter, AE | 1 |
| Sheppard, LN | 1 |
| Martinelli, F | 1 |
| Baldassarri, M | 1 |
| Muretto, P | 3 |
| Kobayashi, M | 1 |
| Yano, K | 1 |
| Fujisawa, S | 1 |
| Töndury, P | 2 |
| Lombardo, T | 1 |
| Frontini, V | 1 |
| Ferro, G | 1 |
| Sergi, P | 1 |
| Guidice, A | 1 |
| Lombardo, G | 1 |
| Dogherty, P | 1 |
| Einarson, T | 1 |
| Koren, G | 10 |
| Sher, G | 1 |
| Ripalti, M | 1 |
| Cabantchik, I | 1 |
| Leonardi, C | 1 |
| Sciuto, C | 1 |
| Cannella, A | 1 |
| Pizzarelli, G | 1 |
| Salhi, Y | 1 |
| Costagliola, D | 1 |
| Rebulla, P | 1 |
| Dessi, C | 2 |
| Karagiorga, M | 2 |
| Lena-Russo, D | 1 |
| de Montalembert, M | 3 |
| Wright, C | 1 |
| Chamoun, FM | 1 |
| Koussa, S | 1 |
| Saad, MA | 1 |
| Khoriaty, AI | 1 |
| Neeman, R | 1 |
| Mourad, FH | 1 |
| Savarino, L | 2 |
| Stea, S | 2 |
| Cervellati, M | 1 |
| Ciapetti, G | 1 |
| Tassinari, L | 1 |
| Pizzoferrato, A | 2 |
| Granchi, D | 1 |
| Visentin, M | 1 |
| Sprocati, M | 1 |
| Govoni, R | 1 |
| Pafumi, C | 1 |
| Zizza, G | 1 |
| Caruso, S | 1 |
| Todaro, AM | 1 |
| Pernicone, G | 1 |
| Bandiera, S | 1 |
| Farina, M | 1 |
| Russo, A | 3 |
| Di Maio, S | 1 |
| Esposito, G | 1 |
| De Martinis, F | 1 |
| De Terlizzi, F | 1 |
| Richardson, DR | 1 |
| Rouan, MC | 1 |
| Marfil, F | 1 |
| Mangoni, P | 1 |
| Séchaud, R | 1 |
| Humbert, H | 1 |
| Maurer, G | 1 |
| Palagiano, A | 1 |
| Pace, L | 1 |
| Dinopoulos, A | 1 |
| Berdousi, H | 1 |
| Hagège, I | 1 |
| Becker, A | 1 |
| Kerdaffrec, T | 1 |
| Kanfer, A | 1 |
| Hussain, MA | 3 |
| Green, N | 2 |
| Hussein, S | 1 |
| Warner, GT | 1 |
| Batey, R | 2 |
| Carboni, C | 1 |
| Gorman, A | 1 |
| Laulicht, M | 2 |
| Garidi, M | 1 |
| Georgipoulou, P | 1 |
| Houang, MT | 1 |
| Arozena, X | 1 |
| Skalicka, A | 1 |
| Shaw, DG | 1 |
| Jones, RL | 1 |
| Kokkini, G | 1 |
| Loukopoulos, D | 1 |
| Cividalli, G | 1 |
| Gertner, JM | 1 |
| Broadus, AE | 1 |
| Anast, CS | 1 |
| Grey, M | 1 |
| Pearson, H | 1 |
| Genel, M | 1 |
| Cromdos, S | 1 |
| O'Brien, RT | 4 |
| Bothwell, TH | 1 |
| Charlton, RW | 1 |
| Scott, J | 1 |
| Jain, S | 1 |
| Sherlock, S | 1 |
| Levine, HG | 1 |
| Hanan, ZI | 1 |
| Gordon, FS | 1 |
| Tomasulo, WJ | 1 |
| Rachmilewitz, EA | 5 |
| Barcellona, R | 2 |
| Masseria, R | 2 |
| Palmigiano, C | 2 |
| Amato, GM | 2 |
| Summers, MR | 1 |
| Jacobs, A | 1 |
| Tudway, D | 1 |
| Perera, P | 1 |
| Ricketts, C | 1 |
| Zuppinger, K | 2 |
| Molinari, B | 1 |
| Hirt, A | 1 |
| Imbach, P | 2 |
| Gugler, E | 1 |
| Tönz, O | 1 |
| Zurbrügg, RP | 1 |
| Bender-Götze, C | 1 |
| Lagos, P | 1 |
| Langona, E | 1 |
| Cooper, B | 2 |
| Bunn, HF | 2 |
| Nathan, DG | 7 |
| Rosenthal, DS | 1 |
| Moloney, WC | 1 |
| Kaye, SB | 1 |
| Owen, M | 1 |
| Markenson, A | 1 |
| Miller, DR | 1 |
| Chang, H | 1 |
| Bestak, M | 1 |
| Meyers, P | 1 |
| Pisciotto, P | 1 |
| Rifkind, A | 1 |
| Weiner, M | 1 |
| Vora, SK | 1 |
| Henry, WL | 1 |
| Cartei, G | 1 |
| Cazzavillan, M | 1 |
| Chisesi, T | 1 |
| Battista, R | 1 |
| Barbui, T | 1 |
| Dini, E | 1 |
| Fairbanks, VF | 1 |
| Esposito, L | 1 |
| Ferrara, M | 1 |
| Galdo Capotorti, M | 1 |
| Pignatti, CB | 1 |
| Young, N | 1 |
| Matthews, R | 1 |
| Delea, C | 1 |
| Aamodt, R | 1 |
| Bartter, F | 1 |
| Rufo, RR | 1 |
| Rosenthal, A | 1 |
| Pollack, S | 1 |
| Aisen, P | 1 |
| Lasky, FD | 1 |
| Vanderhoff, G | 1 |
| Modell, CB | 4 |
| Pearson, HA | 1 |
| Forget, BG | 1 |
| Risdon, RA | 2 |
| Barry, M | 2 |
| Shurin, SB | 1 |
| Chan, KW | 1 |
| Bond, M | 1 |
| Fernandez, W | 1 |
| Berriman, AM | 1 |
| Tyler, BJ | 1 |
| Davis, SA | 1 |
| Francombe, WH | 2 |
| Liu, PP | 1 |
| Orzincolo, C | 1 |
| Scutellari, PN | 1 |
| Castaldi, G | 1 |
| Harris, J | 1 |
| Khattak, S | 1 |
| Freedman, MH | 12 |
| Templeton, DM | 4 |
| Bailey, JD | 1 |
| Reilly, BJ | 1 |
| Ampel, NM | 1 |
| Bejarano, GC | 1 |
| Saavedra, M | 1 |
| Orvieto, R | 1 |
| Leichter, I | 1 |
| Margulies, JY | 1 |
| Jan, D | 1 |
| Clairicia, M | 1 |
| Hannedouche, T | 2 |
| Sidi, D | 1 |
| Angelides, NS | 1 |
| Angastiniotis, C | 1 |
| Nortey, P | 1 |
| Triantafyllou, N | 1 |
| Fisfis, M | 1 |
| Sideris, G | 1 |
| Triantafyllou, D | 1 |
| Rombos, A | 1 |
| Vrettou, H | 1 |
| Mantouvalos, V | 1 |
| Politi, C | 1 |
| Malliara, S | 1 |
| Papageorgiou, C | 1 |
| Kiel, E | 1 |
| Schelle, H | 1 |
| Kochavi-Atiya, Y | 1 |
| Bentur, Y | 6 |
| Chandy, M | 1 |
| Papageorgiou, O | 1 |
| Papanastasiou, DA | 1 |
| Beratis, NG | 1 |
| Korovessis, P | 1 |
| Oikonomopoulos, A | 1 |
| Mazzoleni, G | 1 |
| deSa, D | 1 |
| Gately, J | 1 |
| Riddell, RH | 1 |
| Loew, T | 1 |
| Abcarian, PW | 1 |
| Demas, BE | 1 |
| Brill, PW | 1 |
| Winchester, P | 1 |
| Cunningham-Rundles, S | 1 |
| Vannasaeng, S | 1 |
| Pootrakul, P | 1 |
| Ploybutr, S | 1 |
| Yansukon, P | 1 |
| de Sousa, M | 1 |
| Reimão, R | 1 |
| Porto, G | 1 |
| Jacobs, P | 1 |
| Wood, L | 1 |
| Bird, AR | 1 |
| Ultmann, JE | 1 |
| Hermann, C | 2 |
| Chung, D | 2 |
| Klein, J | 3 |
| St Louis, P | 2 |
| McClelland, RA | 3 |
| Castriota Scanderbeg, A | 1 |
| Izzi, GC | 1 |
| Butturini, A | 1 |
| Benaglia, G | 1 |
| Lesser, ML | 1 |
| Diana, G | 2 |
| Avignone, A | 1 |
| Di Ninni, S | 1 |
| Perrimond, H | 3 |
| Chagnon, C | 1 |
| Moulanier, I | 1 |
| Michel, G | 1 |
| Guidicelli, H | 1 |
| Bernard, PJ | 2 |
| Speer, CP | 1 |
| Gahr, M | 1 |
| Schuff-Werner, P | 1 |
| Aldouri, MA | 4 |
| Ward, SE | 2 |
| Agnew, JE | 1 |
| Hilson, AJ | 1 |
| Allegra, A | 1 |
| Pulejo, ML | 1 |
| Raineri, L | 1 |
| Corselli, F | 1 |
| Traina, MC | 1 |
| Giannola, C | 1 |
| La Grutta, A | 1 |
| Pierron, H | 1 |
| Gillet, R | 1 |
| Broudeur, JC | 1 |
| Soudry, G | 1 |
| Plantaz, D | 1 |
| Pinson, A | 2 |
| Sharma, BK | 1 |
| Choudhury, P | 1 |
| Dubey, AP | 1 |
| Fosburg, M | 1 |
| Wayne, A | 1 |
| Li Volti, S | 1 |
| Burstein, S | 1 |
| Cohen, AR | 2 |
| Lerner, N | 2 |
| Blei, F | 1 |
| Bierman, F | 1 |
| Johnson, L | 1 |
| Tesoro, A | 2 |
| Carley, H | 1 |
| Grisaru, D | 2 |
| MacLusky, I | 1 |
| Thorner, PS | 1 |
| Sabatino, D | 1 |
| Sorcinelli, R | 2 |
| Sitzia, A | 2 |
| Figus, A | 1 |
| Lai, ME | 1 |
| Mizanin, J | 5 |
| Konkle, DF | 1 |
| Bronspiegel-Weintrob, N | 1 |
| Tyler, B | 1 |
| Andrews, DF | 1 |
| Holland, FJ | 1 |
| Cantinieaux, B | 1 |
| Hariga, C | 1 |
| Ferster, A | 1 |
| Toppet, M | 1 |
| Fondu, P | 1 |
| Strong, D | 1 |
| Harvey, E | 1 |
| Baumal, R | 1 |
| Spielberg, SP | 1 |
| Vullo, C | 4 |
| Borgatti, L | 1 |
| Atti, G | 1 |
| Jaswon, MS | 1 |
| East, CA | 1 |
| Hazell, JW | 1 |
| Talley, PA | 1 |
| Murray, IP | 1 |
| Regnat-Lusinchi, A | 1 |
| Hyman, CB | 3 |
| Gonick, HC | 2 |
| Neufeld, N | 1 |
| Agness, CL | 2 |
| Poole, JE | 1 |
| Cohn, RJ | 1 |
| Roode, H | 1 |
| Spector, I | 1 |
| Politi, P | 1 |
| Capriotti, L | 1 |
| Salvadori, P | 1 |
| Dardanelli, C | 1 |
| Beratis, S | 1 |
| Llados, A | 1 |
| Leeder, JS | 1 |
| Freedman, M | 1 |
| Llados i Vallory, EA | 1 |
| Lenoir, G | 1 |
| Payet, M | 1 |
| Houze, P | 2 |
| Bourdon, R | 2 |
| Allen, CJ | 1 |
| Farrell, DE | 1 |
| Harris, JW | 1 |
| Sandri, A | 1 |
| Biginelli, M | 1 |
| Saracco, P | 1 |
| Ferri, M | 1 |
| Katz, M | 1 |
| Hoffbrand, VA | 1 |
| Bagni, B | 1 |
| Cesana, M | 1 |
| Mandelli, C | 1 |
| Tiribelli, C | 1 |
| Bianchi, PA | 1 |
| Conte, D | 1 |
| Aldouri, M | 1 |
| Wickens, D | 1 |
| Flynn, D | 1 |
| Stearns, M | 1 |
| Warner, P | 1 |
| Gayer, R | 1 |
| Chiu, HY | 1 |
| Kelly, D | 1 |
| Price, E | 1 |
| Wright, V | 1 |
| Walker-Smith, J | 1 |
| Rossiter, M | 1 |
| Wang, WC | 1 |
| Ahmed, N | 1 |
| Hanna, M | 2 |
| Fenton, LA | 1 |
| Scheuer, PJ | 1 |
| Kibbler, CC | 1 |
| Allwood, CA | 1 |
| Brown, D | 1 |
| Barr, J | 1 |
| Kourouclaris, T | 1 |
| Sheppard, L | 1 |
| Arcamone, G | 1 |
| Sabato, V | 1 |
| Burattini, MG | 1 |
| Fedele, F | 1 |
| Compagnone, A | 1 |
| Ciavarella, G | 1 |
| Congia, M | 2 |
| Cucca, F | 1 |
| Varsi, A | 1 |
| Podda, G | 1 |
| Fodde, M | 1 |
| Albera, R | 1 |
| Pia, F | 1 |
| Morra, B | 1 |
| Lacilla, M | 1 |
| Bianco, L | 1 |
| Dutta, AK | 1 |
| Ray, R | 1 |
| Chandra, S | 1 |
| Bhattacharya, DK | 1 |
| Masters, AP | 1 |
| Hopkinson, RB | 1 |
| van Deursen, CT | 1 |
| Goey, SH | 1 |
| Fickers, MM | 1 |
| Masala, W | 1 |
| Meloni, F | 1 |
| Gallisai, D | 1 |
| Careddu, M | 1 |
| Secchi, G | 1 |
| Cuccuru, GB | 1 |
| Loriga, V | 1 |
| Salvo, G | 1 |
| Kouides, PA | 1 |
| Slapak, CA | 1 |
| Rosenwasser, LJ | 1 |
| Miller, KB | 1 |
| Maurer, HS | 1 |
| Lloyd-Still, JD | 1 |
| Ingrisano, C | 1 |
| Gonzalez-Crussi, F | 1 |
| Honig, GR | 1 |
| Gelmi, C | 1 |
| Franchin, S | 1 |
| Tacchini, M | 1 |
| Trimarchi, F | 1 |
| Turco, MP | 1 |
| Luzzatto, L | 1 |
| Capalbo, P | 1 |
| Schindléry, C | 1 |
| Jackson, MJ | 2 |
| Kontopoulou-Griva, I | 1 |
| Hatzidimitriou-Papazacharia, K | 1 |
| Spiliotopoulou, J | 1 |
| Tsagarakis, N | 1 |
| Digenopoulou, E | 1 |
| Panthangkura, W | 1 |
| Chuansumrit, A | 1 |
| Kanasit, R | 1 |
| Pleehachinda, R | 1 |
| Tuntawiroon, M | 1 |
| Agness, C | 1 |
| Nadorra, R | 1 |
| Landing, B | 1 |
| Akbar, AN | 1 |
| Fitzgerald-Bocarsly, PA | 1 |
| Huang, CB | 1 |
| Löhr, H | 1 |
| Buncic, JR | 1 |
| Chew, E | 1 |
| Gallant, T | 2 |
| Harrison, RV | 1 |
| Keenan, N | 1 |
| Logan, W | 1 |
| Mitchell, D | 1 |
| Ricci, G | 1 |
| Skarf, B | 1 |
| Stubbe, P | 2 |
| D'Ascola, G | 1 |
| Zeĭnalova, AA | 1 |
| Ragimov, AA | 1 |
| Dashkova, NG | 2 |
| Mamedova, FR | 1 |
| Kurbanova, SA | 1 |
| Chiesa, C | 1 |
| Pacifico, L | 1 |
| Renzulli, F | 1 |
| Midulla, M | 1 |
| Garlaschi, L | 1 |
| Azzia, N | 1 |
| Mancuso, GR | 1 |
| Fallico, R | 1 |
| Sciacca, S | 1 |
| Barratt, PS | 1 |
| Toogood, IR | 1 |
| Babiker, MA | 1 |
| Patel, PJ | 1 |
| Karrar, ZA | 1 |
| Hafeez, MH | 1 |
| Efendieva, EG | 1 |
| Vellend, H | 1 |
| Hoffman, K | 1 |
| Greif, Z | 1 |
| Heno, N | 1 |
| Said, N | 1 |
| Goldfarb, AW | 1 |
| Gotsman, MS | 1 |
| Hasin, Y | 1 |
| Ahmed, NK | 1 |
| Wang, W | 1 |
| Bourdon, S | 1 |
| Abreu de Miani, MS | 1 |
| Sanchis de Herrlein, MS | 1 |
| Peñalver, JA | 1 |
| Wolfe, L | 2 |
| Sallan, D | 2 |
| Rodriguez-Funes, R | 1 |
| Zednikova, M | 1 |
| Ropars, C | 1 |
| Teisseire, B | 1 |
| Avenard, G | 1 |
| Chassaigne, M | 1 |
| Hurel, C | 1 |
| Nicolau, C | 1 |
| Aloia, J | 1 |
| Festa, RS | 1 |
| McCullough, J | 1 |
| Jacob, HS | 1 |
| Kanz, L | 1 |
| Arnold, H | 1 |
| Löhr, GW | 1 |
| Zonta, L | 1 |
| Melevendi, C | 1 |
| Naselli, A | 1 |
| Masera, G | 1 |
| Terzoli, S | 1 |
| Colan, S | 1 |
| Rose, V | 1 |
| Orton, RB | 1 |
| de Veber, LL | 1 |
| Sulh, HM | 1 |
| Ullrich, D | 1 |
| Flückiger, A | 1 |
| Pfenninger, E | 1 |
| Stocker, F | 1 |
| Wagner, HP | 1 |
| Weber, J | 1 |
| Mancuso, L | 1 |
| Iacona, MA | 1 |
| Marchi, S | 1 |
| Geraci, E | 1 |
| Orsini, A | 3 |
| Mattei, M | 1 |
| Khutsishvili, GE | 1 |
| Beard, ME | 1 |
| Necheles, TF | 1 |
| Allen, DM | 1 |
| Masi, M | 1 |
| Seshadri, R | 3 |
| Colebatch, JH | 3 |
| Gordon, P | 1 |
| Ekert, H | 1 |
| Katsantoni, A | 1 |
| Gyftaki, E | 1 |
| Beck, J | 1 |
| Fisher, R | 1 |
| Stockman, JA | 1 |
| Oski, FA | 1 |
| Turbina, NS | 1 |
| Waxman, HS | 1 |
| Phlippen, R | 1 |
| Bonduel, A | 1 |
| Wolman, IJ | 1 |
| Ortolani, M | 1 |
| Wolff, JA | 1 |
| Luke, KH | 1 |
| Danoff, SJ | 1 |
| Becker, MH | 1 |
| Lipera, MJ | 1 |
| Travis, SF | 1 |
| Singh, AK | 1 |
| Bianco, G | 1 |
| Gallo, E | 1 |
| Ramello, A | 1 |
| Ricco, G | 1 |
| Matone, S | 1 |
| Duverne, J | 1 |
| Brizard, CP | 1 |
| Mounier, R | 1 |
| Taccone, F | 1 |
| Monaco, L | 1 |
| Raybaud, C | 1 |
| Aquaron, R | 1 |
| Passeron, P | 2 |
| Diwany, M | 1 |
| Gabr, M | 1 |
| el Hefni, A | 1 |
| Mokhtar, N | 1 |
| Cimino, R | 1 |
| Quattrin, N | 1 |
| Brüster, H | 1 |
| Giraud, F | 1 |
| Bernard, P | 1 |
| McDonald, R | 1 |
| Leggio, ML | 1 |
| Manassero, J | 1 |
| Eskenazi, R | 1 |
| Maissa, S | 1 |
| De Luca, G | 1 |
| Faelli, U | 1 |
| Petrussa, I | 1 |
| Kirimlidis, S | 1 |
| Philippidis, P | 1 |
| Drossos, C | 1 |
| Economidis, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Efficacy and Safety of Ferriprox® for the Treatment of Transfusional Iron Overload in Patients With Sickle Cell Disease or Other Anemias[NCT02041299] | Phase 4 | 230 participants (Actual) | Interventional | 2014-04-17 | Terminated (stopped due to Difficulties with additional recruitment as pool of potential patients was exhausted, and sufficient information for determination of study outcome measure was already obtained) | ||
| Quality of Life and Treatment Satisfaction in β-Thalassemia Patients Receiving Deferasirox[NCT03358498] | 75 participants (Anticipated) | Observational | 2017-12-01 | Not yet recruiting | |||
| A Randomized, Open-label, Multicenter, Two Arm, Phase II Study to Investigate the Benefits of an Improved Deferasirox Formulation (Film-coated Tablet)[NCT02125877] | Phase 2 | 173 participants (Actual) | Interventional | 2014-07-08 | Completed | ||
| Phase IV Study of the Use of Sequential DFP-DFO Versus DFP in Thalassemia Major Patients[NCT00733811] | Phase 4 | 213 participants (Actual) | Interventional | 2000-09-30 | Completed | ||
| Safety of Deferasirox (ICL670) and Deferoxamine (Desferal or DFO) Combined Chelation Therapy in Patients With Transfusion Dependent Thalassemia and Iron Overload[NCT00901199] | Phase 2 | 22 participants (Actual) | Interventional | 2007-09-30 | Completed | ||
| A Longitudinal Cohort Study of Patients With Thalassemia in the Thalassemia Clinical Research Network[NCT00661804] | 416 participants (Actual) | Observational | 2007-05-31 | Completed | |||
| Iron-mediated Vascular Disease in Sickle Cell Disease.[NCT01239901] | 150 participants (Actual) | Observational | 2009-12-31 | Completed | |||
| Randomized Open-label Phase III Study With Deferiprone and/or Desferrioxamine in Iron Overloaded Patients[NCT00350662] | Phase 3 | 95 participants (Actual) | Interventional | 2002-01-31 | Completed | ||
| A Pilot Study of 5-Azacytidine and Oral Sodium Phenylbutyrate in Severe Thalassemia[NCT00005934] | Phase 2 | 24 participants | Interventional | 2000-06-30 | Completed | ||
| Effect of Hydroxyurea on the Level of Ineffective Erythropoiesis, Transfusion Requirement, and Fetal Hemoglobin Synthesis in Patients With Beta-Thalassemia-Intermedia[NCT00001958] | Phase 2 | 100 participants | Interventional | 1999-12-31 | Completed | ||
| [NCT00000595] | Phase 2 | 0 participants | Interventional | 1978-01-31 | Completed | ||
| The Effect of Treatment With the Oral Iron Chelator Deferiprone on the Oxidative Stress of Blood Cells and on Iron Overload Status in Transfusion Dependent, Iron-overloaded Patients With Low Risk Myelodysplastic Syndrome[NCT02477631] | Phase 2 | 19 participants (Actual) | Interventional | 2016-02-29 | Completed | ||
| Double-blind, Randomized, Placebo Controlled, Dose-finding Phase 2 Clinical Trial of Intravenous Deferoxamine in Patients With Acute Ischemic Stroke Treated With Tissue Plasminogen Activator[NCT00777140] | Phase 2 | 62 participants (Actual) | Interventional | 2008-09-30 | Completed | ||
| Safety & Efficacy of Thalidomide in Children With Transfusion Dependent Thalassemia: a Quasi Randomized Control Trial in a Tertiary Care Hospital in Bangladesh[NCT06098014] | Phase 3 | 60 participants (Anticipated) | Interventional | 2023-03-08 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Cardiac iron is measured by MRI in milliseconds (ms). A score of less than 20 ms is indicative of cardiac iron overload. (NCT02041299)
Timeframe: Change from baseline to Week 52
| Intervention | milliseconds (Least Squares Mean) |
|---|---|
| Deferiprone | -0.022068 |
| Deferoxamine | -0.021773 |
LIC was measured by MRI. A score >7 mg/g dw is indicative of iron overload. (NCT02041299)
Timeframe: Change from baseline to Week 52
| Intervention | mg of iron per gram of liver dry weight (Least Squares Mean) |
|---|---|
| Deferiprone | -4.13 |
| Deferoxamine | -4.38 |
Serum ferritin provides a measure of iron level in the blood. Normal levels of serum ferritin are under 300 µg/L for females and 400 µg/L for males. (NCT02041299)
Timeframe: Change from baseline to Week 52
| Intervention | micrograms per liter (Least Squares Mean) |
|---|---|
| Deferiprone | -385.83 |
| Deferoxamine | -760.89 |
Adult patients completed the SF-36 questionnaire and minors completed the CHQ-PF50. These questionnaires yield a profile of functional health and well-being, based on 8 scales of physical and mental health measures: Physical Functioning, Role Limitations due to Physical Health, Bodily Pain, General Health Perceptions, Vitality, Social Functioning, Role Limitations due to Emotional Problems, and Mental Health (MH), and summary scores are produced for physical well-being and mental well-being. The summaries are scored from 0-100, with higher scores reflecting better outcomes. (NCT02041299)
Timeframe: Change from baseline to Week 52
| Intervention | score on a scale (Mean) | |||
|---|---|---|---|---|
| SF-36 Physical Summary | SF-36 Mental Summary | CHQ-PF50 Physical Summary | CHQ-PF50 Psychosocial Summary | |
| Deferiprone | 43.1 | 44.7 | 29.3 | 42.5 |
| Deferoxamine | 43.0 | 40.9 | 30.5 | 41.3 |
Blood samples were collected to assess AUClast. (NCT02125877)
Timeframe: week 1, day 1: pre-dose (0 hour) and 1, 2, 3, 4, 8 and 24 hours post dose; week 3, day 1: pre-dose (0 hour) and 1, 2, 3, 4, 8 and 24 hours post dose
| Intervention | umol/L*h (Mean) | |
|---|---|---|
| week1 (n=14,15) | week 3 (n=13,15) | |
| Deferasirox Dispersible Tablet (DFX-DT) | 1110 | 1590 |
| Deferasirox Film-coated Tablet (DFX-FCT) | 1040 | 2110 |
Blood samples were collected to assess deferasirox concentration. Dose-adjusted calculations are presented: (concentration/actual dose)*20 for participants on DFX-DT and (concentration/actual dose)*14 for participants on DFX-FCT. (NCT02125877)
Timeframe: Week 3, day 1, pre-dose (0 hour (h)) and 2 h post-dose; week 13, day 1, pre-dose (0 hour (h)) and 2 h post-dose; and week 21, day 1, pre-dose (0 hour (h)) and 2 h post-dose
| Intervention | umol/L (Mean) | |||||
|---|---|---|---|---|---|---|
| week 3, pre-dose (n=63,70) | week 3, 2 hours post-dose (n=67,76) | week 13, pre-dose (n=69.56) | week 13, 2 hours post-dose (n=74,59) | week 21, pre-dose (n=54,59) | week 21, 2 hours post-dose (n=59,64) | |
| Deferasirox Dispersible Tablet (DFX-DT) | 39.6 | 80.8 | 37.1 | 78.7 | 46.6 | 89.8 |
| Deferasirox Film-coated Tablet (DFX-FCT) | 27.3 | 95.5 | 31.3 | 92.5 | 43.1 | 105 |
The percentage of participants with any GI adverse event, diarrhea, constipation, nausea, vomiting, abdominal pain was assessed. (NCT02125877)
Timeframe: 28 weeks
| Intervention | Percentage of participants (Number) | |||||
|---|---|---|---|---|---|---|
| Any GI adverse event | Abdominal pain | Constipation | Diarrhea | Nausea | Vomiting | |
| Deferasirox Dispersible Tablet (DFX-DT) | 61.6 | 26.7 | 15.1 | 34.9 | 26.7 | 22.1 |
| Deferasirox Film-coated Tablet (DFX-FCT) | 58.6 | 26.4 | 8.0 | 33.3 | 27.6 | 17.2 |
The modified SICT consisted of 13 items that represent 3 domains: adherence, satisfaction and concerns. The adherence domain consisted of 7 items, 6 which were measured using a 5-point response scale and was calculated by summing the 6 items. The score range from 6 to 30 and higher scores indicated worse adherence. The satisfaction domain consisted of 3 items, 2 which were measured using a 5-point response scale and was calculated by summing the 2 items. The score range from 2 to 10 and higher scores indicated worse satisfaction. The concerns domain consisted of 3 items to address any concerns or worries with his/her medication. All 3 items were measured on a 5-point response scale and were calculated by summing the 3 items. The score range from 3 to 15 and higher scores indicated fewer concerns. For all three domains, the meaningful difference between two treatment arms was determined to be 1 point. (NCT02125877)
Timeframe: weeks 2, 3, 13 and 24 (end of treatment or within 7 days of last dose)
| Intervention | score on a scale (Mean) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| week 2, adherence (n=70,70) | week 2, satisfaction/preference (n=70,70) | week 2, concerns (n=70,70) | week 3, adherence (n=58,51) | week 3, satisfaction/preference (n=58,51) | week 3, concerns (n=58,51) | week 13, adherence (n=59,64) | week 13, satisfaction/preference (n=59,64) | week 13, concerns (n=59,64) | week 24, adherence (n=63,60) | week 24, satisfaction/preference (n=63,60) | week 24, concerns (n=63,60) | |
| Deferasirox Dispersible Tablet (DFX-DT) | 10.3 | 5.2 | 12.9 | 10.9 | 5.4 | 12.4 | 11.2 | 5.4 | 12.7 | 12.5 | 5.8 | 11.8 |
| Deferasirox Film-coated Tablet (DFX-FCT) | 7.6 | 2.8 | 13.8 | 7.7 | 2.6 | 14.0 | 7.8 | 2.9 | 13.6 | 7.5 | 2.9 | 13.7 |
A compliance questionnaire assessed whether the medication was taken. Weekly average compliance was calculated when there were at least four non-missing daily responses. (NCT02125877)
Timeframe: Weeks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24
| Intervention | Participants (Number) | |||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| week 1 | week 2 | week 3 | week 4 | week 5 | week 6 | week 7 | week 8 | week 9 | week 10 | week 11 | week 12 | week 13 | week 14 | week 15 | week 16 | week 17 | week 18 | week 19 | week 20 | week 21 | week 22 | week 23 | week 24 | |
| Deferasirox Dispersible Tablet (DFX-DT) | 56 | 64 | 62 | 58 | 56 | 62 | 55 | 56 | 53 | 52 | 50 | 50 | 49 | 51 | 48 | 48 | 43 | 43 | 40 | 40 | 39 | 38 | 36 | 30 |
| Deferasirox Film-coated Tablet (DFX-FCT) | 53 | 64 | 56 | 58 | 58 | 51 | 48 | 46 | 45 | 46 | 42 | 41 | 47 | 42 | 42 | 40 | 39 | 38 | 37 | 36 | 36 | 34 | 33 | 24 |
Blood samples were collected to assess Cmax. (NCT02125877)
Timeframe: week 1, day 1: pre-dose (0 hour) and 1, 2, 3, 4, 8 and 24 hours post dose; week 3, day 1: pre-dose (0 hour) and 1, 2, 3, 4, 8 and 24 hours post dose
| Intervention | umol/L (Mean) | |
|---|---|---|
| week 1 (n=14,15) | week 3 (n=14,15) | |
| Deferasirox Dispersible Tablet (DFX-DT) | 74.6 | 118 |
| Deferasirox Film-coated Tablet (DFX-FCT) | 79.3 | 139 |
The percentage of participants with post-baseline laboratory values meeting specified criteria for notable/extended range was assessed. The following laboratory parameters were measured: platelet count, absolute neutrophils, serum creatinine , creatinine clearance, urinary protein/urinary creatinine ratio, alanine aminotransferase (ALT) and aspartate aminotransferase (AST). Note that within data categories, creat = creatinine, cons = consecutive, ULN = upper limit of normal and urin = urinary. (NCT02125877)
Timeframe: baseline (BL), 30 weeks
| Intervention | Percentage of participants (Number) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| platelet count, notable range: <100 x 10^9/L | platelet count, extended range: <50 x 10^9/L | absolute neutrophils, notable range: <1.5 x 10^9/L | absolute neut., extended range: <0.5 x 10^9/L | serum creat, 2 cons >33% incr. from BL and >ULN | creat clearance, notable range: 2 cons <60mL/min | creat clearance, extended range: 2 cons <40mL/min | urin protein/urin creat ratio, 2 cons >1.0 mg/mg | ALT, notable range: >5 x ULN and >2 x BL | ALT, extended range: >10 x ULN and >2 x BL | AST, notable range: >5 x ULN and >2 x BL | AST, extended range: >10 x ULN and >2 x BL | |
| Deferasirox Dispersible Tablet (DFX-DT) | 9.3 | 3.5 | 8.1 | 4.7 | 4.7 | 7.0 | 2.3 | 2.3 | 1.2 | 1.2 | 0 | 1.2 |
| Deferasirox Film-coated Tablet (DFX-FCT) | 8.0 | 5.7 | 13.8 | 0 | 3.4 | 2.3 | 2.3 | 0 | 1.1 | 0 | 1.1 | 0 |
The percentage of participants with adverse events, serious adverse events and deaths was assessed. (NCT02125877)
Timeframe: 28 weeks
| Intervention | Percentage of participants (Number) | ||
|---|---|---|---|
| Adverse events | SAEs | Deaths | |
| Deferasirox Dispersible Tablet (DFX-DT) | 89.5 | 15.1 | 0 |
| Deferasirox Film-coated Tablet (DFX-FCT) | 89.7 | 18.4 | 1.1 |
"The palatability questionnaire consisted of 4 items. The first item measured the taste and aftertaste of the medication and were scored a on a 5-point response scale. The second item offered an additional response option of no aftertaste. The last 2 items referred to whether the medication was taken, i.e. swallowed or vomited, and how the participant perceived the amount of medication to be taken. The palatability summary score was calculated using a scoring matrix from items 1, 3 and 4 scores and the score ranges from 0 - 11. Higher scores indicated the best palatability. A meaningful difference between two treatment arms was determined to be 1 point." (NCT02125877)
Timeframe: weeks 2, 3, 13 and 24 (end of treatment or within 7 days of last dose)
| Intervention | score on a scale (Mean) | |||
|---|---|---|---|---|
| week 2 (n=69,70) | week 3 (n=57,51) | week 13 (n=59,62) | week 24 (n=63,60) | |
| Deferasirox Dispersible Tablet (DFX-DT) | 9.0 | 8.8 | 9.3 | 8.8 |
| Deferasirox Film-coated Tablet (DFX-FCT) | 10.8 | 10.8 | 10.8 | 10.9 |
Blood samples were collected to assess Tmax. (NCT02125877)
Timeframe: week 1, day 1: pre-dose (0 hour) and 1, 2, 3, 4, 8 and 24 hours post dose; week 3, day 1: pre-dose (0 hour) and 1, 2, 3, 4, 8 and 24 hours post dose
| Intervention | hour (Median) | |
|---|---|---|
| week 1 (n=14,15) | week 3 (n=14,15) | |
| Deferasirox Dispersible Tablet (DFX-DT) | 3.57 | 2.85 |
| Deferasirox Film-coated Tablet (DFX-FCT) | 2.00 | 2.02 |
The GI symptom diary consisted of 6 items, five which were scored using a 0 - 10 rating scale with item appropriate anchors to rate the symptom, for example, Pain in your belly: 0 = no pain and 10 = worst pain. The GI diary summary score was created using the 10 point response scale for the 5 items. The GI symptom daily diary had a minimum score of 0 and a maximum score of 50. The weekly average score for the 7 days was calculated for each individual item and the GI summary score was created from these weekly averages. Higher scores indicated worse symptoms. A meaningful difference between two treatment arms was determined to be 0.3 point. (NCT02125877)
Timeframe: weeks -1, 4, 8, 12, 16, 20, 24
| Intervention | score on a scale (Mean) | ||||||
|---|---|---|---|---|---|---|---|
| week -1 (n=69,65) | week 4 (n=60,64) | week 8 (n=59,51) | week 12 (n=51,45) | week 16 (n=48,41) | week 20 (n40,39) | week 24 (n32,26) | |
| Deferasirox Dispersible Tablet (DFX-DT) | 1.4 | 1.8 | 1.4 | 1.7 | 1.9 | 1.5 | 1.5 |
| Deferasirox Film-coated Tablet (DFX-FCT) | 1.9 | 1.1 | 1.1 | 1.0 | 0.9 | 0.9 | 1.2 |
The dose violation is defined as a dose either missed completely or not taken in accordance with the timing instruction (no later than 12:00 pm. The rate was calculated as [number of dose violations/drug exposure (days)] x 100. (NCT02125877)
Timeframe: weeks 1, 4, 8, 12, 16, 20, 24
| Intervention | percent dose violation (Mean) | ||||||
|---|---|---|---|---|---|---|---|
| week 1 (n=56,53) | week 4 (n=58,58) | week 8 (n=56,46) | week 12 (n=50,41) | week 16 (n=48,40) | week 20 (n=40,36) | week 24 (n=30,24) | |
| Deferasirox Dispersible Tablet (DFX-DT) | 17.7 | 15.8 | 18.0 | 15.7 | 13.5 | 22.6 | 17.1 |
| Deferasirox Film-coated Tablet (DFX-FCT) | 15.8 | 6.7 | 8.4 | 10.7 | 10.0 | 11.3 | 10.1 |
Comparison of average serum creatinine over 12 months of combined chelation therapy compared with baseline serum creatinine. (NCT00901199)
Timeframe: 12 months
| Intervention | mg/dl (Mean) |
|---|---|
| Deferasirox (Exjade) and Desferal (DFO) | 0.09 |
Change in liver iron concentration from baseline to 12 months with the use of combined chelation therapy. The change was calculated as the liver iron concentration at 12 months minus the value at baseline. (NCT00901199)
Timeframe: 12 months
| Intervention | mg/g (Median) |
|---|---|
| Deferasirox (Exjade) and Desferal (DFO) | -6.2 |
82 reviews available for deferoxamine and Thalassemias
| Article | Year |
|---|---|
Benefits and Risks in Polypathology and Polypharmacotherapy Challenges in the Era of the Transition of Thalassaemia from a Fatal to a Chronic or Curable Disease.
Topics: Benzoates; Deferasirox; Deferiprone; Deferoxamine; Humans; Iron; Iron Chelating Agents; Pyridones; R | 2022 |
Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia.
Topics: Anemia, Sickle Cell; Chelating Agents; Chelation Therapy; Child; Deferoxamine; Drug-Related Side Eff | 2023 |
Clinical Challenges with Iron Chelation in Beta Thalassemia.
Topics: beta-Thalassemia; Deferiprone; Deferoxamine; Humans; Iron; Iron Chelating Agents; Iron Overload; Pyr | 2023 |
Deferasirox for managing iron overload in people with thalassaemia.
Topics: Administration, Oral; Benzoates; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as T | 2017 |
Efficacy and safety of iron chelators in thalassemia and sickle cell disease: a multiple treatment comparison network meta-analysis and trial sequential analysis.
Topics: Anemia, Sickle Cell; Benzoates; Deferasirox; Deferiprone; Deferoxamine; Drug Therapy, Combination; H | 2018 |
Comparison of Deferiprone to Deferasirox and Deferoxamine to Cardiac and Hepatic T2* MRI in Thalassemia Patients: Evidence-based Case Report.
Topics: Benzoates; Child; Deferasirox; Deferiprone; Deferoxamine; Drug Therapy, Combination; Heart; Humans; | 2018 |
The Role of Deferiprone in Iron Chelation.
Topics: Anemia, Sickle Cell; Chelation Therapy; Deferiprone; Deferoxamine; Drug Therapy, Combination; Erythr | 2018 |
Effectiveness and Safety of Deferasirox in Thalassemia with Iron Overload: A Meta-Analysis.
Topics: Databases, Factual; Deferasirox; Deferoxamine; Dose-Response Relationship, Drug; Humans; Iron; Iron | 2019 |
Management of the thalassemias.
Topics: Benzoates; Blood Transfusion; Deferasirox; Deferiprone; Deferoxamine; Ferritins; Humans; Iron; Iron | 2013 |
Desferrioxamine mesylate for managing transfusional iron overload in people with transfusion-dependent thalassaemia.
Topics: Benzoates; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Humans; Iron Chelating Agents; | 2013 |
Oral deferiprone for iron chelation in people with thalassaemia.
Topics: Administration, Oral; Chelation Therapy; Deferiprone; Deferoxamine; Humans; Iron Chelating Agents; I | 2013 |
Comparative efficacy and safety of deferoxamine, deferiprone and deferasirox on severe thalassemia: a meta-analysis of 16 randomized controlled trials.
Topics: Benzoates; Deferasirox; Deferiprone; Deferoxamine; Ferritins; Humans; Iron; Iron Chelating Agents; L | 2013 |
Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with non-transfusion-dependent thalassemia syndromes.
Topics: Benzoates; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Humans; Iron Chelating Agents; | 2016 |
Clinical Management of Patients With Thalassemia Syndromes.
Topics: Benzoates; Chelation Therapy; Deferoxamine; Female; Humans; Iron Chelating Agents; Iron Overload; Ma | 2016 |
Mechanisms of and obstacles to iron cardiomyopathy in thalassemia.
Topics: Blood Pressure; Cardiomyopathies; Deferoxamine; Electrocardiography; Heart; Heart Failure; Humans; I | 2008 |
An update on disordered iron metabolism and iron overload.
Topics: Animals; Blood Transfusion; Deferiprone; Deferoxamine; Drug Therapy, Combination; Humans; Iron; Iron | 2010 |
Iron overload in thalassemia and related conditions: therapeutic goals and assessment of response to chelation therapies.
Topics: Benzoates; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Ferritins; Humans; Iron; Iron | 2010 |
Deferasirox for managing iron overload in people with thalassaemia.
Topics: Benzoates; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deferasirox; Def | 2012 |
Iron mobilization using chelation and phlebotomy.
Topics: Benzoates; Deferasirox; Deferiprone; Deferoxamine; Humans; Iron; Iron Chelating Agents; Iron Overloa | 2012 |
Hematopoietic stem cell transplantation for thalassemia.
Topics: Blood Transfusion; Deferoxamine; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Hum | 2012 |
Results of long term iron chelation treatment with deferoxamine.
Topics: Deferoxamine; Ear, Inner; Endocrine System Diseases; Eye; Heart Diseases; History, 20th Century; Hum | 2002 |
Benefits and risks of deferiprone in iron overload in Thalassaemia and other conditions: comparison of epidemiological and therapeutic aspects with deferoxamine.
Topics: Deferoxamine; Erythrocyte Transfusion; Humans; Iron Chelating Agents; Iron Overload; Risk; Thalassem | 2003 |
Pharmacotherapy of iron overload in thalassaemic patients.
Topics: Clinical Trials as Topic; Deferiprone; Deferoxamine; Drug Therapy, Combination; Ferritins; Humans; I | 2003 |
Combined use of oral chelators and desferrioxamine in thalassemia.
Topics: Chelating Agents; Deferoxamine; Drug Therapy, Combination; Humans; Thalassemia; Treatment Outcome | 2005 |
Desferrioxamine mesylate for managing transfusional iron overload in people with transfusion-dependent thalassaemia.
Topics: Chelation Therapy; Deferiprone; Deferoxamine; Humans; Iron Chelating Agents; Iron Overload; Pyridone | 2005 |
Advances in iron overload therapies. prospects for effective use of deferiprone (L1), deferoxamine, the new experimental chelators ICL670, GT56-252, L1NA11 and their combinations.
Topics: Benzoates; Carboxylic Acids; Deferasirox; Deferiprone; Deferoxamine; Drug Therapy, Combination; Hemo | 2005 |
Objectives and mechanism of iron chelation therapy.
Topics: Animals; Benzoates; Cardiomyopathies; Cells, Cultured; Chelation Therapy; Clinical Trials as Topic; | 2005 |
Recent insights into interactions of deferoxamine with cellular and plasma iron pools: Implications for clinical use.
Topics: Animals; Body Fluid Compartments; Chelation Therapy; Chemical Phenomena; Chemistry, Physical; Defero | 2005 |
Combined therapy with deferoxamine and deferiprone.
Topics: Agranulocytosis; Biological Transport; Cardiomyopathies; Chelation Therapy; Clinical Trials as Topic | 2005 |
Deferiprone: New insight.
Topics: Agranulocytosis; Cardiomyopathies; Clinical Trials as Topic; Deferiprone; Deferoxamine; Follow-Up St | 2005 |
Quality of life in thalassemia.
Topics: Adolescent; Adult; Caregivers; Chelating Agents; Chelation Therapy; Child; Child, Preschool; Cyprus; | 2005 |
Monitoring long-term efficacy of iron chelation treatment with biomagnetic liver susceptometry.
Topics: Algorithms; Benzoates; Blood Transfusion; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; | 2005 |
T2* magnetic resonance and myocardial iron in thalassemia.
Topics: Adult; Calibration; Cardiomyopathies; Chelation Therapy; Child; Cohort Studies; Combined Modality Th | 2005 |
Future chelation monotherapy and combination therapy strategies in thalassemia and other conditions. comparison of deferiprone, deferoxamine, ICL670, GT56-252, L1NAll and starch deferoxamine polymers.
Topics: Benzoates; Carboxylic Acids; Chelation Therapy; Clinical Trials as Topic; Deferasirox; Deferiprone; | 2006 |
Oral deferiprone for iron chelation in people with thalassaemia.
Topics: Chelation Therapy; Deferiprone; Deferoxamine; Humans; Iron Chelating Agents; Iron Overload; Pyridone | 2007 |
Consequences and costs of noncompliance with iron chelation therapy in patients with transfusion-dependent thalassemia: a literature review.
Topics: Adolescent; Adult; Aged; Child; Child, Preschool; Cost of Illness; Deferiprone; Deferoxamine; Humans | 2007 |
Ethical issues and risk/benefit assessment of iron chelation therapy: advances with deferiprone/deferoxamine combinations and concerns about the safety, efficacy and costs of deferasirox.
Topics: Benzoates; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Drug Approval; Drug Therapy, C | 2008 |
Effects of chelation therapy on cardiac function improvement in thalassemia patients: literature review and the Taiwanese experience.
Topics: Cardiomyopathies; Chelation Therapy; Deferiprone; Deferoxamine; Ferritins; Humans; Iron; Iron Chelat | 2008 |
Treatment of iron overload.
Topics: Bloodletting; Carcinoma, Hepatocellular; Deferoxamine; Hemochromatosis; Humans; Liver; Liver Cirrhos | 1984 |
Advances in thalassemia research.
Topics: Animals; Base Sequence; Blood Transfusion; Bone Marrow Transplantation; Chemical Phenomena; Chemistr | 1984 |
[Iron chelation. Biological significance and medical application].
Topics: Animals; Bacterial Infections; Catechols; Deferoxamine; Diabetes Mellitus; Enterobactin; Female; Hum | 1983 |
Clinical removal of iron.
Topics: Adult; Anemia, Sideroblastic; Bloodletting; Carcinoma, Hepatocellular; Deferoxamine; Diet; Erythropo | 1982 |
Iron overload disorders: natural history, pathogenesis, diagnosis, and therapy.
Topics: Anemia, Hypochromic; Biological Transport; Bloodletting; Chelating Agents; Deferoxamine; Disease Mod | 1983 |
The role of ascorbic acid in the turnover of storage iron.
Topics: Adult; Animals; Ascorbic Acid; Deferoxamine; Ferritins; Guinea Pigs; Haplorhini; Hemochromatosis; He | 1983 |
Clinical management of thalassemia. The status of new iron chelators.
Topics: Animals; Chelating Agents; Chemical Phenomena; Chemistry; Cholic Acids; Deferoxamine; Drug Evaluatio | 1980 |
[Recommendations for therapy of juvenile thalassemia major].
Topics: Ascorbic Acid; Blood Transfusion; Child; Deferoxamine; Female; Germany, West; Greece; Hemosiderosis; | 1980 |
Recognition and treatment of iron overload.
Topics: Adult; Blood Grouping and Crossmatching; Bloodletting; Costs and Cost Analysis; Deferoxamine; Ethyle | 1980 |
Problems related to treatment of beta-thalassaemia major.
Topics: Adolescent; Adult; Bone Diseases; Child; Child, Preschool; Deferoxamine; Encephalitis; Female; Hormo | 1982 |
Chelation therapy in beta-thalassemia: the benefits and limitations of desferrioxamine.
Topics: Adolescent; Adult; Chelating Agents; Chelation Therapy; Child; Deferoxamine; Growth Disorders; Heari | 1995 |
Results of long-term iron-chelating therapy.
Topics: Adolescent; Adult; Deferoxamine; Female; Ferritins; Hemosiderosis; Humans; Iron Chelating Agents; Ma | 1996 |
Iron chelators for thalassaemia.
Topics: Administration, Oral; Aza Compounds; Chelating Agents; Deferiprone; Deferoxamine; Edetic Acid; Human | 1998 |
Pathophysiology of iron overload.
Topics: Animals; Cardiomyopathies; Deferoxamine; Free Radicals; Humans; Iron; Siderosis; Thalassemia; Transf | 1998 |
The controversial role of deferiprone in the treatment of thalassemia.
Topics: Agranulocytosis; Arthralgia; Clinical Trials as Topic; Deferiprone; Deferoxamine; Drug Therapy, Comb | 2001 |
Iron overload: clinical and pathologic aspects in pediatrics.
Topics: Abnormalities, Multiple; Adolescent; Adult; Ascorbic Acid Deficiency; Bloodletting; Child; Child, Pr | 1977 |
Chelation therapy for the treatment of thalassemia.
Topics: Chelating Agents; Deferoxamine; Humans; Hydroxamic Acids; Hydroxybenzoates; Pentetic Acid; Rhodotoru | 1977 |
Current problems of iron overload.
Topics: Deferoxamine; Diet; Hemochromatosis; Humans; Iron; Thalassemia; Tissue Distribution | 1979 |
Thalassemia major: molecular and clinical aspects. NIH Conference.
Topics: Blood Transfusion; Chelating Agents; Deferoxamine; DNA; Genes; Globins; Heart; Hemoglobins; Humans; | 1979 |
Advances in the use of iron-chelating agents for the treatment of iron overload.
Topics: Adolescent; Adult; Anemia; Child; Child, Preschool; Deferoxamine; Female; Ferritins; Heart; Hemochro | 1979 |
Management of thalassaemia major.
Topics: Blood Transfusion; Child; Deferoxamine; Ethnicity; Female; Ferritins; Hemoglobins; Humans; Iron; Mal | 1976 |
Thalassemia in Britain and Australia.
Topics: Adolescent; Australia; Chelating Agents; Deferoxamine; Humans; Iron; Liver; Puberty; Thalassemia; Tr | 1976 |
Evaluation of desferrioxamine and ascorbic acid for the treatment of chronic iron overload.
Topics: Adolescent; Adult; Aged; Anemia; Ascorbic Acid; Deferoxamine; Drug Evaluation; Feces; Humans; Iron; | 1976 |
Thalassemia.
Topics: Blood Transfusion; Bone Marrow Examination; Deferoxamine; Diagnosis, Differential; Erythrocyte Count | 1975 |
Management of thalassemia major (Cooley's anemia).
Topics: Blood Transfusion; Bone Marrow Transplantation; Chelation Therapy; Deferoxamine; Humans; Iron; Thala | 1991 |
The management of haemoglobinopathies.
Topics: Adolescent; Anemia, Sickle Cell; Bone Marrow Transplantation; Chelation Therapy; Child; Child, Presc | 1991 |
Iron and lymphocytes: reciprocal regulatory interactions.
Topics: Animals; Bloodletting; CD4-CD8 Ratio; Chelation Therapy; Deferoxamine; Ferric Compounds; Hemochromat | 1991 |
Iron chelation.
Topics: Administration, Oral; Chelation Therapy; Deferoxamine; Drug Design; Drug Evaluation; Free Radicals; | 1990 |
Oral iron chelators.
Topics: Administration, Oral; Chelation Therapy; Deferoxamine; Humans; Iron Chelating Agents; Thalassemia; T | 1990 |
Current status of iron chelation therapy with deferoxamine.
Topics: Chelation Therapy; Deferoxamine; Humans; Iron Chelating Agents; Thalassemia; Transfusion Reaction | 1990 |
Desferrioxamine: its use in iron chelation in thalassemia.
Topics: Chelation Therapy; Child, Preschool; Deferoxamine; Humans; Iron; Thalassemia | 1990 |
Current therapy of Cooley's anemia. A decade of experience with subcutaneous desferrioxamine.
Topics: Blood Transfusion; Deferoxamine; Humans; Infusions, Parenteral; Splenectomy; Thalassemia | 1990 |
[Iron-chelating treatment].
Topics: Chelation Therapy; Deferiprone; Deferoxamine; Erythropoiesis; Hemosiderosis; Humans; Iron; Iron Chel | 1989 |
Beta-thalassaemia--the Johannesburg experience.
Topics: Adolescent; Adult; Blood Transfusion; Child; Child, Preschool; Deferoxamine; Erythrocyte Transfusion | 1989 |
Results of long-term subcutaneous desferrioxamine therapy.
Topics: Deferoxamine; Hemosiderosis; Humans; Infusion Pumps; Infusions, Intravenous; Thalassemia | 1989 |
Biological and toxic properties of deferoxamine.
Topics: Cataract; Cell Division; Deferoxamine; DNA; Drug Hypersensitivity; Hearing Disorders; Humans; Pulmon | 1989 |
Iron chelation.
Topics: Animals; Blood Transfusion; Cells, Cultured; Deferoxamine; Free Radicals; Heart; Humans; In Vitro Te | 1989 |
Measurement of iron status.
Topics: Blood Transfusion; Deferoxamine; Ferritins; Humans; Intestinal Absorption; Iron; Iron Chelating Agen | 1989 |
Management of beta-thalassemia major using transfusions and iron chelation with deferoxamine.
Topics: Blood Component Transfusion; Blood Transfusion; Deferoxamine; Humans; Iron; Thalassemia | 1988 |
Iron overload and iron chelation therapy in thalassaemia and sickle cell haemoglobinopathies.
Topics: Anemia, Sickle Cell; Ascorbic Acid; Deferoxamine; Drug Administration Schedule; Forecasting; Humans; | 1987 |
Modern management of thalassemia.
Topics: Adolescent; Arrhythmias, Cardiac; Ascorbic Acid; Blood Transfusion; Child; Cholelithiasis; Deferoxam | 1985 |
Transfusional iron overload.
Topics: Ascorbic Acid; Blood Transfusion; Deferoxamine; Endocrine Glands; Heart; Humans; Infusions, Parenter | 1985 |
[Use of desferal in treatment of sideroses of different origin. (Literature review)].
Topics: Anemia; Anemia, Aplastic; Anemia, Sideroblastic; Animals; Bile; Child, Preschool; Deferoxamine; Hemo | 1968 |
Clinical usefulness of iron chelating agents.
Topics: Chelating Agents; Deferoxamine; Dimercaprol; Edetic Acid; Hemochromatosis; Humans; Iron; Iron Chelat | 1969 |
29 trials available for deferoxamine and Thalassemias
| Article | Year |
|---|---|
Deferiprone vs deferoxamine for transfusional iron overload in SCD and other anemias: a randomized, open-label noninferiority study.
Topics: Adolescent; Anemia, Sickle Cell; Blood Transfusion; Deferiprone; Deferoxamine; Female; Humans; Iron | 2022 |
Patient-reported outcomes from a randomized phase II study of the deferasirox film-coated tablet in patients with transfusion-dependent anemias.
Topics: Adult; Blood Transfusion; Chelation Therapy; Deferoxamine; Female; Humans; Iron Chelating Agents; Ir | 2018 |
Long-term sequential deferiprone-deferoxamine versus deferiprone alone for thalassaemia major patients: a randomized clinical trial.
Topics: Administration, Oral; Adolescent; Adult; Deferiprone; Deferoxamine; Drug Therapy, Combination; Femal | 2009 |
Reduction of body iron stores to normal range levels in thalassaemia by using a deferiprone/deferoxamine combination and their maintenance thereafter by deferiprone monotherapy.
Topics: Adult; Deferiprone; Deferoxamine; Drug Therapy, Combination; Female; Ferritins; Humans; Iron; Iron C | 2010 |
Combined chelation therapy with deferasirox and deferoxamine in thalassemia.
Topics: Adolescent; Adult; Benzoates; Chelation Therapy; Child; Deferasirox; Deferoxamine; Drug Synergism; F | 2013 |
Bone mass and metabolism in thalassemic children and adolescents treated with different iron-chelating drugs.
Topics: Adolescent; Alkaline Phosphatase; Amino Acids; Body Weights and Measures; Bone and Bones; Bone Densi | 2004 |
Comparative efficacy of desferrioxamine, deferiprone and in combination on iron chelation in thalassemic children.
Topics: Blood Transfusion; Child; Deferiprone; Deferoxamine; Drug Therapy, Combination; Ferritins; Humans; I | 2004 |
New approach for bone marrow transplantation in patients with class 3 thalassemia aged younger than 17 years.
Topics: Adolescent; Age Factors; Antineoplastic Agents; Bone Marrow Transplantation; Chelating Agents; Child | 2004 |
Comparison of subcutaneous infusion needles for transfusion-dependent thalassemia patients by the intrapersonal cross-over assessment model.
Topics: Adolescent; Adult; Chelation Therapy; Child; Cross-Over Studies; Deferoxamine; Edema; Equipment Desi | 2004 |
A prospective randomized controlled trial on the safety and efficacy of alternating deferoxamine and deferiprone in the treatment of iron overload in patients with thalassemia.
Topics: Adolescent; Adult; Deferiprone; Deferoxamine; Drug Therapy, Combination; Female; Humans; Iron Overlo | 2006 |
Iron chelation in thalassemia: combined or monotherapy? The Egyptian experience.
Topics: Adolescent; Adult; Chelation Therapy; Child; Child, Preschool; Deferiprone; Deferoxamine; Drug Admin | 2008 |
Oral desferrioxamine in young patients with thalassaemia.
Topics: Administration, Oral; Child, Preschool; Deferoxamine; Hemosiderosis; Humans; Thalassemia; Transfusio | 1981 |
Survival and desferrioxamine in thalassaemia major.
Topics: Adolescent; Adult; Child; Child, Preschool; Clinical Trials as Topic; Deferoxamine; Dose-Response Re | 1982 |
Growth velocity monitoring of the efficacy of different therapeutic protocols in a group of thalassaemic children.
Topics: Chelation Therapy; Child; Child, Preschool; Chronic Disease; Deferoxamine; Female; Ferritins; Follow | 1995 |
Phlebotomy to reduce iron overload in patients cured of thalassemia by bone marrow transplantation. Italian Cooperative Group for Phlebotomy Treatment of Transplanted Thalassemia Patients.
Topics: Adolescent; Bone Marrow Transplantation; Chelation Therapy; Child; Combined Modality Therapy; Defero | 1997 |
Combined therapy with deferiprone and desferrioxamine.
Topics: Adolescent; Adult; Aged; beta-Thalassemia; Deferiprone; Deferoxamine; Dose-Response Relationship, Dr | 1998 |
Efficacy and side effects of deferiprone (L1) in thalassemia patients not compliant with desferrioxamine.
Topics: Adolescent; Adult; Arthralgia; Child; Deferiprone; Deferoxamine; Female; Ferritins; Follow-Up Studie | 1999 |
Subcutaneous infusion and intramuscular injection of desferrioxamine in patients with transfusional iron overload.
Topics: Adolescent; Adult; Anemia, Sideroblastic; Blood Transfusion; Child; Circadian Rhythm; Deferoxamine; | 1976 |
Chelation therapy in beta-thalassemia major. I. Intravenous and subcutaneous deferoxamine.
Topics: Adolescent; Adult; Age Factors; Antipyrine; Child; Child, Preschool; Deferoxamine; Dose-Response Rel | 1978 |
Editorial: "Propper" use of desferrioxamine.
Topics: Clinical Trials as Topic; Deferoxamine; Humans; Infusions, Parenteral; Thalassemia | 1976 |
Effect of pentoxifylline on treatment of lower limb ulcers in patients with thalassemia major.
Topics: Adult; Deferoxamine; Female; Humans; Leg Ulcer; Male; Pentoxifylline; Recurrence; Thalassemia | 1992 |
Efficacy and possible adverse effects of the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1) in thalassemia major.
Topics: Adult; Deferiprone; Deferoxamine; Female; Ferritins; Follow-Up Studies; Humans; Iron; Iron Chelating | 1992 |
Pituitary function in thalassemic patients and the effect of chelation therapy.
Topics: Adult; Chelation Therapy; Deferoxamine; Female; Ferritins; Follicle Stimulating Hormone; Follow-Up S | 1991 |
Comparison of oral iron chelator L1 and desferrioxamine in iron-loaded patients.
Topics: Adolescent; Adult; Anemia, Aplastic; Animals; Blood Transfusion; Child; Cohort Studies; Combined Mod | 1990 |
Studies of the oral chelator 1,2-dimethyl-3-hydroxypyrid-4-one in thalassemia patients.
Topics: Administration, Oral; Adolescent; Adult; Chelation Therapy; Child; Deferiprone; Deferoxamine; Drug A | 1990 |
Evaluation of the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1) in iron-loaded patients.
Topics: Administration, Oral; Adult; Deferiprone; Deferoxamine; Humans; Iron; Iron Chelating Agents; Pyridon | 1990 |
Noncompliance with iron chelation therapy in patients with beta thalassaemia.
Topics: Administration, Cutaneous; Adolescent; Adult; Blood Transfusion; Child; Clinical Trials as Topic; De | 1989 |
Effective chelation of iron in beta thalassaemia with the oral chelator 1,2-dimethyl-3-hydroxypyrid-4-one.
Topics: Administration, Oral; Adolescent; Adult; Aged; Ascorbic Acid; Clinical Trials as Topic; Deferiprone; | 1987 |
Long-term chelation therapy in thalassaemia major: effect on liver iron concentration, liver histology, and clinical progress.
Topics: Biopsy; Blood Transfusion; Chelating Agents; Child; Deferoxamine; Diethylamines; Female; Humans; Iro | 1974 |
377 other studies available for deferoxamine and Thalassemias
| Article | Year |
|---|---|
Lifting the iron curtain of vision.
Topics: Deferoxamine; Humans; Iron Chelating Agents; Lifting; Thalassemia | 2023 |
An evaluation of deferiprone as twice-a-day tablets or in combination therapy for the treatment of transfusional iron overload in thalassemia syndromes.
Topics: Benzoates; Blood Transfusion; Deferasirox; Deferoxamine; Humans; Iron Chelating Agents; Iron Overloa | 2023 |
Combined chelation with high-dose deferiprone and deferoxamine to improve survival and restore cardiac function effectively in patients with transfusion-dependent thalassemia presenting severe cardiac complications.
Topics: Arrhythmias, Cardiac; Blood Transfusion; Chelation Therapy; Deferiprone; Deferoxamine; Drug Evaluati | 2020 |
Using of deferasirox and deferoxamine in refractory iron overload thalassemia.
Topics: Benzoates; beta-Thalassemia; Deferasirox; Deferoxamine; Humans; Iron Chelating Agents; Iron Overload | 2021 |
Economic burden in the management of transfusion-dependent thalassaemia patients in Malaysia from a societal perspective.
Topics: Benzoates; Blood Transfusion; Cost of Illness; Cross-Sectional Studies; Deferasirox; Deferoxamine; H | 2021 |
Serum Zinc Level in β-Thalassemia Major: A Retrospective Study in Southwest Iran.
Topics: Adult; Benzoates; beta-Thalassemia; Cross-Sectional Studies; Deferasirox; Deferiprone; Deferoxamine; | 2021 |
Thalassemia: Yesterday, Today, Tomorrow.
Topics: Attitude of Health Personnel; Attitude to Health; Chelation Therapy; Cyprus; Deferiprone; Deferoxami | 2017 |
The aim of iron chelation therapy in thalassaemia.
Topics: beta-Thalassemia; Chelation Therapy; Deferoxamine; Humans; Iron; Iron Chelating Agents; Iron Overloa | 2017 |
Chelation protocols for the elimination and prevention of iron overload in thalassaemia.
Topics: Benzoates; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Drug Therapy, Combination; Hum | 2018 |
The effect of desferrioxamine chelation versus no therapy in patients with non transfusion-dependent thalassaemia: a multicenter prospective comparison from the MIOT network.
Topics: Adolescent; Adult; Aged; Chelation Therapy; Child; Deferoxamine; Female; Follow-Up Studies; Heart; H | 2018 |
Pattern dystrophies in patients treated with deferoxamine: report of two cases and review of the literature.
Topics: Deferoxamine; Electroretinography; Female; Humans; Infusions, Subcutaneous; Middle Aged; Retina; Ret | 2018 |
A pharmaco-economic evaluation of deferasirox for treating patients with iron overload caused by transfusion-dependent thalassemia in Taiwan.
Topics: Benzoates; Child, Preschool; Deferasirox; Deferoxamine; Health Care Costs; Humans; Iron Chelating Ag | 2013 |
A record number of fatalities in many categories of patients treated with deferasirox: loopholes in regulatory and marketing procedures undermine patient safety and misguide public funds?
Topics: Benzoates; Deferasirox; Deferiprone; Deferoxamine; Humans; Iron Chelating Agents; Iron Overload; Mar | 2013 |
Impact of psychosocial status and disease knowledge on deferoxamine adherence among thalassaemia major adolescents.
Topics: Adolescent; Cross-Sectional Studies; Deferoxamine; Female; Humans; Male; Patient Compliance; Thalass | 2014 |
Deferoxamine retinopathy: spectral domain-optical coherence tomography findings.
Topics: Adult; Deferoxamine; Dose-Response Relationship, Drug; Fluorescein Angiography; Fundus Oculi; Humans | 2014 |
Incidence of ototoxicity in pediatric patients with transfusion-dependent thalassemia who are less well-chelated by mono- and combined therapy of iron chelating agents.
Topics: Adolescent; Adult; Benzoates; Chelation Therapy; Child; Child, Preschool; Deferasirox; Deferiprone; | 2014 |
The effects of economic sanctions on disease specific clinical outcomes of patients with thalassemia and hemophilia in Iran.
Topics: Adolescent; Adult; Benzoates; Child; Child, Preschool; Deferasirox; Deferoxamine; Female; Ferritins; | 2015 |
Cultural preferences and limited public resources influence the spectrum of thalassemia in Egypt.
Topics: Adolescent; Adult; Blood Transfusion; Child; Child, Preschool; Consanguinity; Culture; Deferoxamine; | 2015 |
Severe bacterial infections in patients with non-transfusion-dependent thalassemia: prevalence and clinical risk factors.
Topics: Adolescent; Adult; Bacterial Infections; Child; Deferoxamine; Female; Ferritins; Humans; Iron Overlo | 2015 |
Dual T-type and L-type calcium channel blocker exerts beneficial effects in attenuating cardiovascular dysfunction in iron-overloaded thalassaemic mice.
Topics: Animals; Benzoates; Calcium Channel Blockers; Calcium Channels, L-Type; Calcium Channels, T-Type; Ca | 2016 |
The Italian multiregional thalassemia registry: Centers characteristics, services, and patients' population.
Topics: Adult; Ambulatory Care Facilities; Blood Transfusion; Chelation Therapy; Deferiprone; Deferoxamine; | 2016 |
Effects of iron overload condition on liver toxicity and hepcidin/ferroportin expression in thalassemic mice.
Topics: Animals; bcl-2-Associated X Protein; Calcium Channel Blockers; Calcium Channels, L-Type; Calcium Cha | 2016 |
Combination of Oral Iron Chelators for Thalassemia.
Topics: beta-Thalassemia; Deferoxamine; Humans; Iron; Iron Chelating Agents; Iron Overload; Thalassemia | 2016 |
ELECTRORETINOGRAPHIC AND VISUAL-EVOKED POTENTIAL CHANGES IN RELATION TO CHELATION MODALITY IN CHILDREN WITH THALASSEMIA.
Topics: Administration, Oral; Adolescent; Benzoates; Cross-Sectional Studies; Deferasirox; Deferoxamine; Dos | 2017 |
Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with nontransfusion-dependent thalassemia syndromes.
Topics: Benzoates; Chelation Therapy; Deferoxamine; Drug Therapy, Combination; Humans; Iron; Iron Chelating | 2016 |
K. pneumoniae liver abscess following deferoxamine subcutaneous self-injection.
Topics: Administration, Oral; Amoxicillin-Potassium Clavulanate Combination; Deferoxamine; Female; Glucoseph | 2017 |
Hepatitis B virus reactivation during combined therapy with deferiprone and desferioxamine in a hepatitis B surface antigen thalassemic carrier.
Topics: Adult; Blood Transfusion; Deferiprone; Deferoxamine; Hepatitis B; Hepatitis B virus; Humans; Iron Ch | 2009 |
Quality of life in transfusion-dependent thalassaemia patients on desferrioxamine treatment.
Topics: Adolescent; Adult; Blood Transfusion; Child; Cross-Sectional Studies; Deferoxamine; Female; Follow-U | 2009 |
Advances in the prevention and treatment are changing thalassemia from a fatal to a chronic disease. experience from a Cyprus model and its use as a paradigm for future applications.
Topics: Chelation Therapy; Chronic Disease; Cyprus; Deferiprone; Deferoxamine; Female; Ferritins; Genetic Te | 2009 |
Uses and limitations of serum ferritin, magnetic resonance imaging T2 and T2* in the diagnosis of iron overload and in the ferrikinetics of normalization of the iron stores in thalassemia using the International Committee on Chelation deferiprone/deferoxa
Topics: Adolescent; Adult; Chelation Therapy; Child; Deferiprone; Deferoxamine; Diagnosis, Differential; Dru | 2009 |
A new era in iron chelation therapy: the design of optimal, individually adjusted iron chelation therapies for the complete removal of iron overload in thalassemia and other chronically transfused patients.
Topics: Blood Transfusion; Chelation Therapy; Clinical Protocols; Deferiprone; Deferoxamine; Drug Therapy, C | 2009 |
Effects of chelators (deferoxamine, deferiprone and deferasirox) on the growth of Klebsiella pneumoniae and Aeromonas hydrophila isolated from transfusion-dependent thalassemia patients.
Topics: Aeromonas hydrophila; Benzoates; Blood Transfusion; Deferasirox; Deferiprone; Deferoxamine; Gram-Neg | 2009 |
Risk/benefit assessment, advantages over other drugs and targeting methods in the use of deferiprone as a pharmaceutical antioxidant in iron loading and non iron loading conditions.
Topics: Animals; Antioxidants; Benzoates; Chelation Therapy; Copper; Deferasirox; Deferiprone; Deferoxamine; | 2009 |
Combining two orally active iron chelators for thalassemia.
Topics: Administration, Oral; Adolescent; Adult; Deferiprone; Deferoxamine; Humans; Iron Chelating Agents; P | 2010 |
Retrospective study on the combination of desferrioxamine and deferasirox for treatment of iron-overloaded thalassemic patients: first evidence of more than 2 years.
Topics: Adolescent; Adult; Benzoates; Child; Deferasirox; Deferoxamine; Drug Therapy, Combination; Female; F | 2010 |
Incidence of hepatocellular carcinoma in a thalassemia unit.
Topics: Adult; Aged; Antibodies; Carcinoma, Hepatocellular; Chelation Therapy; Deferoxamine; Female; Hepatit | 2010 |
Mechanisms for the shuttling of plasma non-transferrin-bound iron (NTBI) onto deferoxamine by deferiprone.
Topics: Adult; Chromatography, High Pressure Liquid; Deferiprone; Deferoxamine; Female; Ferric Compounds; Hu | 2010 |
Pathogenesis and management of iron toxicity in thalassemia.
Topics: Benzoates; Deferasirox; Deferiprone; Deferoxamine; Homeostasis; Humans; Iron; Iron Chelating Agents; | 2010 |
Deferiprone.
Topics: Deferiprone; Deferoxamine; Humans; Iron; Iron Chelating Agents; Liver; Pyridones; Randomized Control | 2010 |
Treatment options for thalassemia patients with osteoporosis.
Topics: Antineoplastic Agents; Bone Density Conservation Agents; Calcitonin; Clinical Trials as Topic; Defer | 2010 |
Iron chelation in thalassemia: time to reconsider our comfort zones.
Topics: Benzoates; Deferasirox; Deferiprone; Deferoxamine; Drug Therapy, Combination; Ferritins; Humans; Iro | 2011 |
Self-reported level of and factors influencing the compliance to desferrioxamine therapy in multitransfused thalassaemias.
Topics: Adolescent; Adolescent Behavior; Blood Transfusion; Caregivers; Child; Child Behavior; Child, Presch | 2011 |
Iron chelation adherence to deferoxamine and deferasirox in thalassemia.
Topics: Adolescent; Adult; Age Factors; Benzoates; Chelation Therapy; Child; Child, Preschool; Deferasirox; | 2011 |
Evaluation of myocardial and hepatic iron loading by MRI T2* in multi-transfused patients with repeated blood loss as compared to thalassaemia major patients and controls.
Topics: Blood Transfusion; Child, Preschool; Deferoxamine; Female; Gastrointestinal Hemorrhage; Humans; Infa | 2011 |
Health-related quality of life in Thai thalassemic children treated with iron chelation.
Topics: Adolescent; Age Factors; Benzoates; Child; Child, Preschool; Cross-Sectional Studies; Deferasirox; D | 2011 |
Thalassemia: cardiac iron and chelators.
Topics: Benzoates; Deferasirox; Deferoxamine; Heart Diseases; Humans; Iron Chelating Agents; Iron Overload; | 2012 |
The proceedings of the 20th International Conference on Chelation held in the USA: advances on new and old chelation therapies.
Topics: Chelating Agents; Chelation Therapy; Deferiprone; Deferoxamine; Edetic Acid; Humans; Iron Overload; | 2013 |
Beliefs about chelation among thalassemia patients.
Topics: Adolescent; Adult; Chelation Therapy; Child; Child, Preschool; Deferoxamine; Female; Ferritins; Heal | 2012 |
Reversal of cardiac complications in thalassemia major by long-term intermittent daily intensive iron chelation.
Topics: Adolescent; Adult; Arrhythmias, Cardiac; Catheterization, Central Venous; Chelation Therapy; Deferox | 2003 |
Bull's eye maculopathy with deferoxamine.
Topics: Adult; Deferoxamine; Female; Humans; Iron Chelating Agents; Macular Degeneration; Thalassemia | 2003 |
Do we need more iron-chelating drugs?
Topics: Benzoates; Deferasirox; Deferiprone; Deferoxamine; Humans; Iron Chelating Agents; Iron Overload; Pyr | 2003 |
[PREVENTION OF HYPERACTIVE ERYTHROPOIESIS AS A THERAPEUTIC CRITERION IN THALASSEMIA AND OTHER CORPUSCULAR ANEMIAS. PRELIMINARY NOTE].
Topics: Anemia; Blood Transfusion; Deferoxamine; Erythropoiesis; Humans; Hydroxamic Acids; Infant; Splenomeg | 1963 |
THE TREATMENT OF HAEMOCHROMATOSIS WITH DESFERRIOXAMINE.
Topics: Anemia; Anemia, Macrocytic; Deferoxamine; Diabetes Mellitus; Ferritins; Hemochromatosis; Hemoglobins | 1963 |
DESFERRIOXAMINE IN HB-E-THALASSAEMIA DISEASE.
Topics: Chelating Agents; Deferoxamine; Hemoglobinopathies; Hemoglobins; Hemoglobins, Abnormal; Humans; Hydr | 1963 |
[THE USE OF DESFERRIOXAMINE IN THE TREATMENT OF HEMOCHROMATOSIS].
Topics: Anemia; Anemia, Aplastic; Blood Chemical Analysis; Body Fluids; Deferoxamine; Hemochromatosis; Hydro | 1964 |
[ERYTHROBLASTOPHTHISIS].
Topics: Adrenal Cortex Hormones; Androgens; Blood Cell Count; Blood Transfusion; Deferoxamine; Electrocardio | 1964 |
SUBSTITUTIVE-INHIBITORY THERAPY IN CONSTITUTIONAL NON-SPHEROCYTIC ERYTHROCYTIC DISEASE.
Topics: Anemia; Anemia, Hemolytic; Anemia, Hemolytic, Congenital Nonspherocytic; Blood Transfusion; Deferoxa | 1964 |
[A NEW TEST FOR ASCERTAINMENT OF STATES OF SIDEROSIS: THE DESFERRIOXAMINE TEST. PRELIMINARY RESULTS].
Topics: Anemia; Anemia, Hypochromic; Biomedical Research; Deferoxamine; Hematologic Diseases; Hemochromatosi | 1964 |
[PRELIMINARY NOTE ON THE THERAPEUTIC USE OF DESFERRIOXAMINE IN COOLEY'S DISEASE].
Topics: Blood Transfusion; Child; Deferoxamine; Hemochromatosis; Humans; Hydroxamic Acids; Infant; Iron; Tha | 1964 |
ENZYMATIC DEFECTS OF HEME SYNTHESIS IN THALASSEMIA.
Topics: Amino Acid Oxidoreductases; Bone Marrow Examination; Deferoxamine; Drug Therapy; Erythropoiesis; Hem | 1964 |
METABOLISM OF IRON, CALCIUM AND MAGNESIUM IN HOMOZYGOUS THALASSEMIA.
Topics: Adolescent; beta-Thalassemia; Blood; Blood Transfusion; Calcium; Child; Deferoxamine; Drug Therapy; | 1964 |
CHELATING AGENTS IN THE DIAGNOSIS AND TREATMENT OF IRON OVERLOAD IN THALASSEMIA.
Topics: Adolescent; Blood Transfusion; Chelating Agents; Child; Deferoxamine; Diagnosis; Drug Therapy; Human | 1964 |
TREATMENT OF PRIMARY AND SECONDARY HEMOCHROMATOSIS AND ACUTE IRON POISONING WITH A NEW POTENT IRON ELIMINATING AGENT (DESFERRIOXAMINE B-DFOM).
Topics: Anemia; Anemia, Aplastic; Anemia, Hemolytic; Anemia, Macrocytic; Deferoxamine; Guinea Pigs; Heavy Me | 1964 |
[TREATMENT OF HEMOSIDEROSIS SECONDARY TO MULTIPLE TRANSFUSIONS, WITH SPECIAL REFERENCE TO COOLEY'S HEMOLYTIC ANEMIA].
Topics: Anemia, Hemolytic; Blood Transfusion; Deferoxamine; Drug Therapy; Hemosiderosis; Humans; Thalassemia | 1964 |
[TREATMENT OF HEMOCHROMATOSIS].
Topics: Deferoxamine; Drug Therapy; Hemochromatosis; Hemosiderosis; Humans; Porphyrias; Thalassemia | 1965 |
[TREATMENT OF SECONDARY HEMOCHROMATOSIS WITH DESFERRIOXAMINE B].
Topics: Child; Deferoxamine; Drug Therapy; Hemochromatosis; Humans; Infant; Thalassemia | 1964 |
[TREATMENT OF HEMOCHROMATOSIS CAUSED BY COOLEY'S ANEMIA BY DESFERRIOXAMINE. PRELIMINARY RESULTS].
Topics: beta-Thalassemia; Deferoxamine; Hemochromatosis; Humans; Thalassemia | 1965 |
Independent clinical trials.
Topics: Anemia, Sickle Cell; Deferiprone; Deferoxamine; Drug Industry; Financial Support; Humans; Multicente | 2004 |
Combined therapy with desferrioxamine and deferiprone: a new protocol for iron chelation in thalassemia.
Topics: Adolescent; Adult; Alanine Transaminase; Child; Deferoxamine; Drug Therapy, Combination; Female; Fer | 2004 |
Adherence to deferoxamine therapy: heeding Hippocrates and Osler.
Topics: Adult; Child; Cross-Over Studies; Deferoxamine; Humans; Iron Chelating Agents; Iron Overload; Needle | 2004 |
Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine.
Topics: Adult; Age Factors; Arrhythmias, Cardiac; Blood Transfusion; Chelation Therapy; Cohort Studies; Defe | 2004 |
Myocardial iron clearance during reversal of siderotic cardiomyopathy with intravenous desferrioxamine: a prospective study using T2* cardiovascular magnetic resonance.
Topics: Adult; Cardiomyopathies; Case-Control Studies; Deferoxamine; Female; Humans; Infusions, Intravenous; | 2004 |
Bone marrow transplantation in adults with thalassemia: Treatment and long-term follow-up.
Topics: Adolescent; Adult; Azathioprine; Bone Marrow Transplantation; Busulfan; Chelation Therapy; Clinical | 2005 |
Effective new treatments of iron overload in thalassaemia using the ICOC combination therapy protocol of deferiprone (L1) and deferoxamine and of new chelating drugs.
Topics: Deferiprone; Deferoxamine; Drug Therapy, Combination; Humans; Iron Chelating Agents; Iron Overload; | 2006 |
Low serum ferritin levels are misleading for detecting cardiac iron overload and increase the risk of cardiomyopathy in thalassemia patients. The importance of cardiac iron overload monitoring using magnetic resonance imaging T2 and T2*.
Topics: Administration, Oral; Adult; Arrhythmias, Cardiac; Cardiomyopathies; Chelation Therapy; Combined Mod | 2006 |
Thalassemia treatment and prevention in Uva Province, Sri Lanka: a public opinion survey.
Topics: Abortion, Eugenic; Adolescent; Adult; Blood Transfusion; Chelation Therapy; Combined Modality Therap | 2006 |
Survival of medically treated thalassemia patients in Cyprus. Trends and risk factors over the period 1980-2004.
Topics: Cyprus; Deferiprone; Deferoxamine; Drug Therapy, Combination; Female; Humans; Iron Chelating Agents; | 2006 |
Physical growth patterns and dental caries in thalassemia.
Topics: Adolescent; Adult; Child; Child, Preschool; Deferiprone; Deferoxamine; Dental Caries; Female; Ferrit | 2006 |
Clinical and economic burden of infused iron chelation therapy in the United States.
Topics: Adolescent; Adult; Blood Transfusion; Child; Cohort Studies; Deferoxamine; Female; Ferritins; Humans | 2007 |
Curcumin contributes to in vitro removal of non-transferrin bound iron by deferiprone and desferrioxamine in thalassemic plasma.
Topics: Chromatography, High Pressure Liquid; Curcumin; Deferiprone; Deferoxamine; Humans; Iron; Iron Chelat | 2007 |
Outcomes, utilization, and costs among thalassemia and sickle cell disease patients receiving deferoxamine therapy in the United States.
Topics: Adolescent; Adult; Anemia, Sickle Cell; Cardiomyopathies; Chelation Therapy; Child; Child, Preschool | 2008 |
Transfusion-dependent thalassaemia: a new era.
Topics: Benzoates; Cardiomyopathies; Deferasirox; Deferiprone; Deferoxamine; Drug Prescriptions; Erythrocyte | 2008 |
Management and clinical outcomes of transfusion-dependent thalassaemia major in an Australian tertiary referral clinic.
Topics: Adult; Age Factors; Australia; Cardiomyopathies; Deferiprone; Deferoxamine; Diabetes Mellitus; Drug | 2008 |
Myocyte damage and loss of myofibers is the potential mechanism of iron overload toxicity in congestive cardiac failure in thalassemia. Complete reversal of the cardiomyopathy and normalization of iron load by deferiprone.
Topics: Cardiomyopathies; Chelation Therapy; Deferiprone; Deferoxamine; Female; Ferritins; Humans; Iron; Iro | 2008 |
Long term comparative studies in thalassemia patients treated with deferoxamine or a deferoxamine/deferiprone combination. Identification of effective chelation therapy protocols.
Topics: Adult; Chelation Therapy; Clinical Protocols; Deferiprone; Deferoxamine; Drug Therapy, Combination; | 2008 |
[Modern therapeutic possibilities in Cooley's disease].
Topics: Adolescent; Antibody Formation; Azathioprine; Betamethasone; Blood Transfusion; Child; Child, Presch | 1966 |
Thalassemia intermedia, with iron overload, cardiac failure, diabetes mellitus, hypopituitarism and porphyrinuria.
Topics: Adult; Blood Transfusion; Deferoxamine; Diabetes Mellitus; Folic Acid; Folic Acid Deficiency; Heart | 1967 |
[Therapeutic results in the treatment of primary and secondary hemochromatoses with Desferal].
Topics: Anemia, Macrocytic; Blood Transfusion; Deferoxamine; Hemochromatosis; Hemosiderosis; Humans; Injecti | 1967 |
Radioactive iron (59Fe) excretion through the urine and feces after intravenous iron-59 administration in congenital hemolytic anemias.
Topics: Anemia, Sickle Cell; Deferoxamine; Feces; Humans; Iron Isotopes; Thalassemia | 1967 |
Iron chelation with oral desferrioxamine.
Topics: Administration, Oral; Adolescent; Adult; Child; Child, Preschool; Deferoxamine; Humans; Iron; Thalas | 1980 |
Iron chelation in red cell ghosts.
Topics: Blood Transfusion; Deferoxamine; Erythrocyte Membrane; Erythrocytes; Humans; Thalassemia | 1981 |
Ocular toxicity of high-dose intravenous desferrioxamine.
Topics: Adolescent; Adult; Cataract; Child; Child, Preschool; Dark Adaptation; Deferoxamine; Female; Follow- | 1983 |
Rapid desensitisation for desferrioxamine anaphylactoid reaction.
Topics: Adult; Anaphylaxis; Deferoxamine; Desensitization, Immunologic; Female; Humans; Thalassemia; Time Fa | 1983 |
Desferrioxamine and systemic yersiniosis.
Topics: Animals; Deferoxamine; Humans; Iron; Mice; Thalassemia; Yersinia enterocolitica; Yersinia Infections | 1983 |
Yersinia pseudotuberculosis septicaemia in thalassaemia major.
Topics: Adolescent; Deferoxamine; Female; Humans; Sepsis; Thalassemia; Yersinia Infections; Yersinia pseudot | 1984 |
High-dose chelation therapy in thalassaemia.
Topics: Deferoxamine; Heart; Humans; Iron; Liver; Thalassemia | 1984 |
Desferrioxamine to improve cardiac function in iron-overloaded patients with thalassemia major.
Topics: Deferoxamine; Heart Diseases; Humans; Iron; Thalassemia; Transfusion Reaction | 1984 |
Visual loss in patient on high-dose subcutaneous desferrioxamine.
Topics: Child; Deferoxamine; Female; Humans; Injections, Subcutaneous; Thalassemia; Vision Disorders | 1984 |
Prophylaxis of systemic yersinosis in thalassaemia major.
Topics: Child; Deferoxamine; Female; Humans; Risk; Sepsis; Thalassemia; Yersinia Infections | 1984 |
[Thalassaemia intermedia. Clinical and laboratory study. Therapeutic suggestions (author's transl)].
Topics: Age Factors; Blood Transfusion; Child; Child, Preschool; Deferoxamine; Female; Fetal Hemoglobin; Hem | 1982 |
Beta thalassemia and heart disease: three decades of gradual progress.
Topics: Blood Transfusion; Cardiomegaly; Child; Deferoxamine; Erythrocyte Transfusion; Heart Diseases; Human | 1985 |
[Iron overload in a beta thalassemia heterozygote of the intermediate type in a subject of Alsation origin. Results of iron chelation treatment].
Topics: Anemia; Deferoxamine; Female; Ferritins; Hemosiderosis; Heterozygote; HLA Antigens; HLA-A3 Antigen; | 1984 |
[Puberty-specific gonadotropin rhythm in girls with homozygous beta-thalassemia during continuous subcutaneous desferrioxamine infusions and a simultaneous blood transfusion regimen].
Topics: Adolescent; Blood Transfusion; Deferoxamine; Female; Follicle Stimulating Hormone; Humans; Infusions | 1983 |
Successful pregnancy in beta-thalassaemia major.
Topics: Adult; Blood Transfusion; Deferoxamine; Female; Glucose; Humans; Hypoglycemia; Infant, Newborn; Infa | 1983 |
A study of the mechanisms and sites of action of desferrioxamine in thalassaemia major.
Topics: Child; Deferoxamine; Erythrocytes; Feces; Humans; Injections, Subcutaneous; Iron; Iron Chelating Age | 1984 |
Allergy to desferrioxamine.
Topics: Child; Deferoxamine; Drug Hypersensitivity; Female; Humans; Thalassemia | 1984 |
[Effect of hematologic treatment on the growth and puberty of children with thalassemia major].
Topics: Adolescent; Blood Transfusion; Body Height; Child; Combined Modality Therapy; Deferoxamine; Female; | 1984 |
Depletion of excessive liver iron stores with desferrioxamine.
Topics: Adolescent; Child; Deferoxamine; Humans; Iron; Liver; Thalassemia | 1984 |
Porphyria cutanea tarda in beta-thalassemia trait carriers.
Topics: Adult; Deferoxamine; Heterozygote; Humans; Liver Diseases; Male; Middle Aged; Porphyrias; Skin Disea | 1984 |
[Deferoxamine in hemosiderosis. Fecal iron excretion during continuous subcutaneous infusion].
Topics: Adolescent; Child; Child, Preschool; Deferoxamine; Feces; Hemosiderosis; Humans; Injections, Subcuta | 1984 |
Ocular changes in patients undergoing long-term desferrioxamine treatment.
Topics: Adolescent; Adult; Child; Deferoxamine; Electrooculography; Electroretinography; Female; Glucose Tol | 1984 |
Thalassemia.
Topics: Blood Transfusion; Chromosome Deletion; Deferoxamine; DNA; Erythrocyte Transfusion; Female; Gene Exp | 1984 |
A successful pregnancy outcome in transfusion dependent thalassaemia major.
Topics: Adult; Blood Transfusion; Deferoxamine; Erythrocyte Transfusion; Female; Humans; Infant, Newborn; Ma | 1984 |
Early left ventricular dysfunction and chelation therapy in thalassemia major.
Topics: Adolescent; Adult; Blood Transfusion; Child; Coronary Vessels; Deferoxamine; Ferritins; Heart Ventri | 1983 |
[Desferrioxamine in thalassemia].
Topics: Adolescent; Blood Transfusion; Child; Child, Preschool; Deferoxamine; Female; Humans; Infusions, Par | 1983 |
Management of thalassaemia major.
Topics: Adolescent; Adult; Blood Transfusion; Child; Child, Preschool; Deferoxamine; Diagnosis, Differential | 1983 |
Management of thalassaemia major.
Topics: Adolescent; Adult; Blood Transfusion; Child; Child, Preschool; Deferoxamine; Diagnosis, Differential | 1983 |
Management of thalassaemia major.
Topics: Adolescent; Adult; Blood Transfusion; Child; Child, Preschool; Deferoxamine; Diagnosis, Differential | 1983 |
Management of thalassaemia major.
Topics: Adolescent; Adult; Blood Transfusion; Child; Child, Preschool; Deferoxamine; Diagnosis, Differential | 1983 |
[Our experience in the treatment of malleolar ulcers in thalassemia].
Topics: Adolescent; Adult; Bandages; Blood Transfusion; Deferoxamine; Female; Humans; Leg Ulcer; Pentoxifyll | 1983 |
Use of the one sample t-test in the real world.
Topics: Deferoxamine; Ferritins; Humans; Research; Statistics as Topic; Thalassemia | 1984 |
Iron absorption in non-transfused iron loading anaemias: prediction of risk for iron loading, and response to iron chelation treatment, in beta thalassaemia intermedia and congenital sideroblastic anaemias.
Topics: Absorption; Administration, Oral; Age Factors; Anemia, Sideroblastic; Chelating Agents; Deferoxamine | 1984 |
The simple rubber band technic for slow subcutaneous infusion of desferrioxamine.
Topics: Child; Deferoxamine; Humans; Infusions, Parenteral; Iron; Male; Methods; Thalassemia | 1984 |
Pituitary-thyroid function in children with beta-thalassaemia major.
Topics: Adolescent; Blood Transfusion; Child; Deferoxamine; Female; Humans; Male; Pituitary Gland, Anterior; | 1981 |
Desferrioxamine-induced iron outputs in Cooley's anemia. Results and perspectives.
Topics: Adolescent; Ascorbic Acid; Blood Transfusion; Child; Deferoxamine; Female; Humans; Iron; Male; Splen | 1981 |
Delayed decrease in serum ferritin in polytransfused children with thalassemia major after continuous subcutaneous infusions of desferrioxamine.
Topics: Blood Transfusion; Child; Child, Preschool; Deferoxamine; Ferritins; Humans; Infusions, Parenteral; | 1981 |
Iron chelation in transfusion-dependent thalassemia with chronic hepatitis.
Topics: Adolescent; Alanine Transaminase; Child; Child, Preschool; Chronic Disease; Deferoxamine; Female; Fe | 1982 |
Survival and desferrioxamine in thalassaemia major.
Topics: Adult; Ascorbic Acid; Deferoxamine; Humans; Iron; Thalassemia | 1982 |
Intensive iron chelation therapy in beta-thalassemia major: some effects on iron metabolism and blood transfusion dependence.
Topics: Adolescent; Adult; Aging; Blood Transfusion; Child; Child, Preschool; Deferoxamine; Feces; Female; F | 1982 |
The management of the improved prognosis in thalassemia major.
Topics: Adolescent; Adult; Attitude to Death; Blood Transfusion; Child; Child, Preschool; Deferoxamine; Empl | 1982 |
Subcutaneous desferrioxamine: the effect of three years' treatment on liver, iron, serum ferritin, and comments on echocardiography.
Topics: Adolescent; Ascorbic Acid Deficiency; Aspartate Aminotransferases; Child; Deferoxamine; Echocardiogr | 1982 |
Therapy of HBsAg-negative chronic active hepatitis in transfusion-dependent thalassemia major.
Topics: Aspartate Aminotransferases; Child; Child, Preschool; Deferoxamine; Hepatitis B; Hepatitis B Surface | 1982 |
Editorial retrospective. Iron loading in thalassemia--five years with the pump.
Topics: Adolescent; Adult; Child; Deferoxamine; Humans; Iron; Thalassemia; Transfusion Reaction | 1983 |
Pancreatic sonography in thalassemia major.
Topics: Adolescent; Adult; Blood Transfusion; Child; Deferoxamine; Hemosiderosis; Humans; Pancreatic Disease | 1983 |
Effect of subcutaneous desferrioxamine on iron balance in young thalassemia major patients.
Topics: Age Factors; Child, Preschool; Deferoxamine; Dose-Response Relationship, Drug; Humans; Infant; Infus | 1983 |
The management of iron chelation therapy.
Topics: Anemia, Hemolytic, Congenital; Ascorbic Acid; Child; Child, Preschool; Deferoxamine; Drug Administra | 1983 |
Iron overload: pathogenesis and treatment with chelating agents.
Topics: Blood Transfusion; Bloodletting; Chelating Agents; Deferoxamine; Hemochromatosis; Humans; Infusions, | 1983 |
[Obstetrical and hematological problems in a pregnant woman with intermediate beta-thalassemia].
Topics: Adult; Blood Transfusion; Deferoxamine; Female; Humans; Pregnancy; Pregnancy Complications, Hematolo | 1983 |
Thalassemia.
Topics: Chelating Agents; Costs and Cost Analysis; Deferoxamine; Humans; Iron; Thalassemia; Transfusion Reac | 1983 |
Current concepts in the overall management of thalassemia.
Topics: Biological Transport; Blood Transfusion; Chelating Agents; Deferoxamine; Erythrocyte Transfusion; Ex | 1980 |
Evaluation of cardiac function in patients with thalassemia major.
Topics: Adolescent; Adult; Ascorbic Acid; Child; Child, Preschool; Deferoxamine; Heart; Heart Diseases; Hear | 1980 |
Clinical management of thalassemia. Decreasing iron stores during intensive chelation therapy.
Topics: Ascorbic Acid; Blood Transfusion; Child; Deferoxamine; Erythrocyte Transfusion; Humans; Iron; Male; | 1980 |
Chelation therapy, transfusion requirement, and iron balance in young thalassemic patients.
Topics: Adolescent; Ascorbic Acid; Blood Transfusion; Child; Child, Preschool; Deferoxamine; Erythrocyte Tra | 1980 |
Combined vitamin D parathyroid defect in thalassemia major.
Topics: 25-Hydroxyvitamin D 2; Adolescent; Adult; Child; Deferoxamine; Ergocalciferols; Female; Humans; Hypo | 1982 |
Zinc deficiency developing in treatment for thalassaemia.
Topics: Child; Deferoxamine; Humans; Male; Pentetic Acid; Thalassemia; Transfusion Reaction; Zinc | 1982 |
[Continuous subcutaneous desferrioxamine infusions in patients with hemosiderosis (author's transl)].
Topics: Adolescent; Adult; Anemia, Aplastic; Child; Child, Preschool; Deferoxamine; Hemosiderosis; Humans; I | 1982 |
Ferrioxamine excretion in iron-loaded man.
Topics: Adult; Ascorbic Acid; Deferoxamine; Dose-Response Relationship, Drug; Feces; Hemosiderosis; Humans; | 1982 |
[Thalassemic cardiopathy: serial echocardiographic evaluation].
Topics: Adolescent; Adult; Child; Child, Preschool; Deferoxamine; Echocardiography; Female; Ferritins; Heart | 1982 |
Reduction of iron overload in thalassemia.
Topics: Adolescent; Adult; Aging; Animals; Cell Separation; Child; Child, Preschool; Deferoxamine; Erythrocy | 1982 |
[Monitoring and appraisal of the effects of blood transfusion and iron chelation in thalassemia major].
Topics: Adolescent; Adult; Blood Group Incompatibility; Child; Child Development; Child, Preschool; Deferoxa | 1982 |
Early iron overload in beta-thalassaemia major: when to start chelation therapy?
Topics: Child, Preschool; Deferoxamine; Hemochromatosis; Humans; Infant; Iron; Thalassemia; Transfusion Reac | 1982 |
Chelation therapy in iron poisoning.
Topics: Animals; Deferoxamine; Dogs; Drug Administration Schedule; Humans; Infusions, Parenteral; Injections | 1982 |
Chelation therapy for iron overload.
Topics: Animals; Chelating Agents; Deferoxamine; Hemochromatosis; Hemosiderosis; Humans; Rats; Thalassemia | 1980 |
Response to long-term deferoxamine therapy in thalassemia.
Topics: Adolescent; Child; Deferoxamine; Ferritins; Humans; Iron; Liver Function Tests; Male; Thalassemia; T | 1981 |
Chelation therapy in beta-thalassemia major. III. The role of splenectomy in achieving iron balance.
Topics: Adolescent; Adult; Age Factors; Blood Transfusion; Child; Child, Preschool; Deferoxamine; Humans; In | 1981 |
Iron overload and desferrioxamine chelation therapy in beta-thalassemia intermedia.
Topics: Adolescent; Age Factors; Child; Child, Preschool; Deferoxamine; Female; Ferritins; Humans; Infant; I | 1981 |
Intravenous and subcutaneous desferrioxamine therapy in children with severe iron overload.
Topics: Adolescent; Anemia, Aplastic; Anemia, Sideroblastic; Child; Child, Preschool; Deferoxamine; Hemoside | 1981 |
Tinnitus in a patient with beta-thalassaemia intermedia on long-term treatment with desferrioxamine.
Topics: Adult; Deferoxamine; Female; Humans; Iron; Thalassemia; Time Factors; Tinnitus | 1981 |
[Monitoring of the harmful effects of iron on the hearts of patients with beta-thalassemia major, using non-invasive cardiological technics].
Topics: Adolescent; Adult; Cardiomyopathies; Child; Child, Preschool; Deferoxamine; Echocardiography; Electr | 1981 |
Depressed serum somatomedin activity in beta-thalassemia.
Topics: Adolescent; Adult; Child; Child, Preschool; Deferoxamine; Female; Growth Disorders; Hemosiderosis; H | 1980 |
Advances in the management of homozygous beta-thalassaemia, including desferrioxamine infusion therapy and prenatal diagnosis.
Topics: Blood Transfusion; Deferoxamine; Female; Fetal Blood; Fetal Diseases; Globins; Humans; Pregnancy; Pr | 1980 |
[Treatment of iron overload due to repeated transfusions with subcutaneous infusions of desferrioxamine (author's transl)].
Topics: Adolescent; Adult; Child; Child, Preschool; Deferoxamine; Female; Ferritins; Hemosiderosis; Humans; | 1980 |
Treatment of iron storage disorders.
Topics: Anemia; Deferoxamine; Hemochromatosis; Humans; Iron; Liver Cirrhosis; Porphyrias; Skin Diseases; Tha | 1980 |
Successful pregnancy in transfusion-dependent thalassaemia.
Topics: Adult; Blood Transfusion; Deferoxamine; Female; Humans; Infant, Newborn; Pregnancy; Pregnancy Compli | 1980 |
Vitamin C and iron.
Topics: Administration, Oral; Adult; Animals; Ascorbic Acid; Ascorbic Acid Deficiency; Deferoxamine; Female; | 1981 |
[Echocardiographic measurements in transfused thalassemic major children].
Topics: Blood Transfusion; Child; Child, Preschool; Deferoxamine; Echocardiography; Female; Ferritins; Hemog | 1980 |
[Role and therapeutic use of deferoxamine in iron overload due to thalassemia (author's transl)].
Topics: Adolescent; Child; Child, Preschool; Deferoxamine; Female; Humans; Iron; Male; Thalassemia | 1980 |
Desferrioxamine therapy accelerates clearance of iron deposits after bone marrow transplantation for thalassaemia.
Topics: Adolescent; Biopsy; Bone Marrow Transplantation; Child; Deferoxamine; Female; Ferritins; Humans; Iro | 1995 |
Autoantibodies in thalassaemia major: relationship with oral iron chelator L1.
Topics: Adolescent; Adult; Antibodies, Antinuclear; Autoimmune Diseases; Blood Transfusion; Child; Deferipro | 1993 |
Zinc concentration in patients with iron overload receiving oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one or desferrioxamine.
Topics: Adolescent; Adult; Blood Glucose; Deferiprone; Deferoxamine; Diabetes Mellitus; Female; Glucose Tole | 1994 |
Development of oral iron chelator L1.
Topics: Agranulocytosis; Deferiprone; Deferoxamine; Humans; Iron Chelating Agents; Pyridones; Thalassemia | 1993 |
Could chelation therapy with deferoxamine enhance the percentage of responders to interferon therapy in chronic hepatitis C?
Topics: Chelation Therapy; Chronic Disease; Combined Modality Therapy; Deferoxamine; Drug Synergism; Ferriti | 1993 |
Differential toxicity of alpha-keto hydroxypyridine iron chelators and desferrioxamine to human haemopoietic precursors in vitro.
Topics: Bone Marrow Cells; Cell Division; Deferiprone; Deferoxamine; Hematopoiesis; Humans; In Vitro Techniq | 1994 |
Liver iron overload and liver fibrosis in thalassemia.
Topics: Adolescent; Adult; Chelation Therapy; Child; Child, Preschool; Combined Modality Therapy; Deferoxami | 1993 |
[Long-term efficacy of subcutaneous administration of deferoxamine in patients with secondary hemochromatosis].
Topics: Aged; Anemia, Aplastic; Deferoxamine; Female; Hemochromatosis; Humans; Injections, Subcutaneous; Mal | 1996 |
[Thalassemia today].
Topics: Adolescent; Adult; Child; Comorbidity; Deferoxamine; Humans; Life Expectancy; Patient Compliance; Qu | 1996 |
Laboratory evaluation of a new delivery system to improve patient compliance with chelation therapy.
Topics: Adolescent; Adult; Chelation Therapy; Deferoxamine; Drug Delivery Systems; Humans; Infusions, Intrav | 1996 |
The effectiveness of deferiprone in thalassemia.
Topics: Deferiprone; Deferoxamine; Humans; Iron; Iron Chelating Agents; Pyridones; Thalassemia | 1997 |
[Intensive intravenous chelation in thalassemic patients with iron overload].
Topics: Adolescent; Adult; Chelation Therapy; Deferoxamine; Echocardiography; Humans; Infusions, Intravenous | 1998 |
Serum ferritin, desferrioxamine, and evolution of HIV-1 infection in thalassemic patients.
Topics: Child; Cohort Studies; Confounding Factors, Epidemiologic; Deferoxamine; Disease Progression; Dose-R | 1998 |
Microstructural analysis of severe bone lesions in seven thalassemic patients treated with deferoxamine.
Topics: Adolescent; Apatites; Biopsy; Bone and Bones; Chelating Agents; Child; Deferoxamine; Female; Humans; | 2000 |
Osteochondrodystrophic lesions in chelated thalassemic patients: an histological analysis.
Topics: Adolescent; Biopsy; Bone Diseases; Cartilage; Chelating Agents; Child; Deferoxamine; Female; Fractur | 2000 |
Pregnancy outcome of a transfusion-dependent thalassemic woman.
Topics: Blood Transfusion; Chelating Agents; Deferoxamine; Female; Ferritins; Humans; Pregnancy; Pregnancy C | 2000 |
Persistence of delayed adrenarche in boys with thalassemia.
Topics: Adolescent; Age Determination by Skeleton; Blood Transfusion; Body Height; Body Mass Index; Bone Den | 2001 |
Determination of a new oral iron chelator, ICL670, and its iron complex in plasma by high-performance liquid chromatography and ultraviolet detection.
Topics: Benzoates; Calibration; Chromatography, High Pressure Liquid; Deferasirox; Deferiprone; Deferoxamine | 2001 |
[Pregnancy in women with thalassaemia].
Topics: Adult; Blood Transfusion; Chelating Agents; Deferoxamine; Female; Folic Acid; Hematinics; Humans; In | 2001 |
Variations of ferritin levels over a period of 15 years as a compliance chelation index in thalassemic patients.
Topics: Adolescent; Adult; Chelation Therapy; Child; Child, Preschool; Deferoxamine; Drug Monitoring; Ferrit | 2001 |
Long-term administration of high-dose deferoxamine 2 days per week in thalassemic patients.
Topics: Adult; Chelating Agents; Chelation Therapy; Deferoxamine; Female; Ferritins; Humans; Infusion Pumps; | 2001 |
Reversibility of cirrhosis in patients cured of thalassemia by bone marrow transplantation.
Topics: Adolescent; Adult; Antiviral Agents; Biopsy; Bone Marrow Transplantation; Child; Combined Modality T | 2002 |
Summaries for patients. Reversibility of liver scarring in patients who are cured of thalassemia.
Topics: Adolescent; Adult; Antiviral Agents; Bone Marrow Transplantation; Child; Combined Modality Therapy; | 2002 |
Effect of dose, time, and ascorbate on iron excretion after subcutaneous desferrioxamine.
Topics: Administration, Oral; Adolescent; Adult; Anemia, Sideroblastic; Ascorbic Acid; Child; Deferoxamine; | 1977 |
Chelation regimens with desferrioxamine.
Topics: Deferoxamine; Dose-Response Relationship, Drug; Infusions, Parenteral; Thalassemia | 1977 |
Iron absorption in iron-loading anaemias: Effect of subcutaneous desferrioxamine infusions.
Topics: Administration, Oral; Adolescent; Adult; Anemia, Aplastic; Anemia, Sideroblastic; Ascorbic Acid; Bin | 1977 |
Iron absorption in iron-loading anaemias.
Topics: Deferoxamine; Humans; Intestinal Absorption; Iron; Thalassemia | 1977 |
Prevention of iron loading in transfusion-dependent thalassaemia.
Topics: Adolescent; Adult; Age Factors; Child; Child, Preschool; Deferoxamine; Dose-Response Relationship, D | 1978 |
Subcutaneous desferrioxamine in homozygous beta-thalassaemia.
Topics: Adolescent; Adult; Age Factors; Child; Child, Preschool; Deferoxamine; Hemosiderosis; Homozygote; Hu | 1978 |
Improvement in iron status and liver function in patients with transfusional iron overload with long-term subcutaneous desferrioxamine.
Topics: Adolescent; Adult; Aged; Anemia, Aplastic; Anemia, Sideroblastic; Aspartate Aminotransferases; Child | 1979 |
Correlation between computed tomographic values and liver iron content in thalassaemia major with iron overload.
Topics: Adolescent; Biopsy; Blood Transfusion; Child; Deferoxamine; Female; Humans; Iron; Liver; Male; Thala | 1979 |
Rhodotorulic acid--investigation of its potential as an iron-chelating drug.
Topics: Adult; Animals; Deferoxamine; Dogs; Female; Haplorhini; Humans; Hydroxamic Acids; Hydroxybenzoates; | 1979 |
The clinical management of homozygous beta-thalassemia.
Topics: Blood Transfusion; Deferoxamine; Endocrine System Diseases; Growth Disorders; Humans; Splenectomy; T | 1979 |
Impaired parathyroid response to induced hypocalcemia in thalassemia major.
Topics: Adolescent; Adult; Blood Transfusion; Child; Deferoxamine; Edetic Acid; Ferritins; Humans; Hypocalce | 1979 |
Drugs in current use: thalassaemia.
Topics: Deferoxamine; Humans; Thalassemia | 1978 |
Acute renal insufficiency occurring during intravenous desferrioxamine therapy.
Topics: Acute Kidney Injury; Adolescent; Deferoxamine; Hemosiderosis; Humans; Injections, Intravenous; Male; | 1979 |
Pharmacist involvement in a deferoxamine education program for patients with Cooley's anemia.
Topics: Ascorbic Acid; Asepsis; Deferoxamine; Drug Therapy, Combination; Evaluation Studies as Topic; Humans | 1979 |
Mechanism of desferrioxamine-induced iron excretion in thalassaemia.
Topics: Adolescent; Adult; Child; Child, Preschool; Cholecystectomy; Deferoxamine; Humans; Iron; Iron Chelat | 1979 |
[Experience with desferrioxamine treatment by slow subcutaneous administration, in thalassemia].
Topics: Adolescent; Adult; Child; Deferoxamine; Female; Humans; Injections, Intramuscular; Male; Siderosis; | 1979 |
[Experience with desferrioxamine treatment by intravenous administration, in thalassemia].
Topics: Child; Deferoxamine; Female; Humans; Infusions, Parenteral; Male; Siderosis; Thalassemia; Transfusio | 1979 |
Studies in desferrioxamine and ferrioxamine metabolism in normal and iron-loaded subjects.
Topics: Blood Transfusion; Deferoxamine; Ferric Compounds; Humans; Iron; Iron Chelating Agents; Thalassemia; | 1979 |
Increased risk of diabetes mellitus in beta- thalassemia major due to iron overload.
Topics: Adolescent; Arginine; Blood Glucose; Child; Child, Preschool; Deferoxamine; Diabetes Mellitus, Type | 1979 |
[Therapy of thalassemias].
Topics: Ascorbic Acid; Blood Transfusion; Deferoxamine; Humans; Splenectomy; Thalassemia | 1979 |
Chelation therapy and ferritin levels in patients with homozygous beta-thalassemia.
Topics: Adolescent; Blood Transfusion; Child; Child, Preschool; Deferoxamine; Ferritins; Humans; Infant; Iro | 1979 |
Iron loading and thalassemia--experimental successes and practical realities.
Topics: Child; Deferoxamine; Humans; Injections, Intramuscular; Injections, Subcutaneous; Iron; Thalassemia; | 1977 |
Evaluation of continuous desferrioxamine administration in adults with transfusional hemosiderosis.
Topics: Adult; Anemia, Sideroblastic; Ascorbic Acid; Deferoxamine; Drug Administration Schedule; Female; Hem | 1977 |
Cardiac arrhythmias in thalassaemia major: evaluation of chelation treatment using ambulatory monitoring.
Topics: Adolescent; Adult; Ambulatory Care; Arrhythmias, Cardiac; Child; Deferoxamine; Humans; Monitoring, P | 1978 |
Iron burden in sickle cell anemia.
Topics: Adolescent; Adult; Anemia, Sickle Cell; Body Burden; Child; Child, Preschool; Deferoxamine; Ferritin | 1978 |
Iron chelation therapy with deferoxamine in Cooley anemia.
Topics: Adolescent; Adult; Ascorbic Acid; Child; Child, Preschool; Deferoxamine; Female; Humans; Infusions, | 1978 |
Cooley anemia: high transfusion regimen and chelation therapy, results, and perspective.
Topics: Adolescent; Ascorbic Acid; Blood Transfusion; Child; Child, Preschool; Deferoxamine; Erythrocyte Tra | 1978 |
[Further experiences with iron-chelating therapy (desferrioxamine and ascorbic acid) in siderochromatosis and Cooley's disease].
Topics: Adolescent; Adult; Aged; Ascorbic Acid; Deferoxamine; Drug Evaluation; Female; Hemochromatosis; Hemo | 1978 |
Chronic iron overload: new chelators and new strategies.
Topics: Anemia, Sideroblastic; Animals; Ascorbic Acid; Chelating Agents; Deferoxamine; Hemosiderosis; Humans | 1978 |
[Changes in urinary iron in thalassemia major in relation to the administration of desferrioxamine].
Topics: Child; Child, Preschool; Deferoxamine; Hemosiderosis; Humans; Infant; Iron; Thalassemia | 1978 |
Intensive iron-chelation in thalassaemia.
Topics: Child; Child, Preschool; Deferoxamine; Humans; Infusions, Parenteral; Iron; Thalassemia; Transfusion | 1978 |
Intensive iron-chelation in thalassaemia.
Topics: Adolescent; Child; Child, Preschool; Deferoxamine; Female; Humans; Infant; Injections, Subcutaneous; | 1978 |
Iron chelation in thalassemia: mechanism of desferrioxamine action.
Topics: Adolescent; Adult; Child; Child, Preschool; Deferoxamine; Ferritins; Humans; Iron; Liver; Spleen; Th | 1978 |
Treatment of primary hemochromatosis with deferoxamine.
Topics: Adult; Arrhythmias, Cardiac; Deferoxamine; Female; Heart Failure; Hemochromatosis; Humans; Male; Ped | 1979 |
Pathogenesis and management of iron overload in thalassemia.
Topics: Deferoxamine; Hemochromatosis; Humans; Iron; Pentetic Acid; Thalassemia | 1975 |
Total management of thalassaemia major.
Topics: Adolescent; Adult; Ascorbic Acid; Child; Child, Preschool; Deferoxamine; Humans; Hypersplenism; Infa | 1977 |
Continuous subcutaneous administration of deferoxamine in patients with iron overload.
Topics: Administration, Oral; Adolescent; Adult; Aged; Ascorbic Acid; Child; Child, Preschool; Deferoxamine; | 1977 |
The inhibitory effect of vitamin E on desferrioxamine-induced iron excretion in rats.
Topics: Animals; Deferoxamine; Female; Ferritins; Iron; Liver; Rats; Spleen; Thalassemia; Vitamin E | 1976 |
Chelate mediated transfer of iron from transferrin to desferrioxamine.
Topics: Chelating Agents; Deferoxamine; Humans; Iron; Thalassemia; Transferrin | 1976 |
The thalassaemias.
Topics: Adolescent; Blood Transfusion; Child, Preschool; Deferoxamine; Humans; Infant; Mass Screening; Prena | 1976 |
Practical approaches to the control of thalassaemia.
Topics: Blood Transfusion; Deferoxamine; Female; Genetic Counseling; Humans; Male; Pregnancy; Prenatal Diagn | 1976 |
The management of thalassemia major.
Topics: Adolescent; Adult; Blood Transfusion; Chelating Agents; Child; Child, Preschool; Deferoxamine; Diet | 1975 |
Transfusional iron overload: the relationship between tissue iron concentration and hepatic fibrosis in thalassaemia.
Topics: Adolescent; Adult; Age Factors; Biopsy; Child; Child, Preschool; Deferoxamine; Humans; Iron; Iron Ch | 1975 |
Reassessment of the use of desferrioxamine B in iron overload.
Topics: Adolescent; Adult; Child; Child, Preschool; Deferoxamine; Depression, Chemical; Humans; Infusions, P | 1976 |
Desferrioxamine in acute iron poisoning.
Topics: Child; Deferoxamine; Humans; Infusions, Intravenous; Iron; Respiratory Distress Syndrome; Thalassemi | 1992 |
Reduction in tissue iron stores with a new regimen of continuous ambulatory intravenous deferoxamine.
Topics: Adolescent; Adult; Ambulatory Care; Deferoxamine; Ferritins; Humans; Infusions, Intravenous; Injecti | 1992 |
Growth plate injury of the long bones in treated beta-thalassemia.
Topics: Adolescent; Chelation Therapy; Child; Child, Preschool; Deferoxamine; Female; Follow-Up Studies; Gro | 1992 |
Growth failure and bony changes induced by deferoxamine.
Topics: Alkaline Phosphatase; Body Height; Bone Development; Child, Preschool; Deferoxamine; Growth Plate; H | 1992 |
Deferoxamine increases the susceptibility of beta-thalassemic, iron-overloaded mice to infection with Listeria monocytogenes.
Topics: Animals; Colony Count, Microbial; Deferoxamine; Disease Susceptibility; Female; Injections, Intraper | 1992 |
Bone density, mineral content, and cortical index in patients with thalassemia major and the correlation to their bone fractures, blood transfusions, and treatment with desferrioxamine.
Topics: Adolescent; Adult; Blood Transfusion; Bone and Bones; Bone Density; Child; Deferoxamine; Female; Fra | 1992 |
[Intensifying iron chelating therapy with desferrioxamine using implantable venous access catheters (Port-A-Cath)].
Topics: Acute-Phase Reaction; Adolescent; Adult; Catheters, Indwelling; Deferoxamine; Female; Heart Failure; | 1992 |
Neurophysiological and neuro-otological study of homozygous beta-thalassemia under long-term desferrioxamine (DFO) treatment.
Topics: Adult; Audiometry, Pure-Tone; Auditory Threshold; Blood Transfusion; Brain Stem; Deferoxamine; Elect | 1991 |
[Nursing and psychosocial care of patients with homozygote beta-thalassemia].
Topics: Deferoxamine; Humans; Iron; Patient Compliance; Social Support; Thalassemia | 1991 |
The effects of subcutaneous deferoxamine administration on renal function in thalassemia major.
Topics: Adolescent; Adult; Child; Deferoxamine; Female; Glomerular Filtration Rate; Humans; Injections, Subc | 1991 |
Iron chelation.
Topics: Chelation Therapy; Deferiprone; Deferoxamine; Hemochromatosis; Humans; Iron; Iron Chelating Agents; | 1991 |
Scoliosis in beta thalassemia.
Topics: Age Determination by Skeleton; Blood Transfusion; Child; Deferoxamine; Female; Ferritins; Humans; Ma | 1991 |
Yersinia enterocolitica infection with ileal perforation associated with iron overload and deferoxamine therapy.
Topics: Adolescent; Blood Transfusion; Deferoxamine; Humans; Ileal Diseases; Intestinal Perforation; Iron; L | 1991 |
Systemic Yersinia enterocolitica infection associated with iron overload and deferoxamine therapy.
Topics: Blood Transfusion; Child, Preschool; Deferoxamine; Gastroenteritis; Humans; Male; Mesenteric Lymphad | 1991 |
Deferoxamine-induced bone dysplasia in patients with thalassemia major.
Topics: Adolescent; Age Factors; Blood Transfusion; Bone Diseases, Developmental; Child; Deferoxamine; Femal | 1991 |
Pseudo deep-vein thrombosis following desferrioxamine infusion: a previously unreported adverse reaction?
Topics: Deferoxamine; Humans; Infusion Pumps; Male; Thalassemia; Thrombophlebitis | 1990 |
Pulmonary syndrome and intravenous high-dose desferrioxamine.
Topics: Adolescent; Child; Deferoxamine; Humans; Infusions, Intravenous; Pulmonary Fibrosis; Thalassemia | 1990 |
Prolonged survival in patients with beta-thalassemia major treated with deferoxamine.
Topics: Adolescent; Adult; Blood Transfusion; Body Burden; Chelation Therapy; Child; Child, Preschool; Combi | 1991 |
Hearing impairment during deferoxamine therapy for thalassemia major.
Topics: Adolescent; Child; Child, Preschool; Deferoxamine; Hearing Loss, Sensorineural; Humans; Thalassemia | 1991 |
[The value of nuclear magnetic resonance in the study of iron overload in thalassemia patients].
Topics: Adolescent; Adult; Alanine Transaminase; Cardiomyopathies; Child; Deferoxamine; Ferritins; Hemosider | 1991 |
Immunologic evaluation of children with homozygous beta-thalassemia treated with desferrioxamine.
Topics: Adolescent; Antibody Formation; Blood Bactericidal Activity; Cell Adhesion; Chemotaxis, Leukocyte; C | 1990 |
High incidence of cardiomyopathy in beta-thalassaemia patients receiving regular transfusion and iron chelation: reversal by intensified chelation.
Topics: Adolescent; Adult; Blood Transfusion; Chelation Therapy; Child; Combined Modality Therapy; Deferoxam | 1990 |
Hypogonadism in beta-thalassemic adolescents: a characteristic pituitary-gonadal impairment. The ineffectiveness of long-term iron chelation therapy.
Topics: Adolescent; Chelation Therapy; Child; Deferoxamine; Dose-Response Relationship, Drug; Estradiol; Fem | 1990 |
[Yersinia infection and hemoglobin disorder. Apropos of 4 cases].
Topics: Anemia, Sickle Cell; Child; Deferoxamine; Female; Humans; Iron; Male; Thalassemia; Yersinia enteroco | 1990 |
[Intravenous administration of deferoxamine in over-night hospitalization: efficacy and good psychological tolerance in thalassemic children].
Topics: Adolescent; Child; Child, Hospitalized; Deferoxamine; Follow-Up Studies; Humans; Infusion Pumps, Imp | 1990 |
Treatment of Cooley's anemia: deferoxamine provocation test.
Topics: Deferoxamine; Humans; Iron Chelating Agents; Spectrophotometry, Atomic; Thalassemia | 1990 |
Acute changes in renal function associated with deferoxamine therapy.
Topics: Deferoxamine; Humans; Kidney Diseases; Thalassemia | 1990 |
Current treatment of Cooley's anemia. Intravenous chelation therapy.
Topics: Adult; Anemia, Sickle Cell; Deferoxamine; Female; Ferritins; Humans; Infusions, Intravenous; Thalass | 1990 |
Chelation therapy and cardiac status in older patients with thalassemia major.
Topics: Adolescent; Adult; Chelation Therapy; Child; Deferoxamine; Drug Administration Schedule; Electrocard | 1990 |
Comparison of deferoxamine pharmacokinetics between asymptomatic thalassemic children and those exhibiting severe neurotoxicity.
Topics: Adolescent; Adult; Child; Child, Preschool; Chromatography, High Pressure Liquid; Deferoxamine; Dose | 1990 |
Pulmonary syndrome in patients with thalassemia major receiving intravenous deferoxamine infusions.
Topics: Adolescent; Adult; Child; Child, Preschool; Deferoxamine; Drug Hypersensitivity; Female; Humans; Imm | 1990 |
Rapid removal of excessive iron in thalassemia by high-dose intravenous chelation therapy.
Topics: Adolescent; Adult; Chelation Therapy; Deferoxamine; Ferritins; Humans; Thalassemia | 1990 |
Ocular findings in beta-thalassemia.
Topics: Adolescent; Adult; Blood Transfusion; Cataract; Child; Deferoxamine; Eye Diseases; Female; Humans; M | 1990 |
Vision and hearing during deferoxamine therapy.
Topics: Adolescent; Adult; Anemia, Sickle Cell; Chelation Therapy; Child; Deferoxamine; Ferritins; Hearing L | 1990 |
Effect of age at the start of iron chelation therapy on gonadal function in beta-thalassemia major.
Topics: Adolescent; Age Factors; Body Height; Child; Deferoxamine; Female; Ferritins; Growth Hormone; Humans | 1990 |
Desferrioxamine improves neutrophil phagocytosis in thalassemia major.
Topics: Adolescent; Adult; Child; Child, Preschool; Deferoxamine; Female; Humans; Male; Neutrophils; Phagocy | 1990 |
Acute changes in renal function associated with deferoxamine therapy.
Topics: Adolescent; Adult; Animals; Blood Urea Nitrogen; Child, Preschool; Creatinine; Deferoxamine; Dogs; F | 1989 |
Desferrioxamine ototoxicity: evaluation of risk factors in thalassaemic patients and guidelines for safe dosage.
Topics: Adolescent; Adult; Child; Child, Preschool; Deferoxamine; Drug Evaluation; Female; Ferritins; Hearin | 1989 |
Sustained normalization of cardiac function by chelation therapy in thalassaemia major.
Topics: Adolescent; Adult; Australia; Blood Transfusion; Chelation Therapy; Child; Combined Modality Therapy | 1989 |
Use of the ferritin/alanine aspartate transaminase ratio as an iron overload marker independent of liver cell damage.
Topics: Alanine Transaminase; Aspartate Aminotransferases; Biomarkers; Blood Transfusion; Combined Modality | 1989 |
Mineral balance (iron, aluminum, copper, zinc) after high-dose intravenous Desferal in a child with hemoglobin Hammersmith and Turner's syndrome.
Topics: Child; Deferoxamine; Feces; Female; Hemoglobins, Abnormal; Humans; Minerals; Thalassemia; Turner Syn | 1989 |
Liver iron stores before and after bone marrow transplantation for thalassemia.
Topics: Bone Marrow Transplantation; Busulfan; Child; Cyclophosphamide; Deferoxamine; Ferritins; Graft vs Ho | 1989 |
Iron excretion in thalassemia children treated with deferoxamin methansulfonat: intravenous drip compared to the subcutaneous routes.
Topics: Adolescent; Child; Deferoxamine; Humans; Infusion Pumps; Infusions, Intravenous; Iron; Male; Thalass | 1989 |
[Treatment of post-transfusion iron overload by deferoxamine].
Topics: Adolescent; Adult; Anemia, Sickle Cell; Child; Deferoxamine; Ferritins; Hemochromatosis; Humans; Tha | 1989 |
Rapid removal of excessive iron with daily, high-dose intravenous chelation therapy.
Topics: Adolescent; Adult; Anemia, Aplastic; Anemia, Sickle Cell; Catheterization, Central Venous; Deferoxam | 1989 |
A high-performance liquid chromatographic method for the measurement of deferoxamine in body fluids.
Topics: Adolescent; Animals; Chromatography, High Pressure Liquid; Ciprofloxacin; Deferoxamine; Dogs; Humans | 1989 |
Studies of variations of subcutaneously infused desferrioxamine and iron movements in thalassaemia children.
Topics: Adolescent; Child; Deferoxamine; Female; Ferric Compounds; Hemochromatosis; Humans; Infusions, Paren | 1989 |
Hepatic iron stores in thalassemia: non-invasive magnetic measurements.
Topics: Blood Transfusion; Deferoxamine; Ferritins; Humans; Iron Chelating Agents; Liver; Magnetics; Thalass | 1989 |
High-dose intravenous chelation therapy with deferoxamine.
Topics: Adolescent; Adult; Anemia, Sickle Cell; Blood Transfusion; Deferoxamine; Ferritins; Humans; Infusion | 1989 |
Medical management of beta-thalassemia.
Topics: Adolescent; Adult; Blood Transfusion; Child; Deferoxamine; Erythrocyte Transfusion; Ferritins; Heart | 1989 |
Quality of life and life expectancy in thalassemic patients with complications.
Topics: Adolescent; Adult; Blood Transfusion; Child; Deferoxamine; Diabetes Mellitus, Type 1; Heart Diseases | 1989 |
Compliance with therapy in Cooley's anaemia.
Topics: Blood Transfusion; Deferoxamine; Humans; Iron; Iron Chelating Agents; Patient Compliance; Penicillin | 1989 |
Cardiac complications in homozygous beta-thalassemia.
Topics: Adolescent; Adult; Blood Transfusion; Child; Deferoxamine; Female; Heart Diseases; Homozygote; Human | 1989 |
Endocrine complications in thalassaemia major.
Topics: Adolescent; Adult; Blood Transfusion; Deferoxamine; Diabetes Mellitus, Type 1; Female; Humans; Hypog | 1989 |
Concomitant primary hemochromatosis and beta-thalassemia trait: iron depletion by erythrocytapheresis and desferrioxamine.
Topics: Adult; Blood Component Removal; Deferoxamine; Erythrocytes; Female; Ferritins; Hemochromatosis; Huma | 1989 |
Reversal of desferrioxamine induced auditory neurotoxicity during treatment with Ca-DTPA.
Topics: Adolescent; Adult; Audiometry; Blood Transfusion; Child; Child, Preschool; Deferoxamine; Female; Fer | 1989 |
Long-term effect of splenectomy on transfusion requirements in thalassemia major.
Topics: Adolescent; Adult; Blood Transfusion; Child; Child, Preschool; Deferoxamine; Ferritins; Humans; Iron | 1989 |
Infection with Yersinia enterocolitica in patients with iron overload.
Topics: Adult; Anemia, Sideroblastic; Blood Transfusion; Deferoxamine; Female; Hemosiderosis; Humans; Male; | 1986 |
Yersinia and iron overload.
Topics: Deferoxamine; Female; Humans; Infant; Thalassemia; Yersinia enterocolitica; Yersinia Infections | 1986 |
Non-transferrin-bound iron in long-term transfusion in children with congenital anemias.
Topics: Adolescent; Adult; Anemia, Hemolytic, Congenital; Anemia, Sickle Cell; Anemia, Sideroblastic; Bindin | 1986 |
Reappraisal of high-dose desferrioxamine therapy.
Topics: Deferoxamine; Hemosiderosis; Humans; Thalassemia; Transfusion Reaction | 1986 |
Iron state and hepatic disease in patients with thalassaemia major, treated with long term subcutaneous desferrioxamine.
Topics: Adolescent; Adult; Child; Deferoxamine; Female; Ferritins; Hepatitis; Hepatitis B Core Antigens; Hep | 1987 |
Coagulation contact phase factors and inhibitors in beta-thalassemia major children.
Topics: Adolescent; Blood Coagulation Disorders; Child; Combined Modality Therapy; Deferoxamine; Humans; Pla | 1987 |
Deferoxamine-induced growth retardation in patients with thalassemia major.
Topics: Body Height; Bone and Bones; Deferoxamine; Dose-Response Relationship, Drug; Female; Growth Disorder | 1988 |
Hearing loss and desferrioxamine in homozygous beta-thalassemia.
Topics: Adolescent; Audiometry; Child; Deferoxamine; Female; Hearing Loss, Conductive; Hearing Loss, Sensori | 1988 |
Desferrioxamine and ascorbic acid supplement in E-B thalassaemia.
Topics: Ascorbic Acid; Child; Child, Preschool; Deferoxamine; Humans; Thalassemia | 1988 |
Yersinia enterocolitica septicaemia.
Topics: Adult; Deferoxamine; Hemosiderosis; Humans; Sepsis; Thalassemia; Yersinia enterocolitica; Yersinia I | 1988 |
Maintenance treatment with desferrioxamine via subcutaneous injections in a patient with HbE thalassaemia.
Topics: Adult; Deferoxamine; Hemoglobin E; Hemoglobins, Abnormal; Humans; Injections, Subcutaneous; Male; Th | 1988 |
Can deferoxamine be considered an ototoxic drug?
Topics: Adolescent; Adult; Child; Deferoxamine; Hearing Loss, Sensorineural; Humans; Thalassemia | 1988 |
Pneumocystis carinii pneumonia as a complication of desferrioxamine therapy.
Topics: Adult; Deferoxamine; Humans; Male; Pneumonia, Pneumocystis; Thalassemia | 1988 |
A prospective evaluation of iron chelation therapy in children with severe beta-thalassemia. A six-year study.
Topics: Adolescent; Adult; Child; Child, Preschool; Deferoxamine; Growth; Heart Diseases; Humans; Iron; Live | 1988 |
Electroretinographic and visual-evoked potential abnormalities in patients with beta-thalassemia major.
Topics: Adolescent; Adult; Child; Deferoxamine; Electroretinography; Evoked Potentials, Visual; Eye; Humans; | 1988 |
Depletion of trace elements and acute ocular toxicity induced by desferrioxamine in patients with thalassaemia.
Topics: Adolescent; Child; Copper; Deferoxamine; Electroretinography; Humans; Infusions, Intravenous; Retina | 1988 |
High-dose desferrioxamine as a cause of growth failure in thalassemic patients.
Topics: Child; Child, Preschool; Deferoxamine; Female; Ferritins; Growth Disorders; Humans; Male; Thalassemi | 1988 |
Hearing loss attributed to desferrioxamine in patients with beta-thalassaemia major.
Topics: Deferoxamine; Hearing Loss, Sensorineural; Humans; Thalassemia | 1988 |
Subcutaneous diethylene triamine pentaacetic acid: comparison with desferrioxamine in thalassemic patients with iron overload.
Topics: Adult; Child; Deferoxamine; Female; Humans; Infusions, Parenteral; Iron; Male; Pentetic Acid; Thalas | 1988 |
Iron status in thalassemia major patients after long-term subcutaneous desferrioxamine.
Topics: Adolescent; Adult; Child; Deferoxamine; Female; Humans; Infusions, Parenteral; Iron; Male; Splenecto | 1988 |
Normal serum ferritin levels following prolonged desferrioxamine therapy: Melbourne experience.
Topics: Adolescent; Adult; Child; Child, Preschool; Deferoxamine; Ferritins; Humans; Thalassemia; Time Facto | 1988 |
Rubber band technique for slow subcutaneous infusion of desferrioxamine (Desferal).
Topics: Adolescent; Child; Child, Preschool; Deferoxamine; Female; Humans; Infusions, Parenteral; Iron; Male | 1988 |
Oral ascorbic acid and iron excretion in thalassemic children treated with desferrioxamine-methansulfonate (Desferal).
Topics: Administration, Oral; Adolescent; Ascorbic Acid; Child; Child, Preschool; Deferoxamine; Drug Therapy | 1988 |
Effects of deferoxamine on renal function in thalassemia.
Topics: Adolescent; Adult; Child; Deferoxamine; Female; Humans; Kidney; Kidney Function Tests; Male; Thalass | 1988 |
Iron balance and the management of iron overload in beta-thalassemia intermedia.
Topics: Administration, Cutaneous; Administration, Oral; Adolescent; Adult; Deferoxamine; Female; Humans; Ir | 1988 |
Iron chelation in thalassemia.
Topics: Ascorbic Acid Deficiency; Deferoxamine; Dose-Response Relationship, Drug; Humans; Iron; Thalassemia | 1988 |
Modulation of the defective natural killer activity seen in thalassaemia major with desferrioxamine and alpha-interferon.
Topics: Cytotoxicity, Immunologic; Deferoxamine; Fibroblasts; Herpes Simplex; Humans; Interferon Type I; Kil | 1987 |
[Yersinia septicemia in children with thalassaemia major].
Topics: Child; Child, Preschool; Deferoxamine; Female; Hemosiderosis; Humans; Male; Risk Factors; Sepsis; Th | 1987 |
Visual and auditory neurotoxicity in patients receiving subcutaneous deferoxamine infusions.
Topics: Adolescent; Adult; Age Factors; Anemia, Aplastic; Audiometry; Child; Child, Preschool; Color Vision | 1986 |
[Continuous subcutaneous deferoxamine infusions in thalassemia major. Improvement in glucose tolerance].
Topics: Adolescent; Adult; alpha-Amylases; Blood Glucose; Child; Child, Preschool; Deferoxamine; Diabetes Co | 1986 |
The development of diabetes mellitus and chronic liver disease in long term chelated beta thalassaemic patients.
Topics: Adolescent; Adult; Blood Glucose; Child; Chronic Disease; Deferoxamine; Diabetes Mellitus; Female; F | 1986 |
[Hypertransfusion, chelating and immunocorrective therapy in beta-thalassemia major].
Topics: Blood Transfusion; Chelating Agents; Child; Child, Preschool; Combined Modality Therapy; Deferoxamin | 1987 |
Yersinia hepatic abscesses and iron overload.
Topics: Child; Child, Preschool; Deferoxamine; Female; Humans; Iron; Male; Thalassemia; Yersinia enterocolit | 1987 |
Leukocyte alkaline phosphatase (LAP). A useful marker of zinc status in beta-thalassemic patients.
Topics: Adolescent; Alkaline Phosphatase; Child; Child, Preschool; Deferoxamine; Humans; Leukocytes; Neutrop | 1987 |
Hearing loss attributed to desferrioxamine in patients with beta-thalassaemia major.
Topics: Adolescent; Adult; Child; Deferoxamine; Drug Administration Schedule; Hearing Loss, Sensorineural; H | 1987 |
Comparison between serum ferritin and computed tomographic densities of liver, spleen, kidney and pancreas in beta-thalassaemia major.
Topics: Blood Transfusion; Child; Child, Preschool; Deferoxamine; Ferritins; Humans; Liver; Liver Cirrhosis; | 1987 |
[Effect of desferal therapy on indices of iron metabolism in patients with intermediate forms of beta-thalassemia].
Topics: Adolescent; Adult; Blood Transfusion; Deferoxamine; Female; Globins; Homozygote; Humans; Iron; Iron | 1987 |
Yersinia sepsis in patients with iron overload treated with deferoxamine.
Topics: Adult; Deferoxamine; Female; Humans; Iron; Thalassemia; Yersinia enterocolitica; Yersinia Infections | 1986 |
Iron chelation using subcutaneous infusions of diethylene triamine penta-acetic acid (DTPA).
Topics: Administration, Oral; Adult; Ascorbic Acid; Child; Deferoxamine; Dose-Response Relationship, Drug; D | 1986 |
Effect of desferrioxamine on salivary iron in thalassemic children.
Topics: Child; Deferoxamine; Humans; Iron; Saliva; Thalassemia | 1986 |
Deferoxamine improves left ventricular function in beta-thalassemia.
Topics: Adolescent; Adult; Child; Deferoxamine; Echocardiography; Female; Ferritins; Heart; Heart Ventricles | 1986 |
Nontransferrin-bound serum iron in thalassemia and sickle cell patients.
Topics: Adult; Anemia, Sickle Cell; Chromatography, Ion Exchange; Deferoxamine; Electrophoresis, Polyacrylam | 1986 |
Quantification of desferrioxamine in blood plasma by inductively coupled plasma atomic emission spectrometry.
Topics: Colorimetry; Deferoxamine; Humans; Indicators and Reagents; Kidney Failure, Chronic; Quality Control | 1987 |
[Thalassemia major: chelating therapy with deferoxamine].
Topics: Adolescent; Blood Transfusion; Child; Child, Preschool; Deferoxamine; Female; Ferritins; Humans; Inj | 1985 |
Current therapy and new approaches to the treatment of thalassemia major.
Topics: Adolescent; Blood Transfusion; Child; Deferoxamine; Erythrocytes; Humans; Iron; Male; Pyruvate Kinas | 1985 |
Treatment of iron overload in Cooley's anemia.
Topics: Adolescent; Adult; Blood Transfusion; Chelating Agents; Child; Child, Preschool; Deferoxamine; Eryth | 1985 |
The effect of subcutaneous deferoxamine on the cardiac profile of thalassemia major: a five-year study.
Topics: Adolescent; Adult; Arrhythmias, Cardiac; Child; Child, Preschool; Deferoxamine; Echocardiography; El | 1985 |
Combined subcutaneous and high-dose intravenous deferoxamine therapy of thalassemia.
Topics: Adolescent; Adult; Blood Transfusion; Child; Child, Preschool; Deferoxamine; Echocardiography; Ferri | 1985 |
Improved oxygen delivery to tissues and iron chelator transport through the use of lysed and resealed red blood cells: a new perspective on Cooley's anemia therapy.
Topics: Animals; Blood Transfusion; Chelating Agents; Deferoxamine; Erythrocyte Aging; Erythrocyte Transfusi | 1985 |
Defective vitamin D metabolism in thalassemia major.
Topics: Adolescent; Adult; Calcitriol; Calcium; Chelating Agents; Child; Child, Preschool; Deferoxamine; Erg | 1985 |
The chronically transfused patient: advances in treatment.
Topics: Acquired Immunodeficiency Syndrome; Adult; Blood Grouping and Crossmatching; Blood Transfusion; Chil | 1985 |
[Longitudinal growth of patients with homozygote beta-thalassemia during continuous subcutaneous infusion of deferoxamine].
Topics: Age Determination by Skeleton; Body Height; Child; Child, Preschool; Deferoxamine; Female; Greece; H | 1986 |
High-dose desferoxamine and Diamond-Blackfan anemia.
Topics: Adolescent; Anemia; Deferoxamine; Heart Failure; Humans; Infusions, Parenteral; Thalassemia; Transfu | 1986 |
Growth and sexual maturation in thalassemia major.
Topics: Adolescent; Adult; Age Determination by Skeleton; Amenorrhea; Blood Transfusion; Body Height; Child; | 1985 |
Prevention of cardiac disease by subcutaneous deferoxamine in patients with thalassemia major.
Topics: Adolescent; Arrhythmias, Cardiac; Aspartate Aminotransferases; Cardiomyopathies; Child; Deferoxamine | 1985 |
Prevention of cardiac disease by subcutaneous deferoxamine in patients with thalassemia major.
Topics: Adolescent; Arrhythmias, Cardiac; Aspartate Aminotransferases; Cardiomyopathies; Child; Deferoxamine | 1985 |
Prevention of cardiac disease by subcutaneous deferoxamine in patients with thalassemia major.
Topics: Adolescent; Arrhythmias, Cardiac; Aspartate Aminotransferases; Cardiomyopathies; Child; Deferoxamine | 1985 |
Prevention of cardiac disease by subcutaneous deferoxamine in patients with thalassemia major.
Topics: Adolescent; Arrhythmias, Cardiac; Aspartate Aminotransferases; Cardiomyopathies; Child; Deferoxamine | 1985 |
Ocular and auditory toxicity of long-term, high-dose subcutaneous deferoxamine therapy.
Topics: Child, Preschool; Deferoxamine; Ear; Eye; Female; Hearing Loss, Sensorineural; Humans; Injections, S | 1985 |
[Continuous subcutaneous deferoxamine treatment in thalassemia major. Decrease of hemosiderosis and improvement of liver function].
Topics: Adolescent; Adult; Child; Child, Preschool; Deferoxamine; Hemosiderosis; Humans; Injections, Subcuta | 1985 |
[Effect of two years of deferoxamine therapy on iron balance, ferritin, liver and heart in patients with thalassemia major].
Topics: Adolescent; Child; Child, Preschool; Deferoxamine; Ferritins; Heart; Humans; Iron; Liver; Patient Co | 1985 |
[Severe cardiomyopathy in a woman with intermediate beta-thalassemia. Regression of cardiac failure with desferrioxamine].
Topics: Adult; Deferoxamine; Echocardiography; Electrocardiography; Female; Heart Failure; Humans; Thalassem | 1985 |
[Current treatment of Cooley's disease].
Topics: Blood Grouping and Crossmatching; Blood Transfusion; Child; Deferoxamine; Erythrocyte Transfusion; H | 1985 |
[Desferal test in the diagnosis of hemosiderosis in patents with hemoglobinopathies].
Topics: Adolescent; Adult; Aged; Anemia, Sickle Cell; Child; Child, Preschool; Deferoxamine; Female; Hemoglo | 1971 |
Clinical experience with intensive transfusion therapy in Cooley's anemia.
Topics: 17-Ketosteroids; Blood Transfusion; Bone Development; Calcium; Child; Deferoxamine; Electrocardiogra | 1969 |
[Research on the effect of desferrioxamine B in patients with Cooley's disease].
Topics: Adolescent; Adult; Cardiomegaly; Child; Child, Preschool; Deferoxamine; Female; Hepatomegaly; Humans | 1967 |
Long-term administration of desferrioxamine in thalassaemia major.
Topics: Adolescent; Adult; Aspartate Aminotransferases; Bilirubin; Blood Protein Electrophoresis; Blood Tran | 1974 |
Ascorbic acid enhancement of desferrioxamine-induced urinary iron excretion in thalassemia major.
Topics: Administration, Oral; Adolescent; Adult; Age Factors; Ascorbic Acid; Child; Child, Preschool; Defero | 1974 |
Combined long-term treatment of hemosiderosis with desferioxamine and DTPA in homozygous beta-thalassemia.
Topics: Adolescent; Adult; Blood Transfusion; Child; Deferoxamine; Drug Therapy, Combination; Erythrocytes; | 1974 |
Long-term desferrioxamine therapy in thalassemia.
Topics: Adolescent; Ascorbic Acid; Child; Child, Preschool; Cyprus; Deferoxamine; Drug Synergism; Humans; Ir | 1974 |
Urinary iron excretion in thalassaemia after desferrioxamine administration.
Topics: Adolescent; Adult; Blood Transfusion; Child; Child, Preschool; Deferoxamine; Female; Hemoglobins; Hu | 1974 |
Editorial: Thalassemia major: a problem of iron overload.
Topics: Ascorbic Acid; Chelating Agents; Child; Child, Preschool; Deferoxamine; Humans; Intestinal Absorptio | 1974 |
[Hemochromatosis].
Topics: Adult; Anemia, Macrocytic; Bloodletting; Deferoxamine; Diagnosis, Differential; Diet Therapy; Female | 1972 |
The effective use of oxymetholone in the therapy of thalassaemia with anaemia.
Topics: Adult; Child; Deferoxamine; Hemosiderosis; Humans; Oxymetholone; Thalassemia | 1972 |
[Treatment of Cooley's anemia].
Topics: Blood Transfusion; Deferoxamine; Glucocorticoids; Humans; Splenectomy; Thalassemia | 1971 |
Some clinical features of Cooley's anemia patients as related to transfusion schedules.
Topics: Blood Transfusion; Deferoxamine; Fetal Hemoglobin; Growth Disorders; Hematopoiesis; Humans; Iron; Li | 1969 |
Management of thalassemia: a comparative program.
Topics: Adolescent; Asian People; Blood Transfusion; Body Height; Body Weight; Child; Child, Preschool; Defe | 1969 |
Prevention of bone malformations and cardiomegaly in Cooley's anemia by early hypertransfusion regimen.
Topics: Blood Transfusion; Bone Diseases, Developmental; Cardiomyopathies; Child; Child, Preschool; Deferoxa | 1969 |
A comparison of desferrioxamine-induced sideruria and measurement of labile iron store as indices of body iron status.
Topics: Adult; Anemia, Hypochromic; Anemia, Macrocytic; Autoanalysis; Body Composition; Chelating Agents; De | 1971 |
[Therapy of primary siderochromatosis and siderosis: experimental and clinical study].
Topics: Bloodletting; Deferoxamine; Hemochromatosis; Humans; Intestinal Absorption; Iron; Porphyrias; Primar | 1969 |
[Inveterate leg ulcer in a constitutional hemolytic syndrome with dermosiderosis. Cure by desfrrioxamine].
Topics: Adult; Deferoxamine; Humans; Leg Ulcer; Male; Siderosis; Skin Diseases; Thalassemia | 1967 |
[Importance of treatment with deferoxamine in children with Cooley's disease].
Topics: Child; Child, Preschool; Deferoxamine; Female; Humans; Male; Thalassemia | 1967 |
[Current status of treatments with desferrioxamine B in post-transfusion hypersiderosis in children].
Topics: Adolescent; Anemia, Aplastic; Anemia, Hemolytic; Child; Child, Preschool; Deferoxamine; Female; Hemo | 1967 |
Desferrioxamine in thalassaemia.
Topics: Adolescent; Bone Marrow; Cataract; Child; Child, Preschool; Deferoxamine; Female; Hemoglobinometry; | 1968 |
[Clinical and metabolic research on treatment with desferrioxamine B in various hemosiderotic erythrocyte diseases].
Topics: Adolescent; Adult; Aged; Anemia; Child; Child, Preschool; Deferoxamine; Female; Hemosiderosis; Human | 1965 |
[Remarks on the treatment of thalassemia major].
Topics: Child; Child, Preschool; Deferoxamine; Humans; Splenectomy; Thalassemia | 1965 |
[Use of desferrioxamine B in the treatment of post-transfusion hypersiderosis].
Topics: Adolescent; Anemia, Hemolytic; Child; Child, Preschool; Deferoxamine; Female; Humans; Male; Siderosi | 1965 |
Deferoxamine and diethylenetriaminepentaacetic acid (DTPA) in thalassemia.
Topics: Child; Deferoxamine; Female; Humans; Infant; Iron; Male; Pentetic Acid; Thalassemia | 1966 |
[Effects of desferrioxamine on iron elimination in children after multiple transfusions].
Topics: Blood Transfusion; Child; Deferoxamine; Hemosiderosis; Humans; Iron; Thalassemia | 1966 |
[Thoughts apropos of 2 cases of major thalassemia and its treatment by desferrioxamine B].
Topics: Child; Deferoxamine; Female; Humans; Infant; Male; Splenectomy; Thalassemia | 1966 |
[Desferrioxamine-B in the diagnosis of hemosiderotic states and in the therapy of thalassemia. Apropos of 2 cases].
Topics: Child; Child, Preschool; Deferoxamine; Hemosiderosis; Humans; Iron; Male; Thalassemia | 1966 |
The treatment of hemosiderosis in thalassaemia major with desferrioxamine-B.
Topics: Adolescent; Anemia, Sickle Cell; Biopsy; Child; Deferoxamine; Female; Hemochromatosis; Hemosiderosis | 1966 |